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INTRODUCTION 
Over the past decade, impressive antineoplastic activity of somatostatin analogues has been 
demonstrated in many in vitro and in vivo tumour models, including breast cancer (1,2). 
Somatostatin analogues, e.g. octreotide, exert their antiproliferative effects directly through 
upregulation of intracellular tyrosine phosphatase activity as a consequence of ligand binding 
to somatostatin receptors (SSTRs) leading to deactivation of growth-factor receptors as well 
as indirectly by suppressing levels of tumour growth factors such as insulin-like growth factor 
1 (IGF-1) and growth hormone (figure B) (3). Together with oestradiol, insulin-like growth 
factors (IGF-1 and IGF-2)) are the most potent mitogens for breast cancer cells and their 
growth effect is mediated predominantly via IGF-1 receptors (IGF-1Rs) (4,5). Somatostatin, 
suppresses IGF-1 secretion both through reduction of growth-hormone (GH)-dependent 
hepatic IGF-1 expression as through direct inhibition of IGF-1 gene transcription (3)
The excellent preclinical results obtained with somatostatin analogues in experimental tumour 
models led to clinical trials in patients suffering from metastasised breast cancer. 
Unfortunately, enrolment of heavily pretreated metastasised patients in early clinical trials did 
not allow for definitive conclusions as to the antitumour activity of these agents 
. 
(6,7,8,9). More 
recent clinical trials assessed the efficacy of somatostatin analogues in combination treatment 
in untreated metastasised breast cancer patients. Bontenbal et al randomized 22 
postmenopausal metastasised breast cancer patients to receive either 40mg of the 
antioestrogen tamoxifen per day or the combination 40mg tamoxifen plus 75µg of the 
antiprolactin CV 205-502 orally and thrice a day 0.2mg of octreotide subcutaneously as first 
line endocrine therapy (10). An objective response was found in 36 % of patients treated with 
tamoxifen in monotherapy and in 55% of patients treated with combination therapy. Median 
time to progression was 33 weeks for patients treated with tamoxifen and 84 weeks for 
patients treated with combination therapy. Unfortunately, the numbers were too small to draw 
definite conclusions and the addition of CV 205-502 did not permit direct assessment of the 
contribution of the octreotide to overall gain when compared to tamoxifen in monotherapy. 
Ingle et al included 135 eligible postmenopausal metastasised breast carcinoma patients which 
were randomized to tamoxifen 10mg twice daily alone or tamoxifen plus octreotide at a dose 
of 150µg thrice daily (11). The two groups were well balanced, except the tamoxifen group had 
higher proportions of patients with visceral disease (50% versus 37%) and of patients with a 
disease free interval longer than 5 years (47% versus 34%). The median time to progression 
was estimated to be 14.2 months with tamoxifen and 10.3 months with tamoxifen plus 
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octreotide. No significant difference in progression free survival time (P=0.26) and 
distribution of survival times  (P=0.92) was found between both groups. When considering 
the 106 patients with measurable disease, the objective response rate was 49% with tamoxifen 
alone and 43% with tamoxifen plus somatostatin analogue (P=0.70). Of interest, the 
percentage of decline in serum IGF-1, from pretreatment levels to those following 3-6 weeks 
of treatment, was significantly greater (P<0.01) with tamoxifen plus octreotide than with 
tamoxifen alone. 
So far, no convincing clinical benefit of adding somatostatin analogues to tamoxifen has been 
demonstrated in metastasised breast cancer patients. The question is, can we really expect 
benefit of adding somatostatin analogues to tamoxifen in patients with metastasised breast 
cancer?  
Firstly, although the combination of tamoxifen and somatostatin results in a more pronounced 
reduction of tumour growth factor IGF-1 levels, the level of circulating IGF-1 may be less 
relevant. In this regard, Guvakova and Surmacz demonstrated that in ER-positive MCF-7 
tamoxifen-responsive breast cancer cells and in derived clones overexpressing either IGF-1R 
or its major substrate IRS-1, a 4-day treatment with 10nM tamoxifen produced a similar 
cytostatic effect, regardless of the amplification of IGF signalling (figure C) (12)
Secondly, cell line experiments suggest that in breast carcinoma the SSTR, predominantly 
subtype 2, is an oestrogen response element that is upregulated in the presence of oestradiol 
and downregulated in the presence of antiestrogens such as tamoxifen (figure A), similar to 
the progesterone receptor. Oestradiol was shown to time- and dose-dependently upregulate 
transcription of the SSTR2 gene in both oestrogen receptor (ER)-positive, endocrine-
responsive breast tumour cell lines, T47D and ZR75-1, but not in the ER-negative MDA 
MB231 cell line (figure C) 
. It was shown 
that tamoxifen resulted in functional uncoupling of ligand-receptor signalling by 
downregulation of IGF-1 induced tyrosine phosphorylation of IGF-1R and inhibition of IRS-
1/phosphatidylinositol 3’ (IP3)-kinase signalling. Thus, tamoxifen treatment when effective 
may result in functional uncoupling of  IGF-1/IGF-1R signalling in patients suffering from 
breast carcinoma. This could explain why the higher reduction in IGF-1 levels obtained by 
combining tamoxifen and somatostatin does not result in a higher response rate when 
compared to tamoxifen in monotherapy.  
(13). Conversely, in both T47D and ZR75-1 cells the pure 
antioestrogen ICI 182 780 inhibited oestradiol-induced SSTR2 mRNA expression. Thus, in 
breast carcinoma patients, effective antioestrogen treatment may result in downregulation of 
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SSTR thereby preventing somatostatin analogues from exerting their direct tumour growth 
inhibitory activity. 
Hence, as tamoxifen administration in oestrogen-dependent tumours may result in 
downregulation of the somatostatin receptor and inhibition of phosphorylation of IGF-1R, 
somatostatin could neither directly or indirectly exert its inhibitory activity. 
If cell line data prove correct in humans, response to tamoxifen treatment could be monitored 
noninvasively by means of sequential somatostatin receptor scintigraphy respectively prior to 
and rapidly, within 3 weeks, following tamoxifen treatment initiation. Uptake of radiolabelled 
somatostatin derivatives through SSTR2 binding in human breast carcinoma has been 
previously described (14)
 
.  In tamoxifen-responsive tumours, and not -unresponsive tumours, a 
decrease in tumour uptake of radiolabelled octreotide is to be expected.  
 
FIGURES 
 
Figure A . Binding of oestradiol (E2) to a functional oestrogen receptor (ER) in oestrogen-
dependent tumour cells results in upregulation of the somatostatin receptor (subtype 2, 
SSTR2). Insulin like growth factor-1 (IGF-1) binding to the IGF-1 receptor (IGF-1R) results 
in autophosphorylation, triggering a cascade of events, ultimately leading to cell division. 
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Figure B. Somatostatin decreases cell proliferation indirectly (1.) by reducing the circulating 
levels of the tumour growth factor IGF-1 and directly (2.) through binding to its receptor 
thereby activating a phosphatase which can dephosphorylate IGF-1R thereby also inhibiting 
signalling to the nucleus and thus cell proliferation. 
 
 
Figure C. Tamoxifen prohibits E2 from binding to ER, in oestrogen-dependent tumour cells 
resulting in downregulation of SSTR2 (1.). Additionally tamoxifen inhibits phosphorylation 
of IGF-1R (2.). In this setting, somatostatin can neither directly or indirectly exert its 
inhibitory activity. 
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OUTLINE OF THE THESIS 
This thesis aims to elucidate the role of oestrogen in SSTR expression and to explore the 
potential of the visualization of this molecular event by means of nuclear medicine techniques 
for selection of breast cancer patients likely to respond to endocrine treatment. 
In chapter 2 receptor imaging in oncology by means of nuclear medicine is reviewed 
extensively. 
In chapter 3 oestrogen-mediated regulation of SSTR expression is demonstrated on a protein 
level in 3 human breast cancer cell lines. 
In chapter 4 the biodistribution and dosimetry of 99m
In chapter 5 
Tc-depreotide (P829) is validated in 
patients suffering from breast carcinoma. 
99mTc-depreotide scintigraphy is compared with 99m
In chapter 6 the potential of sequential 99mTc-depreotide scintigraphy for early endocrine 
therapy prediction is investigated in advanced breast cancer patients.  
Tc-MDP bone scan for the 
detection of bone metastases in patients with breast cancer. 
In chapter 7 the general discussion and future perspectives are given. 
In chapter 8 the thesis is briefly summarized in English, French and Dutch. 
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Receptor Imaging in Oncology by means of Nuclear Medicine: Current 
Status 
Bieke Van Den Bossche1 and Christophe Van de Wiele1. 
1
Journal of Clinical Oncology 2004; 22(17):3593-3607. 
Division of Nuclear Medicine, Ghent University Hospital, Ghent, Belgium 
 
1. Abstract 
To date, our understanding of the role of receptors and their cognate ligands in cancer is being 
successfully translated into the design and development of an arsenal of new, less toxic and 
more specific anticancer drugs. As most of these novel drugs are cytostatic, objective 
response as measured by morphological imaging modalities (eg, computed tomography or 
magnetic resonance imaging) cannot be used as a surrogate marker for drug development or 
for clinical decision making. Positron emission tomography (PET) can be used to image and 
quantify the in vivo distribution of positron-emitting radioisotopes such as oxygen-15, 
carbon-11 and fluorine-18 that can be substituted or added into biologically relevant and 
specific receptor radioligands. Similarly, single-photon emission computed tomography 
(SPECT) can be used to image and quantify the in vivo distribution of receptor-targeting 
compounds labeled with indium-111, technetium-99m and iodine-123. By virtue of their 
whole-body imaging capacity and the absence of errors of sampling and tissue manipulation 
as well as preparation, both techniques have the potential to address locoregional receptor 
status noninvasively and repetitively. This article reviews available data on the in vivo 
evaluation of receptor systems by means of PET or SPECT for identifying and monitoring 
patients with sufficient receptor overexpression for tailored therapeutic interventions, and also 
for depicting tumor tissue and determining the currently largely unknown heterogeneity in 
receptor expression among different tumor lesions within and between patients. 
 
2. Introduction 
Key to the coordination of the functions of individual cells within the intact organism is 
intercellular communication, a means by which the individual cell is regulated in its 
specialized functions in a manner that serves the integrated needs of the organism as a whole. 
The process of intercellular signaling is achieved through myriad molecules that interact 
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specifically with their respective docking sites or receptor proteins. Subsequent to binding of 
ligand, either in endocrine, paracrine or autocrine function, the receptor proteins serve a 
transducing function and signal to intracellular portions of themselves or other associated 
proteins that ligand has been bound. This in turn activates specific effector pathways, 
resulting in metabolic and structural changes in the cell that constitute the signature effect of 
the agonist. Many receptor systems are widely expressed, suggesting a core of regulatory 
interactions that are common to all cell types. Under normal physiological conditions, 
receptors and their cognate ligands collaborate and succeed in selecting one of a few mutually 
exclusive programs: temporary quiescence, cell division, terminal differentiation or activation 
of differential activities, senescence, or apoptosis (programmed cell death). However, in 
cancer, several receptor systems are subverted, most commonly by mutations, ranging from 
upregulation, downregulation and deregulation to deactivation, deletion or constitutive 
activation. 
  To date, our understanding of the role of receptors and their cognate ligands in cancer 
is being successfully translated into the design and development of an arsenal of new, less 
toxic and more specific anticancer drugs (eg, growth-factor– and receptor-specific inhibitors). 
These drugs are designed specifically to correct the precise molecular abnormalities that are 
responsible for the causation and progression of human tumors. Because most of these novel 
drugs are cytostatic, objective response as measured by morphological imaging modalities eg, 
computed tomography [CT] or magnetic resonance imaging) cannot be used as a surrogate 
marker for drug development or for clinical decision making.  
Although survival is the gold standard end point for registration of an experimental anticancer 
drug, its use for guiding early clinical development decisions is not practical. One alternative 
would be an end point of time to progression (TTP), suggesting that stable disease will result 
from cytostatic therapy. However, in the past, criteria for determining progressive disease and 
their diagnostic correlates have not been standardized, which is one of the principal reasons 
that TTP usually is not an acceptable registration end point for the Food and Drug 
Administration. In addition, accurate information related to prior treatment, extent of disease, 
comorbidity, and performance status at regular intervals in control patients is not only 
difficult to collect in a systematic fashion but is also difficult to analyze appropriately. Thus, 
the opportunity presented is to replace morphological imaging criteria and clinical criteria 
such as TTP by more specific end points that are made for specific molecular receptor 
targeting pathways. Although the use of nucleic acid microarrays is a potential alternative, the 
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need for repetitive invasive biopsies does not allow the assessment of heterogeneity between 
tumor lesions or of sequential changes within one lesion in routine clinical practice. In 
addition, levels of nucleic acids are not necessarily related to protein levels.  
Positron emission tomography (PET) can be used to image and quantify the in vivo 
distribution of positron-emitting radioisotopes such as oxygen-15, carbon-11 and fluorine-18 
(18F) that can be substituted or added into biologically relevant and specific receptor 
radioligands. Similarly, single-photon emission computed tomography (SPECT) can be used 
to image and quantify the in vivo distribution of receptor-targeting compounds labeled with 
indium-111 (111In), technetium-99m (99mTc) and iodine-123 (123
 
I). By virtue of their whole-
body imaging capacity and the absence of errors of sampling and tissue manipulation as well 
as preparation, both techniques have the potential to address locoregional receptor status 
noninvasively and repetitively. Thus, in vivo evaluation of receptor systems by means of PET 
or SPECT might prove useful not only to identify and monitor patients with sufficient 
receptor overexpression for tailored therapeutic interventions, but also to depict tumor tissue 
and determine the currently largely unknown heterogeneity in receptor expression among 
different tumor lesions within and between patients.  
3. SPECT versus PET  
The gamma camera or SPECT camera is able to detect scintillations (flashes of light) 
produced when gamma rays resulting from radioactive decay of single-photon–emitting 
radioisotopes interact with a sodium iodide crystal at the front of the camera (1).The 
scintillations are detected by photomultiplier tubes, and although the areas of crystal seen by 
tubes overlap, the location of each scintillation can be computed from the relative response in 
each tube (Fig 1). The energy of each scintillation is also measured from the response of the 
tubes, and the electrical signal to the imaging computer consists of the location and photon 
energy. In front of the crystal resides a collimator that is made of lead and usually 
manufactured with multiple elongated holes (parallel-hole collimator). The holes allow only 
gamma rays that are traveling perpendicular to the crystal face to enter. The gamma photons 
absorbed by the crystal therefore form an image of the radiopharmaceutical distribution in 
front of the camera. By rotating the camera around the patient and acquiring images at 
different angles, tomographic images or SPECT images can be generated through the use of 
specific reconstruction algorithms (2).  
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BGO, bismuth germanate; NaI, sodium iodide; Tl, thallium. 
Figure 1. Single-photon emission computed tomography (SPECT) versus positron emission 
tomography (PET). Triple headed gamma-camera (left). Through rotation of the camera around the 
patient, tomographic SPECT images are acquired. Dedicated PET camera (right). Through 
simultaneous detection of two annihilation photons, the localization of the positron emitter is 
measured (coincidence detection).  
 
As with SPECT, PET relies on computerized reconstruction procedures to produce 
tomographic images; PET, however, indirectly detects positron emission (3). Positrons, when 
emitted by radioactive nuclei, combine with an electron from the surroundings and are 
annihilated. On annihilation, both the positron and the electron are then converted to 
electromagnetic radiation in the form of two high-energy photons, which are emitted 180 
degrees away from each other. It is this annihilation radiation that can be detected externally 
and is used to measure both the quantity and the location of the positron emitter. 
Simultaneous detection of two of these photons by detectors on opposite sides of an object 
places the site of the annihilation on or about a line connecting the centers of the two 
opposing detectors. At this point, the distribution of annihilations is mapped by computer. If 
the annihilation originates outside the volume between the two detectors, only one of the 
photons can be detected, and because the detection of a single photon does not satisfy the 
coincidence condition, the event is rejected.  
Given that radioisotopes suitable for PET have a short half-life (eg, 110 min for 18F), an on-
site cyclotron is needed for production of such isotopes (4). In addition, special radiosynthesis 
SPECT PET 
NaI(Tl)-
crystal 
collimator 
BGO-
crystal 
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facilities are required, restricting the availability of noncommercially available PET 
radiopharmaceuticals to specialized centers. In contrast, the synthesis of SPECT 
radiopharmaceuticals is relatively less expensive. Because the half-lives of the isotopes used 
in SPECT are longer than those of isotopes used in PET (hours versus minutes), longer 
acquisition times are possible in SPECT. This allows receptor imaging at equilibrium, a 
prerequisite in order to obtain reliable information with respect to relative receptor density 
measurements. Conversely, the resolution of a conventional PET camera is twice as good as 
that of a conventional gamma camera, and PET allows for more accurate quantitation when 
compared with SPECT. 
 
4. Receptor radiopharmaceutical prerequisites 
The general structure of a radiophamaceutical targeting a receptor is shown in Figure 2 (5). A 
ligand such as a peptide, protein, hormone or organic molecule for the target has to be 
defined. The second important component of the molecule is the radioactive part. This 
consists of an organic molecule (chelator or tyrosine) to which the radionuclide can be 
attached. The two parts can be connected with a linker (organic molecule). In some special 
cases, the radionuclide can be attached directly to the ligand. 
 
 
 
 
 
 
Figure 2. Body of a radiopharmaceutical. 
For imaging purposes, receptor radiopharmaceuticals need to fulfill the following three 
requirements: high specific activity (radioactivity per unit mass of the radiopharmaceutical, > 
1Ci/mmol) because receptors are satiable systems with limited uptake capacity in vivo, high 
receptor affinity with low nonspecific binding, and appropriate metabolic and clearance 
characteristics (6;7). Because of the high specific activity available with receptor 
radiopharmaceuticals and the concern of excessive dosimetry to humans, the dissociation 
constant (Kd) as a measure of affinity of the ligand to the receptor, should be in the range of 
0.1-50 nmol/L. If affinity is too high (Kd < 0.1 nmol/L), the rate-limiting step becomes a 
target 
attach 
structure 
radionuclide linker 
ligand 
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measure of flow rate or membrane transport, rather than the ligand-receptor binding process. 
If affinity is too low (Kd
Finally, to reduce adverse pharmacological effects and decrease receptor occupancy or 
saturation of receptor sites, usually, only a minimized amount of radiopharmaceutical is 
administered. Nevertheless, occasionally, some radiopharmaceuticals may have significant 
pharmacological effects, even at sub-nanogram quantities. 
 > 50 nmol/L), the signal-to-noise ratio may be significantly 
decreased because of the large amount of unbound free tracer in circulation, and tumor 
visualization may merely reflect vasculature or blood volume in the tissue of interest. Low 
nonspecific binding and appropriate metabolic and clearance characteristics are required to 
obtain optimal tumor-to-background ratios that allow depiction of tumor lesions.  
 
5. Imaging intracellular receptors 
I. ESTROGEN RECEPTOR IMAGING 
Radiolabeled estradiol derivatives: Pretreatment imaging. Several halogenated derivatives 
of estradiol, such as vynilestradiol (steroidal) and hexestrol (nonsteroidal) have been 
synthesized, a number of which have reached the clinical stage. These include substituents of 
estradiol halogenated at the 16α-position and vynilestradiol derivatives halogenated at the 
17α-position, either in cis (Z) or trans (E) position (Table 1).  
In a feasibility study using a bromoestradiol tracer on four primary and four metastatic breast 
carcinoma patients, McElvany et al. found three abnormal scintigrams in patients with 
primary breast carcinoma, two of whom underwent a biopsy and found to be estrogen receptor 
(ER) -positive (8). Two patients with advanced tumors who were receiving antiestrogen 
therapy showed negative results and one abnormal scan was obtained in an ER-positive 
patient with chest wall metastases. No uptake of tracer was seen in the single ER-negative 
primary tumor.  
In a series of 28 breast carcinoma patients, SPECT imaging performed using 16α-123-
iodoestradiol-17β demonstrated eight of nine patients with histologically proven breast 
cancers, four of which were ER-positive, three were ER-negative and two were of 
undetermined ER status (9). There was one false-negative of unknown ER status. Four of four 
metastases and six of six known axillary nodes were visualized. Initially there were 12 false-
positive axillary nodes and two false-positive scans showing mediastinal involvement. 
However, with clinical follow-up, two of 12 axillae and one of 12 mediastinums were found 
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to contain cancer of adequate volume to be detected by common radiographic techniques. In a 
series of 21 women, 14 with breast carcinoma and seven with benign breast tumors, seven of 
nine ER-positive (> 10 fmol/mg tissue) tumors were visualized using 16α-123-iodoestradiol-
17β, whereas all 12 ER-negative tumors (seven of which had benign disease) were not (10). 
In 42 patients of 62 patients with known ER status, an overall sensitivity of 66% (20 of 30) 
and specificity of 92% (11 of 12) was found by Scheidhauer et al. in a multicenter study using 
16α-123 iodoestradiol-17β.  In a series of 29 women undergoing diagnosis for primary or 
recurrent breast carcinoma, using 16α-123 iodoestradiol-17β, Kenady et al. found that 
scintigraphic detection was most noteworthy in patients with chest wall tumors and 
inflammatory breast cancer (12). Data on the sensitivity and specificity when compared with 
ER status in this series, however, are lacking.   
Mintun et al. found a correlation of 0.96 (P <.001) between 18-fluorine-fluoroestradiol (18F-
FES) uptake values, expressed as percentage of injected dose (ID)/ ml x 10-4, and ER 
concentration (in femtomoles per milligram protein) of breast tumor specimen obtained from 
nine patients with primary breast carcinoma (13). This high correlation, however, is likely an 
overestimation because the linear regression line in this series is fully determined by the two 
patients with the highest ER concentration. In a subsequent study by the same group on 16 
patients with clinical or radiographic evidence of metastatic disease, metastatic lesions within 
the regions imaged on PET studies were identified by other imaging studies in 14 of 16 
patients (14). The pretherapy PET images with FES demonstrated accumulation of the 
radiopharmaceutical in the lesion or lesions of 11 of these 14 patients (79%) and in 53 of 57 
lesions (93%). In vivo regional uptake values expressed as percentage ID per milliliter, 
however, were not systematically available. On the basis of the available data in a small 
subgroup of seven patients, the correlation between pretherapy percentage ID per milliliter 
uptake versus ER status (r=0.36; P=.43) was much poorer when compared with the initial 
results presented by Mintun et al in primary tumors. Dehdashti et al  in a series of 53 patients 
(32 patients with primary breast tumors and 21 with clinical or radiologic evidence of distant 
metastases or disease recurrence) found a good overall agreement 88% (35 of 40) between in 
vitro ER assays and FES-PET percentage ID per milliliter (15). Of interest, all five patients 
for whom results did not agree were positive on in vitro ER status but negative on FES-PET 
(standardized uptake value [SUV] < 1.0). Only one of these patients was treated with 
hormonal therapy and she did not respond. 
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Mortimer et al. assessed the value of FES in women with breast cancer for predicting 
response to systemic therapy (16). Results of FES-PET were related to ER status. Cancers 
were considered functionally hormone sensitive if the SUV of the lesion on FES-PET was > 
1.0 and were considered hormone resistant if FES SUV was less than 1.0. In this series, all 20 
ER-negative tumors were also FES-negative. However, of the 21 ER-positive tumors, 16 were 
FES-positive and five were FES-negative. Thirteen patients were treated with hormone 
therapy, and eight (61%) responded to that therapy. Only one of five patients whose tumors 
were ER-positive but FES-negative received hormone therapy, and this treatment resulted in 
disease stabilization only. When compared with the in vitro assays of ER status, FES-PET had 
a sensitivity of 76 % and specificity of 100 %. More recently, the same group investigated the 
ability of FES-PET to detect hormone-induced changes in tumor metabolism (metabolic flare) 
and changes in available levels of ER, and the potential of FES-PET to predict hormonal 
responsiveness of breast cancer. Forty women with biopsy-proved advanced ER-positive 
breast cancer underwent FES-PET before and 7 to 10 days after initiation of tamoxifen 
therapy and results were correlated with response to hormonal treatment. Lesions of 
responders had higher baseline FES uptake (SUV, 4.4 + 2.4) than those of nonresponders 
(SUV, 1.8 + 1.3; P = .0007), and the degree of ER blockade was greater in the responders 
(mean percentage decrease, 54.8% + 14.2%) than in the nonresponders (mean percentage 
decrease, 19.4% + 17.3%; P = .0003) (17). Mankoff et al. examined the heterogeneity of ER 
expression in 27 patients with metastatic breast cancer from ER-positive primary tumors 
using dynamic FES-PET. One of 18 patients without prior hormonal therapy and two of nine 
patients with prior therapy had one or more ER-negative sites of disease (18).  
123I-labeled cis-methoxy-iodovinylestradiol (123
Rijks et al. reported on their results obtained using 
I-cis-MIVE) was injected into 19 women, 
eight of whom were referred for initial evaluation of breast cancer and 11 of whom were 
referred for postoperative follow-up (19). Nine of the latter patients had bone metastases. The 
primary tumor (size, 8 to 10 mm) was visualized in two of four patients with high ER 
concentration (162 to 455 fmol/mg) and was not detectable in four patients with low ER 
concentration (6 to 32 fmol/mg). Axillary lymph node metastases were detected in two 
patients and bone metastases were detected in four of 10 patients with metastasized disease. 
123I-cis-MIVE in 25 patients, 12 with 
primary breast cancer and 13 with metastasis evident from other imaging modalities (20). 
Planar imaging showed uptake in 11 of 12 primary carcinomas and in nine of 13 patients with 
metastasized disease. ER immunohistochemistry data available in 10 of 12 primary and 11 of 
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13 patients with metastasized disease were concordant with 123
Authors 
I-cis-MIVE imaging in all 10 
primary and in 10 of 11 patients with metastasized disease. 
Tracer Nb 
patients 
M0/M+ ER status 
assessment 
cut-off for 
ER-positivity 
McElvany et al., 1982 
Preston et al., 1990 
Schober et al., 1990 
Scheidhauer et al., 1991 
Kenady et al., 1993 
Mintun et al., 1988 
McGuire et al., 1991 
Dehdashti et al., 1995 
Mortimer et al., 1996 
Mankoff et al., 2000 
Mortimer et al., 2001 
Ribeiro-Barras et al., 1992 
Rijks et al., 1997 
Nachar et al., 1999 
Bennink et al., 2001 
Bennink et al., 2004 
BES 
IES 
IES 
IES 
IES 
FES 
FES 
FES 
FES 
FES 
FES 
cis-MIVE 
cis-MIVE 
cis-MIVE 
cis-MIVE 
cis-MIVE 
8 
28 
14 
30 
29 
13 
16 
53 
43 
27 
40 
19 
25 
10 
22 
23 
4/4 
NA 
NA 
19/11 
NA 
13/0 
3/13 
32/21 
26/17 
0/27 
19/21 
10/9 
12/13 
10/0 
22/0 
0/23 
LBA 
NA 
LBA 
LBA 
LBA 
LBA 
LBA 
LBA 
LBA 
IHC 
IHC 
LBA 
IHC 
LBA 
IHC 
IHC 
> 10 
NA 
> 10 
> 10 
> 3 
> 3 
> 3 
> 3 
> 3 
-/+ 
-/+ 
> 6 
-/+ 
> 9 
-/+ 
-/+ 
Abbreviations: ER, estrogen receptor; BES, 1677 -bromoestradiol; LBA, ligand binding assay (units are in 
femtomoles per milligram cytosol protein); IES, 16α-123-iodoestradiol-17β; NA, not available; IHC, 
immunohistochemistry; FES, 16α-18-fluoroestradiol; MIVE, methoxy-123-iodovynilestradiol; M0, 
nonmetastasised; M+, metastasized; -, negative staining; +, positive staining. 
Table 1. Methodologic and population characteristics of available data on radiolabeled estradiol 
derivative imaging in patients with breast carcinoma. 
 
In a series of 13 patients studied by Nachar et al and referred for 123I-cis-MIVE scintigraphy 
because of abnormal mammography or a suspected mass at physical examination, five of 10 
histologically proven breast carcinoma showed specific tracer uptake. In eight breast 
carcinoma patients a good agreement with in vitro ER determination was found whereas in 
two patients scan results were false-positive (21). Bennink et al compared 123I-cis-MIVE 
scintigraphy with immunohistologic staining for determination of ER status in 22 patients 
with primary palpable breast cancer. Staining was positive in 18 patients and 123I-cis-MIVE 
scintigraphy was concordantly positive in 17 patients with planar imaging and in 18 patients 
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with SPECT imaging, resulting in sensitivities of 94% and 100%, respectively. The 
correlation between immunohistologic and planar scintigraphic scores of ER status was 0.72 
(P<.01) (22). The same group studied the ability of  123I-cis-MIVE scintigraphy to predict 
response or resistance to antiestrogen therapy in patients with metastatic ER-positive breast 
carcinoma. They included 23 patients with a positive 123I-cis-MIVE scan and repeated 
scintigraphy 4 weeks after initiation of tamoxifen therapy. Seventeen of 21 patients with clear 
uptake on baseline scintigraphy showed complete blockade of ER activity on 123
Radiolabeled estradiol derivatives: Pre- and post-treatment imaging. Tamoxifen treatment 
results in a decrease of absolute and free or bioavailable plasma estradiol as well as in an 
increase in blood protein-bound estradiol, resulting in a reduction of cellular uptake and 
membrane sequestration (24-26). In addition, tamoxifen decreases intra-tumoral estradiol 
synthesis resulting in a higher occupation of ERs by tamoxifen and consequently a reduced 
bioavailability to the free fraction of estradiol (27-29). This should result in a decrease of 
radiolabeled estradiol uptake after effective tamoxifen treatment that can be visualized by 
sequential imaging, before and as early as 3 to 4 weeks after treatment initiation. In turn, 
sequential imaging could thus allow prediction of response to antiestrogen treatment with a 
higher accuracy than that of single radiolabeled estradiol derivative imaging or ER 
measurements, as recently suggested using sequential 
I-cis-MIVE 
scintigraphy and four showed mixed or no blockade. All patients with clear baseline uptake 
and complete ER blockade after tamoxifen had a significantly longer progression-free 
survival (14.4 months v 1.8 months; P<.01) (23). 
18
FES and 11β-methoxy-
F- 
123I-vinylestradiol (123
Radiolabeled tamoxifen derivatives. To avoid the need for two scanning episodes to rapidly 
monitor or predict response to tamoxifen treatment, as is the case with 
I-z-MIVE) imaging in a small series of 11 and 
23 patients, respectively, in whom tamoxifen treatment was initiated. In the latter series the 
accuracy for prediction of response to tamoxifen treatment was 100% (30;31). 
18F-FES and 123I-z-
MIVE, a number of authors have focused on the development of radiolabeled tamoxifen 
derivatives. Because tamoxifen has several other cellular antiproliferative effects including 
inhibiting the intracellular signal transducer protein kinase C, binding to membranous 
calmodulin, and inducing functional uncoupling of breast tumor cell insulin-like growth 
factor-1 (IGF-1) receptors, measuring tumor uptake of radiolabeled tamoxifen could provide 
more accurate information about the effect of antiestrogen therapy when compared with 
radiolabeled estradiol derivatives (32-34). In addition, in vivo imaging of radiolabeled 
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tamoxifen tumor uptake, retention, and eventually efflux not only could help to increase our 
understanding of the action of tamoxifen, it also could help to increase our knowledge of the 
mechanisms involved in resistance to the drug. This in turn could provide new targets for the 
design of therapeutic agents that can both effectively antagonize ER-dependent pathways and 
circumvent or prevent the emergence of inevitable resistance to the drug in vivo. To date, 
tamoxifen has been labeled with 18F, 123I and, after borohydride coupling with 
diethylenetriamine pentaacetic acid (DTPA), also with 111
In contrast both 
In (35;36). Human breast carcinoma 
xenografts were imaged successfully in rats with the latter agent. However, proof of specific 
receptor interaction of this tamoxifen analog by saturation studies has yet to be established.  
18F and 123I tamoxifen derivatives were shown to specifically interact with the 
ER. In addition, PET using 18F-tamoxifen recently was shown to provide useful information 
in predicting the effect of tamoxifen therapy in patients with recurrent or metastatic ER-
positive breast cancers (37). Those tumors that showed good uptake of radiolabeled tamoxifen 
showed a positive response to tamoxifen therapy. Conversely, the SPECT ligand 123
 
I-
dimethyl-N,N-tamoxifen (ITX) has shown favorable biodistribution and dosimetry 
characteristics in humans and preferential uptake in ER and progesterone receptor (PR) -
positive tumors, which are more likely to respond to antiestrogen treatment (Fig 3) (38;39). 
Additional studies assessing the predictive value of ITX imaging for therapy response 
prediction to tamoxifen are mandatory.  
 
 
 
 
Figure 3. Imaging of breast cancer with trans-(iodine-123) iodomethyl-N,N-diethyltamoxifen (ITX). 
ITX uptake in the primary breast tumor of a 66-year-old patient  with T3N1Mo
 
 breast carcinoma as 
visualized by single-photon emission tomography (transaxial,sagittal and coronal slice) performed 30 
minutes after injection of ITX. Physiological uptake in homolateral and contralateral noninvolved 
breast tissue, as well as persisting (intracardiac) blood pool activity, are also visualized. 
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II. PR IMAGING 
Since the PR is an estrogen response element that is transcribed after effective binding of the 
estradiol-ER complex to DNA in ER-positive, estradiol-responsive breast tumor cells, 
visualization of PR-positive breast tumors by means of PR-specific radioligands may also 
prove valuable for therapy response prediction to antiestrogen treatment. Several PR-specific 
radioligands have been synthesized and validated in animal models. Their potential for PR 
imaging human breast tumors, however, needs to be assessed (40-42). 
 
III. ANDROGEN RECEPTOR IMAGING 
Although androgen receptor (AR) concentrations are not very reliable predictors of prostate 
carcinoma patient response to hormonal therapy, an AR-based radiotracer might be useful for 
imaging the disease to assist in its staging but especially to monitor treatment response 
through sequential imaging. Hormonal therapy of prostate cancer consists of treatment with 
inhibitors of androgen production aiming at a reduction of endogenous androgen levels and 
thus an increase of the number of unoccupied ARs that could be assessed noninvasively by 
means of receptor radiopharmaceutical imaging, thus providing information on treatment 
response.  
Several 18F-labeled androgens have been synthesized and evaluated in estrogen-treated rats, 
which lack the glycoprotein sex hormone-binding globulin (SHBG) that binds androgen with 
high affinity, with promising results (43-45). These include derivatives of testosterone, 
dihydrotestosterone (an in vivo reduction product of testosterone) and miboreline (a synthetic 
androgen). Given that SHBG in prostate model systems significantly affects the metabolism, 
clearance, and distribution of radiolabeled androgens in several tissues, the biodistribution and 
prostate imaging potential of 18F-labeled dihydrotestosterone and miboreline were also 
studied in baboons, which are known to display high levels of circulating SHBG, similar to 
men (46). Prostate uptake was observed with all 18F-androgens studied. The highest levels of 
unmetabolized radioligand in blood up to 45 minutes postinjection and prostate-to-bone ratios 
37-fold greater when compared with those in rats, however, were obtained using a 18
 
F-
miboreline derivative that was selected for additional evaluation in men with prostate cancer. 
To the best of our knowledge no studies were reported with this agent in humans. 
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6. Imaging cell surface receptors 
Cell surface receptor-targeting radiopharmaceuticals developed for imaging human 
malignancies target either proteins formed of a core structure of seven transmembrane α-
helical sequences with intracellular coupling to trimeric G-proteins or G-protein coupled 
receptors (GPCR’s) (Fig 4); or target large glycoproteins that generally possess a single 
transmembrane sequence and tyrosine kinase activity grouped into four families (Fig 5). The 
families are grouped on the basis of sequence homology of their kinase domains, their 
structure, and the structural similarity of their ligands, the tyrosine kinase receptors (TKRs).  
 
 
 
 
 
 
 
 
 
 
E1-E4, extracellular loops; H1-H7, transmembrane domains; C1-C3, cytosolic loops GDP, guanosine 
diphosphate; GTP, guanosine triphosphate. 
Figure 4. Schematic diagram of the general structure of G-protein–coupled receptors. All receptors of 
this type contain seven transmembrane α-helical regions. Loop C3 and in some cases C2 are important 
for interactions with the coupled G-protein. Agonist binding results in a conformational change of the 
cytosolic portion of the molecule, permitting binding of G-protein complex consisting of 3 subunits 
termed alpha, beta and gamma.  
 
The final common pathway for most of these receptor systems is activation of a kinase 
cascade culminating in activation of extracellular signal-regulated kinase (ERK). This serine 
plus threonine kinase translocates into the cell nucleus where it propagates the mitogenic 
signal by phosphorylating and activating appropriate transcription factors to induce the 
expression of genes necessary for initiating the cell division cycle. Cell surface growth factor 
receptor-targeting radiopharmaceuticals developed to date are predominantly radiolabeled 
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peptides and to a lesser degree radiolabeled monoclonal antibodies or fragments of 
monoclonal antibodies. This is not surprising because the slow blood clearance and low tumor 
targeting of the latter, related to their high molecular weight, often results in suboptimal 
tumor-to-background ratios (47). Conversely, peptides bearing specific receptor recognition 
units exhibit more favorable pharmacokinetic characteristics, such as rapid uptake by target 
tissue and rapid blood clearance (48). However, their short biological plasma half-life, caused 
by rapid proteolytic cleavage, may prove to be a major obstacle because peptides may not live 
long enough to reach their intended target. Thus, peptides may need to be metabolically 
stabilized for imaging purposes. This can be achieved by introducing molecular modifications 
such as substitution of D-amino acids for L-amino acids, incorporation of amino-alcohols, or 
insertion of unusual amino acids or side chains (49). After binding to their receptor, 
radiolabeled agonist peptides are rapidly internalized and digested by intralysosomal 
proteolytic enzymes. In the case of 123I-labeled peptides, the radioactive iodine label usually is 
rapidly released from the tumor cell, compromising sensitivity. In contrast, the use of 
radiometal chelators (eg, DTPA or tetraazacyclododecanetetraacetic acid [DOTA]) or 
conjugated amino acids allowing complexation of 111In or 99mTc as well as the use of 
prosthetic groups such as N- succinimidyl-4-(18F)-fluorobenzoate for incorporation of 18
 
F in 
peptides, results in intralysosomal entrapment of the label and/or transchelation to 
intracellular proteins, enhancing residence time at the target site (50). Accordingly, these 
residual zing labels are preferable to radioiodinated labels (51). 
 
 
 
 
 
 
 
 
 
 
ATP, adenosine triphosphate; ADP, adenosine diphosphate. 
Figure 5. General structure and activation of receptor tyrosine kinases (RTKs). Ligand binding causes 
autophosphorylation of a distinct set of tyrosine residues in the cytosolic domain of the dimer partner.  
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I. IMAGING OF G-PROTEIN–COUPLED RECEPTORS  
Somatostatin receptor(s). Both in vitro and in vivo studies suggest that a wide variety of 
tumors express somatostatin receptors (SSTRs). Of the five different subtypes of SSTRs 
known to date, subtypes 1 and 2 appear to be most prominent in most SSTR-overexpressing 
tumors (52). The latter can be visualized using both 111In- and 99m
In neuroendocrine tumors, despite a high expression of SSTRs on growth hormone producing 
pituitary adenomas, the diagnostic value of 
Tc-radiolabeled octreotide 
analogs. 
111In-DTPA-octreotide (Octreoscan; Mallinckrodt 
Medical, Petten, the Netherlands) SSTR imaging (SSTRI) is limited because other pituitary 
tumors, pituitary metastases from other malignancies, and granulomatous diseases of the 
pituitary may also be positive (53). For the purpose of visualizing gastrinomas, 111In-DTPA-
octreotide scintigraphy is as sensitive as other imaging techniques combined, including 
angiography and ultrasonography; however, it is simpler to perform and more cost effective 
(54). Results of SSTRI in large cohorts of gastrinoma patients caused physicians to alter 
patient management in up to 25% to 50% of patients. In insulinoma patients, on the other 
hand, results obtained by SSTRI are poor (55-57). In carcinoid tumors, 111In-DTPA-octreotide 
scintigraphy identifies 80% to 100% of known localizations as well as unexpected tumor 
sites, not suspected with conventional imaging (Fig 6) (58). In these patients, SSTRI could be 
used to select patients who are more likely to respond to octreotide treatment (SSTR-positive 
patients) or more likely to benefit from chemotherapy (SSTR-negative patients) (59).  
 
Figure 6. 111
 
In-DTPA-octreotide scan (planar and SPECT) in carcinoid tumor. The planar octreotide 
image (A) demonstrates multiple areas of abnormal tracer uptake within the liver which is massively 
enlarged in a patient with metastatic carcinoid to the liver. Transaxial SPECT (B) and CT (C) slices 
show multiple liver lesions on corresponding sites. 
 
A B C 
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In paraganglioma, the documented potential of 111In-DTPA-octreotide scintigraphy to 
visualize multicentricity and distant metastases, occurring in up to 10% of patients, suggests 
SSTRI could be used as a screening test, to be followed by morphological imaging (60;61). 
Early studies in small-cell lung cancer (SCLC), performed using 111In-DTPA-octreotide, were 
encouraging, and SCLC tumors and metastases were detected in 86% to 100% of patients 
(62). However, more recent studies were disappointing, suggesting that 111In-DTPA-
octreotide scintigraphy misses a large number of metastases and primary tumors (63;64). 
Nevertheless, it seems that 111
Finally, results obtained with the PET tracer gallium-86-DOTA-Tyr-octreotide (
In-DTPA-octreotide scintigraphy might have some specific 
value in the detection of brain involvement in patients with limited disease (65;66).  
68Ga-DOTA-
TOC) in patients with neuroendocrine tumors proved promising, with high tumor-to-
nontumor contrast and higher detection rates when compared with 111
The 
In-DTPA-octreotide 
(67;68) 
99mTc-labeled octreotide analog depreotide (NeoTect; Diatide Inc, Londonderry, NH), a 
10–amino acid peptide with affinity for SSTR2, SSTR3 and SSTR5 was successfully used to 
characterize malignancy in solitary pulmonary nodules, including SCLC (Fig 7) (69). 
Conversely, the detection rate of 99mTc-depreotide scintigraphy was lower than that of 111In-
DTPA-octreotide scintigraphy in patients with endocrine tumors (70). Another 99mTc-labeled 
octreotide derivative, ethylenediamine N,N-diacetic acid/hydrazinonicotinic acid–Tyr-
octreotide (99mTc-EDDA/HYNIC-TOC), exhibited similar capacity for differentiation 
between benign and malignant solitary pulmonary nodules as 99mTc-depreotide, and overall 
had a higher sensitivity for the localization of SSTR-expressing tumors compared with 111
In other tumors, such as in non-Hodgkin’s lymphoma, a substantial number of lesions are not 
visualized and uptake is low when compared with neuroendocrine tumors; the role of 
In-
DTPA-octreotide (71;72).  
111In-
DTPA-octreotide scintigraphy in this patient population is limited (73;74). In contrast, the 
sensitivity of SSTRI for detection of Hodgkin’s lymphoma lesions is higher than that of 
conventional imaging, resulting in a clinical stage upgrading in up to 30% of patients. 
Therefore, 111In-DTPA-octreotide scintigraphy may be useful in the clinical staging and 
management of patients with Hodgkin’s disease (75;76). Although the majority of well-
differentiated astrocytomas are SSTR-positive as compared with undifferentiated 
glioblastomas, the prerequisite of a locally open blood-brain barrier, often unperturbed in low-
grade astrocytomas, limits the role of SSTRI for the grading of glia-derived tumors (77;78).  
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Finally, data on SSTRI in patients suffering from breast carcinoma are limited and additional 
studies are needed to define its potential in this patient population (79). 
 
 
 
 
 
 
Figure 7. Technetium-99m (99mTc)-depreotide single-photon emission tomography (SPECT) in non-
small-cell lung cancer (NSCLC) in a 45-year-old male, former smoker (39 pack years). Computed 
tomography for coronary calcium evaluation shows solitary pulmonary nodule in right lower lobe (B). 
99m
 
Tc-depreotide SPECT shows a hot spot at the corresponding site (A, arrow). The patient was 
diagnosed with stage I squamous cell cancer after biopsy and resection. 
Bombesin, gastrin releasing peptide receptor. The main mammalian member of the 
bombesin family of peptides is gastrin-releasing peptide (GRP), a 27–amino acid peptide 
isolated first from porcine antral mucosa (80). Existing experimental evidence supports an 
important role for this peptide in the growth of a variety of cancer tumor cell lines, either in 
vitro or grown in nude mice, through direct interaction with GRP receptors (GRP-Rs) (81-84). 
In human tumors, the role of GRP/GRP-R is less clear. Overexpression of GRP-R when 
compared with normal surrounding noncancerous tissue has been described in SCLC, 
prostate, breast, colorectal and gastric cancer (85-89). In these tumors, stimulation of GRP-R 
may occur through paracrine-produced GRP released by neuroendocrine cells (present in, eg, 
human prostate and lung), particularly because GRP may diffuse several micrometers through 
tissue to exert its effect on nearby cells. Conversely, stimulation of GRP-R may occur through 
tumor-produced and -released GRP. Interestingly, therapeutic interventions targeting the 
GRP/GRP-R system have proven successful in animal models as well as in humans (90-94).  
During the past few years, several radiolabeled GRP analogs with delayed proteolysis have 
been developed for the purpose of GRP-R imaging in vivo (see Table 1). Although of 
potential interest, with the exception of 99mTc-RP527 (an N3S core containing peptide), none 
of these ligands has been studied in humans (95-98).  99mTc-RP527 showed specific tumor 
uptake in four of six breast cancer and one of four prostate carcinoma patients (99). 
A B 
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Cholecystokinin B receptor. Gastrin and cholecystokinin, both found in the brain and the 
intestines, exert their functions through interaction with cholecystokinin B (CCK-B) and 
CCK-A receptors. Autoradiography studies demonstrate that CCK-B/gastrin receptors are 
overexpressed in up to 90% of medullary thyroid cancers (MTC), in approximately 60% of 
SCLC, and to a lesser extent in stromal ovarian tumors, gastrointestinal adenocarcinomas, 
neuroendocrine tumors, and malignant gliomas, which is not so for the CCK-A receptor 
(100;101).  
Several groups have synthesized CCK peptide analogs that can be labeled with radionuclides. 
111In-DOTA-CCK was internalized by CCK-B–receptor-positive CA20948 cells and 
specifically taken up in xenografted CA20948 tumors as well as in stomach tissue (fundic 
mucosa) in Lewis rats (102;103). Behr et al studied 45 metastatic MTC patients, 23 of whom 
had known disease and 22 of whom had occult disease, with 111In-DTPA-D-glutamic acid(1)-
minigastrin (104). Normal uptake was confined essentially to the stomach as a result of CCK-
B–receptor-specific binding and to the kidneys as excretory organs. All tumor manifestations 
known from conventional imaging were visualized as early as 1 hour postinjection, with 
increasing tumor-to-background ratios over time. In 20 of 22 patients with occult disease, at 
least one lesion was identified (patient-based sensitivity, 91%). Among them were local 
recurrences and lymph node, pulmonary, hepatic, splenic and bone marrow metastases. 
Kwekkeboom et al studied the efficacy of an octapeptide 111In-DTPA-CCK analog in seven 
patients with biochemical or radiological evidence of MTC (105). In four of five patients in 
whom serum calcitonin levels were monitored, a significant rise was found after the injection, 
indicating retained biological activity of the radiopeptide. In all patients there was 
visualization of the CCK-B–receptor-positive stomach. In one of two patients with known 
MTC lesions, some of the lesions were visualized. In addition, some lesions were visualized 
in one of five other patients who had elevated serum tumor markers but negative localizing 
studies. The uptake in the presumed tumor sites was low― four-fold lower than after 
injection of 111
Vasoactive Intestinal Peptide receptor. Vasoactif intestinal peptide (VIP), a 28–amino acid 
peptide, has been shown to stimulate growth and proliferation of a wide variety of cancer cell 
lines and human cancers, including tumors of the gastrointestinal tract and lung (amongst 
others) (106-109). Two different types of receptors for VIP have been identified: Vpac1 and 
Vpac2 receptors. Although the majority of tumors express Vpac2 receptors (eg, up to 60% of 
In-DTPA-D-Phe1-octreotide. 
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human non-small-cell lung cancer [NSCLC]), few cancers (mainly tumors of the central 
nervous system) express Vpac1 receptors, which have low affinity for VIP (110;111).  
123I-VIP scintigraphy has been used successfully to image endocrine tumors of the 
gastrointestinal tract, pancreatic cancer, colorectal cancer and liver cancer (112-116). In a 
cohort of carcinoid patients undergoing 123I-VIP imaging, 82% of scans (32 of 38) were 
positive in primary or recurrent tumors, 82% (53 of 65) in patients with metastatic sites, and 
25% (four of 16) were positive in patients with symptoms but otherwise negative work-ups. 
Overall, additional lesions not seen on conventional imaging were noticed in 25% (25 of 103) 
of scans as verified by surgical intervention or long-term follow-up (114). In a group of 60 
pancreatic cancer patients, primary pancreatic tumors were visualized by 123I-VIP in 90% (19 
of 21) patients with disease confined to the pancreas and in 32% (eight of 25) patients with 
both locoregional and disease metastatic to the liver.  The overall sensitivity for primary 
pancreatic adenocarcinoma was 58% (27 of 46 scans). Liver metastases were imaged in 29 of 
32 patients (scan sensitivity, 90%) and abdominal lymph node metastases were imaged in four 
of five patients. In five patients, 123I-VIP scintigraphy indicated the malignant lesion before 
CT (115). Of 80 consecutive patients with histologically verified colorectal cancer, seven of 
eight primary (87%) and 21 of 24 (82%) locally relapsing cancers were imaged with 123I-VIP. 
Negative scans were obtained in all 13 patients in whom the cancer had been curatively 
resected. All patients with lymph node metastases showed positive 123I-VIP scans (four of 
four), and positive scans were obtained in 25 of 28 patients (89%) with liver metastases and in 
two of three patients with lung metastases. In four patients with relapsing cancer, the 123I-VIP 
scan indicated the presence of disease before CT, and in two patients the diagnosis of scar 
tissue instead of a local recurrence of rectal cancer as suggested by CT could be established. 
The authors concluded that 123
To date, there are no reports of the potential of 
I-VIP receptor scanning is a sensitive method for radioimaging 
of colorectal cancer with the potential to provide valuable additional information to 
conventional radiological methods (116).  
123I-VIP to visualize NSCLC. Because of the 
high levels of pulmonary VIP receptor expression and related prominent physiologic lung 
uptake of 123I-VIP, a low sensitivity for the detection of primary and secondary lung lesions is 
to be anticipated. However, a more favorable distribution pattern with low lung uptake in 
humans was recently reported for 99mTc-TP 3654, a VIP modified at the C-terminus (117). 
Initial results of the imaging potential of this radiopharmaceutical are promising and warrant 
additional study. 
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Sigma receptors. To date, two sigma receptor subtypes, type 1 and 2, have been identified. 
Overexpression of both receptor subtypes as compared with normal tissue has been reported 
to occur in a wide variety of neural and non-neural human cancer cell lines as well as human 
tumor biopsy tissue samples (118;119). Although the exact role of both receptors in tumor 
growth needs to be elucidated further, available data suggest that sigma-2 receptors may serve 
as biomarkers of tumor proliferation (120).  
High-affinity sigma receptor radiopharmaceuticals developed for imaging include N-[2-
(1’piperidinyl)ethyl]-3-[123I]iodo-4-methoxybenzamide (P-123IMBA), halogenated 
arylsulfonamides, [18F]N-4’-fluoronezyl-4-(3-bromophenyl)acetamide, and a number of 
99mTc-ethylenediamines (121-127). P-125IMBA demonstrated saturable binding to T47D 
human ductal cells line and in vivo uptake in a rat mammary tumor model (121). Caveliers et 
al. injected 10 patients who had a newly diagnosed breast mass and two control patients with 
148 to 185 MBq P-123
Neurotensin receptor. Several neurotensin analogs, among others with the dimethyl Gly-Ser-
Cys-(Acm)-Gly (RP414) chelating sequence, allowing complexation of 
IMBA and found uptake in eight of 10 masses (122). Control patients 
with benign breast conditions presented a normal scan. The relationship between in vivo 
uptake and sigma receptor status was not established. 
99m
Other receptors. Radiolabeled peptides targeting the melanocortin receptor-1 include the 
melanocyte stimulating hormone analogs 
Tc, have been 
shown to bind to neurotensin receptors with high affinity (128;129). With the exception of the 
RP414-NT(B8-13) analog, which had biologic half-life in human plasma of up to 30 minutes, 
all of these are rapidly degraded in human plasma, limiting their clinical usefulness. Studies 
assessing the imaging potential of RP414-NT(B8-13) are underway.  
99mTc-labeled Ac-Nle-Ala-His-D-Phe-Arg-Cys-Trp-
NH2 and the metal-cyclized 99m
The calcitonin receptor has been targeted using the calcitonin receptor binding peptide P1410, 
which has a four–amino acid chelating sequence that can bind 
Tc-Cys-3,4,10,D-Phe-7)-a-melanocyte stimulating hormone 
(130). These radiopharmaceuticals may prove to be attractive vehicles for the diagnosis and 
treatment monitoring of human malignant melanoma. 
99mTc. This 
radiopharmaceutical was shown to bind to calcitonin receptor expressing T47D and MCF-7 
breast tumor cells, both in vitro and in nude mice xenografts. Tumor-to-muscle and tumor-to-
blood ratios were 4.5 and 5.7 (90 min postinjection), respectively. Additional studies with this 
radiopharmaceutical are awaited (131). 
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II. IMAGING OF TYROSINE-KINASE RECEPTORS  
Epidermal growth factor/epidermal growth factor receptor. The epidermal growth factor 
receptor (EGFR) is frequently overexpressed in NCSLC, bladder, cervical, ovarian, kidney, 
and pancreatic cancers, and occurs with high incidence in squamous cell carcinomas of the 
head and neck (132-137). The predominant mechanism leading to EGFR overexpression is 
EGFR gene amplification, with more than 15 copies per cell reported in certain tumors (138). 
In general, elevated levels of EGFR expression are associated with late stage of disease 
progression and often correlate with high metastatic rate and increased tumor proliferation 
(139;140). Accordingly, an association between the expressions of these molecules and 
shortened survival has been reported in a variety of human malignancies (141-143). Several 
cytostatic molecules, which either target the EGFR or interfere with its signal transduction 
pathway, are currently being studied for their antineoplastic potential (eg, monoclonal 
antibody C225) (144;145). 
Intracutaneous injection of 123I-EGF allowed the visualization of pathologic, but also 
nonpathologic, lymph nodes in patients with cervix carcinoma (146). Direct intravenous 
injection of recombinant 131I-EGF localized to squamous lung cancer efficiently; six of nine 
patients imaged showing positive tumor scans. The best tumor-to-background ratio was 
obtained at 50 to 74 hours (147). 111In-DTPA-EGF was significantly internalized by EGFR 
expressing MDA-MB-468 breast cancer cell lines (1.3x106 EGFRs/cell) but not by MCF-7 
cells (1.5x104
Of the radiolabeled antibodies, 
 EGFRs/cell) (148).  
99mTc-labeled anti-EGF monoclonal antibody was shown to 
visualize NSCLC, breast tumors, and a number of other tumor types with fairly high 
sensitivity (149). Other radiolabeled antibodies that have been validated in vitro and in vivo in 
tumor-xenografted nude mice, include 123I- or 111In-labeled monoclonal antibody 425 and 
111
HER2/Neu receptor. The orphan Her2/Neu receptor (HER2/NeuR) is significantly enhanced 
in several types of human cancers, including breast, ovarian, gastric, lung, bladder, and kidney 
carcinomas (153-158). A number of studies suggest a pivotal role for HER2/NeuR in 
determining the prognosis for individual breast and lung cancer patients (159-162). In 
addition, HER2/NeuR is also a predictive marker for response to hormonal treatment as well 
as to chemotherapy in cancer patients (163). Despite the absence of ligands for HER2/Neu, 
HER2/Neu can be activated in response to EGF and transforming growth factor alpha by 
forming heterodimers with EGFR, resulting in the most potent activation of downstream 
In-DTPA-poly(ethylene glycol) monoclonal antibody 225 (150-152).  
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pathways and cell proliferation (164). Several approaches towards the selective prevention 
and interception of HER2/Neu relevant signaling are being investigated. The most effective 
approach so far reported is the development of the recombinant humanized version of murine 
monoclonal antibody 4D5, better known as trastuzumab (Herceptin; Genentech, San 
Francisco, CA), which is approved by the US Food and Drug Administration. In single-agent 
therapy, up to 15% responses have been reported in HER2/Neu–overexpressing breast 
cancers. In combination with paclitaxel or doxorubicin plus cyclophosphamide, trastuzumab 
was shown to significantly increase response duration, time to progression, and survival in 
first-line metastatic breast cancer patients (165).   
As shown by Behr et al in breast carcinoma patients, pretherapeutic immunoscintigraphy by 
means of 111
IGF-1 receptors. IGF-1 receptors (IGF-1R) are involved in the pathogenesis of a variety of 
human tumors but especially in breast and prostate carcinoma (167;168). IGF-1Rs 
upregulated on epithelial breast tumor cells are stimulated in a paracrine manner IGF release 
from stromal fibroblasts surrounding the normal and malignant epithelium (169). Several 
approaches have been initiated to develop small molecule inhibitors or other strategies to 
interfere with the pathogenic IGF-1R signaling (170;171).  
In-DTPA-trastuzumab holds potential to more accurately predict therapeutic 
efficacy and cardiotoxicity compared with immunohistochemistry (the current basis for 
patient selection). Cardiotoxicity is a well-known adverse effect from trastuzumab therapy 
(166).  
In circulation, IGFs are complexed to a number of different IGF-binding proteins (IGFBPs), 
explaining the high blood pool activity and low tumor-to-background ratios obtained after 
injection of 123I-IGF-1 (172). In contrast,  123
Vascular endothelial growth factor and fibroblast growth factor receptors. Vascular 
endothelial growth factor (VEGF) is one of the main inducers of endothelial cell proliferation 
and permeability of blood vessels through direct binding with VEGF receptor 1 (VEGFR-1) 
and VEGFR-2 (173). Similarly, fibroblast growth factors (FGFs) have been implicated in 
background angiogenesis, although their exact role is less well known. With the aim of 
visualizing ongoing background angiogenesis, VEGF and FGF-1 have both been radiolabeled 
for SPECT imaging. VEGF (165) and VEGF(121) were radiolabeled with 
I-des(1-3)IGF-1, which lacks the N-terminal 
tripeptide Gly-Pro-Glu, does not bind significantly to one of the six known circulating binding 
proteins targeting the IGF-1, and yields more favorable tumor-to-background ratios in tumor 
mice models (unpublished data). 
123I (174). Both 
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bound more specifically to a variety of human tumor cells and tissues as compared with 
normal peripheral-blood cells and adjacent non-neoplastic tissue. In comparison with 123I-
VEGF(121), 123I-VEGF(165) not only bound to a higher number of different tumors but also 
with higher capacity, suggesting 123
Recombinant human FGF-1 was radiolabeled with 
I-VEGF(165) may be a useful tracer for in vivo imaging, 
as recently confirmed in a small series of 18 patients (175).  
99mTc by the HYNIC method (176). The 
radiopharmaceutical retained its representative molecular mass, heparin affinity, cellular 
binding to both low- and high-affinity sites, and mitogenic activity. Gamma camera imaging 
in rats confirmed high liver uptake that was significantly decreased by heparin. Finally, FGF-
2 has been directly targeted using 111
 
In-3H3, a murine monoclonal antibody that recognizes 
FGF-2 (177). This molecule was retained at high levels in tumor tissue expressing FGF-2 but 
not in non-FGF-2– producing tumors. Whether in the long run VEGF or FGF receptor 
targeting radioligands will be successful to monitor antiangiogenic treatment is uncertain 
because the detailed angiogenic profile of most human tumors still needs to be established, 
and it is possible that signaling through VEGFRs and FGFRs may be subject to acquired 
resistance mechanisms over time. 
7. General discussion 
Intracellular Receptors 
The tumor’s need of estradiol to bring about a biologic effect is highly variable among 
tumoral and can vary over time within tumors, depending on local environmental conditions 
(178). The local estradiol needs are provided through both uptake and local biosynthesis, 
which in ER-positive tumors are inversely related (179). Thus, a lack of concordance between 
radiolabeled estradiol uptake and ER status, as well as of predictive value of radiolabeled 
estradiol uptake for tamoxifen therapy response, may be anticipated. Currently, available data 
on imaging of radiolabeled estradiol derivative uptake in human breast carcinoma for 
measuring ER status in vivo are limited to halogenated estradiol-17β and vynilestradiol 
derivatives (8-23). Because of the use of different methodologies and cutoff values for 
measuring ER positivity, the use of both quantitative PET and semiquantitative SPECT, and 
the difference in patient populations studied, direct comparison of these data is not possible. 
Individual data, however, fail to substantiate a direct relationship between estradiol receptor 
radioligand uptake and ER status, in keeping with pathophysiologic findings. 
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Most of the hormonal treatment strategies targeting the ER pathway result in a decrease of 
absolute and free or bioavailable plasma estradiol as well as in an increase in steroid-binding-
protein–bound estradiol, resulting in a reduction of cellular uptake and membrane 
sequestration (24-26;180).  
In addition, blocking agents such as antiestrogens decrease intratumoral estradiol synthesis, 
resulting in a higher occupation of ERs by the antiestrogen itself, and consequently, a reduced 
availability to the already reduced available free fraction of estradiol (27-29). Theoretically, 
this should also result in a decreased uptake of radiolabeled estradiol derivatives after 
tamoxifen treatment initiation when compared with baseline uptake. Available data, although 
limited, support the usefulness of sequential radiolabeled estradiol derivative imaging for the 
purpose of predicting response to treatment as early as 1 week after treatment initiation, in 
keeping with pathophysiologic data (30;31).  
Reported intratumoral levels of tamoxifen and its metabolites after steady-state are five- to 
seven-fold greater when compared with serum or plasma levels, suggesting accumulation 
against a concentration gradient (181;182). In patients treated for less than 2 weeks with 
tamoxifen 30 mg/d, a significant difference in the intratumoral tamoxifen concentration 
between ER-positive and ER-negative tumors was observed (450.1 ± 75.3 and 120.9 ± 49.9 
ng/g, respectively; P = .04) (183). However, after at least 2 weeks of therapy, approaching 
steady-state conditions, no significant difference was found, with both ER-positive and ER-
negative tumors accumulating high intratumoral concentrations. Thus, both ER-positive and 
ER-negative breast tumors progressively accumulate tamoxifen but ER-positive tumors do so 
much more rapidly. The use of a bolus injection of ITX and consecutive imaging should allow 
for this difference in ER-related uptake kinetics to emerge visually, with higher expected 
uptake values for ER -positive tumors. However, given that the apparent distribution volume 
for tamoxifen is 50 to 60 L/kg, suggesting extensive tissue binding related to its lipophilic 
characteristics, a high background activity may be anticipated (184). In this regard, in a study 
from patients receiving 40 mg/d for at least 30 days (ie, steady-state), tamoxifen and its 
metabolites were found to accumulate in nonmalignant human tissues 10- to 60-fold above 
serum levels expressed as nanograms per gram wet weight tissue to nanograms per milliliter 
serum (185). Despite this drawback, depiction of uptake of 123I- and 18F-labeled tamoxifen 
derivatives in human breast carcinoma has proven feasible, albeit with fairly low tumor-to-
background ratios (37;39). Although uptake of 18F-tamoxifen has been shown to provide 
useful information in predicting the effect of tamoxifen therapy, this was only true in a limited 
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number of patients (37). Larger studies assessing the potential of radiolabeled tamoxifen 
derivatives for predicting response to tamoxifen therapy are mandatory. 
Although more significant correlations with the response to hormonal treatment in clinical 
studies have been observed with PR positivity than with ER positivity, to date, a clinically 
useful PR-targeting radiopharmaceutical is lacking  (40;186). Similarly, attempts to delineate 
the AR in humans also have been less successful than for the ER. A number of derivatives 
have been suggested, but have had only limited evaluation in humans (40;43;46).  
 
Cell Surface Receptors 
The concept that targeting cell surface receptor–expressing tumor cells in vivo by means of a 
radiolabeled ligand is feasible and clinical relevant is now well substantiated. Multiple studies 
have shown that 111In-DTPA-octreotide is an effective imaging agent that can be useful in the 
management of patients with neuroendocrine tumors not only for the detection of occult 
metastases and monitoring therapy, but also for predicting response to therapy with octreotide 
or beta-emitting analogs (eg, yttrium-90-DOTA-Tyr(3)-octreotide) (54, 58-62,65,66,187). As 
compared with 111In-labeled octreotide, the recently developed 99mTc-labeled octreotide 
analogs have several advantages, such as reduced radiation burden, improved availability, and 
improved image quality. Nevertheless, only one analog, 99mTc-depreotide, has become 
commercially available and introduced in clinical practice (67). In the future, both 111In-DTPA 
and 99mTc-labeled octreotide analogs are likely to be replaced by PET analogs such as 68
Aside from SSTRs, a large variety of other cell surface receptors appear to be (over)expressed 
on a multitude of tumor types, and few radiopharmaceuticals targeting these receptors have 
reached the clinical stage and have been tested in phase I or II studies. In a number of clinical 
studies, radiolabeled VIP has shown promising results in imaging a broad variety of cancer 
types (112-117). Behr et al and others have introduced CCK-B receptor–binding peptides for 
imaging of CCK-B receptor–expressing tumors (104,105). Although these 
radiopharmaceuticals may in the future prove relevant in the clinical oncologic practice, at 
this point it is too early to appreciate their clinical potential. 
Ga-
labeled octreotide analog. The higher sensitivity and better resolution of PET allows a more 
straightforward detection of small tumors or tumors bearing only a low density of SSTRs, 
such as breast carcinoma (67;68).  
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In summary, radiolabeled receptor-binding pharmaceuticals allow for noninvasive assessment 
of regional receptor proteomics in vivo by means of nuclear medicine. Information obtained 
by means of these radiopharmaceuticals in oncology patients may prove useful for diagnostic 
purposes and for predicting and monitoring response to anticancer treatment options in the 
future. 
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1. Abstract 
Investigating three somatostatin receptor (SSTR)-positive(+) breast cancer cell lines, Xu et al. 
found a time- and dose-dependent up- or down-regulation of SSTR2 mRNA expression by 
respectively 17β-oestradiol (E2) or the antioestrogen tamoxifen, respectively, in the two 
oestrogen receptor-positive (ER+) cell lines but not in the oestrogen receptor-negative (ER–) 
cell line. This study aimed to confirm the findings of Xu et al. at the protein level by means of 
western blotting and saturation binding studies using 99mTc-depreotide (NeoSpect). The ER+/ 
SSTR+ ZR75-1 and T47D and SSTR+/ER– MDA MB231 breast cancer cell lines were 
exposed to 1 nM E2 or a combination of 1nM E2 plus 100 nM tamoxifen or ICI 182 780 
(Faslodex) for 48 h. Exposed and non-exposed controls were incubated with increasing 
concentrations of 99mTc-depreotide (0.5 nM-15 nM) in the absence and the presence of 20 µM 
of octreotide. Scatchard-Rosenthal plots were derived using commercially available software. 
SSTR subtypes responsible for E2-induced changes in 99mTc-depreotide binding were 
identified by means of western blotting. Mean Kd values  for 99mTc-depreotide were 13 nM, 7 
nM, 4 nM for T47D, ZR75-1 and MDA MB231 cells, respectively. After stimulation with E2, 
the ER+ cell line T47D demonstrated a mean increase of 81 % (P< 0.05) in 99mTc-depreotide 
binding. Adding the partial agonist tamoxifen and full antagonist ICI 182 780 to E2 blocked 
the induced increase in T47D cells, either reducing SSTR expression or restoring it to control 
levels. ZR75-1 cells stimulated with E2 showed a mean decrease in 99mTc-depreotide binding 
of 36% as compared to control cells; this difference, however, proved to be not statistically 
significant. Similarly, Bmax values did not change in ZR75-1 cells exposed to E2 in 
combination with an ER-antagonist as compared to control cells. Finally, no influence of E2 
on 99mTc-depreotide binding was noticed on the ER– cell line MDA MB231. Both SSTR2 and 
SSTR5 were expressed at high levels in T47D cells and ZR75-1 cells. SSTR5 drastically 
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increased in the absence of E2 and was restored to a original detection level after E2
  
 treatment. 
The presented findings support an oestrogen-dependent regulation of SSTR expression in 
breast cancer cell lines. 
1.   Introduction 
Somatostatin (SST), or somatotropin release inhibiting factor (SRIF), is a tetradecapeptide 
originally isolated from the hypothalamus by Brazeau in 1972 and produced by neuro-
endocrine, inflammatory and immune cells. It potently inhibits basal and stimulated secretion 
from a wide variety of endocrine and exocrine cells and functions as a neuromodulator in the 
central nervous system, with effects on locomotor activity and cognitive functions (1,2). 
Somatostatin also exerts an antiproliferative effect on a wide variety of human malignancies. 
Although the mechanism of the antiproliferative effect of long-acting SS-analogues has not 
been well characterized, a prerequisite for SST-induced inhibition of tumour growth is the 
presence of high affinity SST receptors on neoplastic tissues (3-6). 
To date, five different subtypes of SST seven transmembrane-spanning domain G (guanine 
nucleotide binding)-protein-coupled receptors (SSTR1-5, with SSTR2 having two splice 
variant isoforms, respectively SSTR2A-SSTR2B), encoded by separate genes, have been 
identified (3,7-10). 
Somatostatin receptors have been found in a variety of endocrine and non-endocrine tumours  
(5-7).  In  primary breast carcinoma, reported incidences of SSTR expression vary from 46% 
to 98% depending on the methodology used to assess SSTR status (13-16).  The majority of 
primary breast carcinoma express SSTR2 and to a lesser extent SSTR1, 3 and SSTR5 (13, 17-
18). As shown by Reubi and Torhorst in 1989, SSTR-positive (SSTR+) breast tumours are 
also frequently steroid receptor-positive (19). Evidence in favour of an interaction between 
both receptor systems in breast carcinoma was provided more recently in a paper by Xu et 
al.(20). Investigating three SSTR-positive human breast cancer cell lines, these authors found 
a time- and dose-dependent up- or down-regulation of SSTR2 mRNA expression by 17β-
oestradiol (E
On the basis of their structural and pharmacological characteristics,  
SSTRs can be classified into two classes. Class SRIF1 receptors, comprising SSTR2A, 2B, 3 
and 5, have high affinity for octreotide, a synthetic octapeptide analogue. Class SRIF2 
receptors, comprising SSTR1 and 4, have low affinity for octreotide (11,12).  
2) or the antioestrogen tamoxifen, respectively, in the oestrogen receptor-positive 
(ER+) cell lines T47D and ZR75-1 but not in the oestrogen receptor-negative (ER–) cell line 
MDA MB231. This study aimed to confirm the findings of Xu et al. at the protein level by 
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means of western blotting and saturation binding studies using 99m
 
Tc-depreotide (NeoSpect), a 
cyclic decapeptide with high affinity for SSTR2, 3 and 5 (21-23). 
2. Materials and Methods 
Materials 
Reagents were purchased as follows: Media were obtained from Invitrogen, Belgium. Sera 
were obtained from Perbio Science, Belgium. E2
 
 and 4-OH-tamoxifen were purchased from 
Sigma-Aldrich, Belgium. The antioestrogen ICI 182 780 (Faslodex) was purchased from 
Tocris Cookson Ltd (UK). NeoSpect was kindly provided by Nycomed-Amersham, London, 
UK. Antisera against hSSTR1-5 were kindly provided by Dr. C.E. Stidsen, Novo Nordisk, 
Denmark. 
99m
NeoSpect (kit for the preparation of 
Tc-depreotide radiosynthesis  
99mTc-depreotide injection) vials were reconstituted with 
296 MBq 99mTc-pertechnetate. Each vial contained 50 µg depreotide, 5 mg sodium 
glucoheptonate dihydrate, 50 µg stannous chloride dihydrate. All experiments were performed 
within a 5 h-interval after preparation of the kit. Radiochemical purity of 99m
 
Tc-depreotide 
was > 97% in all experiments. 
Cell cultures and exposure experiment 
The ZR75-1 and T47D cell line are ER+ and SSTR+ while the MDA MB231 cell line is ER– 
and SSTR+.  
Cells were grown in either Dulbecco’s Modified Eagle Medium (DMEM) (T47D), RPMI 
1640 Medium (ZR75-1) or Leibovitz’s L15 Medium (MDA MB231), supplemented with 10% 
FBS, 100 IU/ml penicillin/streptomycin solution and 0.14 µg/ml Fungizone in 10% CO2 / 
90% air (DMEM) or 5% CO2 
All three cell lines were exposed to 1 nM E
/ 95% air (RPMI) at 37°C. Before exposure experiments, cells 
were transferred to phenol red-free medium plus 10% charcoal dextran-treated foetal bovine 
serum (CS-FBS) for 48 h to remove endogenous oestrogens. Phenol red, a pH indicator 
present in complete media, exerts a weak estrogenic activity (24).  
2 or a combination of 1 nM E2 plus 100 nM 
tamoxifen or ICI 182 780 (Faslodex) for 48 h. E2 and antioestrogens were added from stocks 
prepared in 100% ethanol. All cells received an equal volume of ethanol 100%. Non-exposed, 
oestrogen-depleted, cells served as controls.  
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Exposed and non-exposed cells were subsequently washed twice with Hanks’ Balanced Salt 
Solution without calcium, magnesium or phenol red (CMF-HBSS) to remove all calcium and 
incubated in CMF-HBSS at 37°C to obtain separate cells. After 30 min, cells were scraped 
and counted to prepare a final solution of 5x105
 
 cells/250µl of buffer solution. 
99m
Saturation studies were performed under steady-state conditions at 4°C to prevent receptor 
internalisation, allowing identification of B
Tc-depreotide binding assay 
max and Kd values. Intact cells obtained as 
described above were incubated with increasing concentrations of 99m
After incubation of cells for 60 min at 4°C, the reaction mixture was diluted 1:2 with assay 
buffer (CMF-HBSS at 4°C) and rapidly centrifuged (4,000 rpm for 5 minutes at 4°C) to 
separate bound from free ligand. The resulting pellet was washed twice with buffer and 
counted in a NaI-gamma counter (Cobra, Packard, USA). 
Tc-depreotide (0.5 nM-
15 nM) in the absence (total binding) and the presence of 20 µM (non-specific binding) of 
octreotide. Although depreotide has a markedly higher binding affinity for SSTR3 than 
octreotide, we used the latter for calculation of non-specific binding in appropriate 
concentrations because of availability reasons (10). 
Specific binding was determined as the difference between total and non-specific binding. 
Scatchard-Rosenthal plots were derived using the commercially available software package 
GraphPad Prism.  
 
Western blotting 
Cells were washed trice with phosphate-buffered saline (PBS) incubated and scraped into lysis 
buffer (PBS, 1% v/v Triton X-100, 1% v/v NP-40, PMSF 0.35 mg/ml of 2 mM, leupeptin 10 
µg/ml, aprotinin 10 µg/ml, NaVO3 1 mM, Na4P2O7
To determine the SSTR subtypes responsible for E
 2.5 mg/ml and NaF 100x 0.1 mM) at 
4°C. After centrifugation at 14,000 rpm for 10 min at 4°C, the supernatant was removed and 
stored at –80°C. Protein concentration was measured using the Lowry assay. 
2
Briefly, 10-20 µg of membrane protein was solubilised in sample buffer (125 mM Tris-HCl, 
12.3% glycerol, 2.3% SDS, 5% β-mercapto ethanol, 0.0125% bromophenol blue, pH 6.8) by 
incubation in a Thermomixer at 95°C for 5 min, centrifuged at room temperature for 10 min 
-induced changes in 99mTc-depreotide 
binding, we measured the subtype-specific SSTR protein amount with western blot under 
similar conditions as the binding assays. Specific receptor proteins were detected using 
subtype-selective antibodies developed by Helboe et al (25). 
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at 14,000 rpm and fractionated on a 10% sodium dodecyl sulfate-polyacrylamide gel (SDS-
PAGE 10%). Electrophoresed proteins were transferred to a nitrocellulose membrane 
(Hybond ECL, Amersham PB, UK). The blot was saturated with 5% defatted dry milk in PBS 
free of calcium and magnesium (PBSD- ) containing 0.5% Tween-20 (buffer A) for 1 h at 
room temperature and reacted with antisera against each of the five somatostatin receptors at 
dilutions 1:500 or 1:1,000 in buffer A for 1 h at room temperature. Membranes were washed 
4x10 min with buffer A, incubated for 45 min at room temperature with horseradish 
peroxidase-conjugated goat anti-rabbit IgG (Amersham Pharmacia Biotech, UK) at 1:4,000, 
and consecutively washed 4x10 min with buffer A and 2x10 min with PBSD-
Estimation of relative molecular size was performed using a broad molecular weight marker 
(45 – 210 kDa). 
+0.5% Tween-
20. Immunoreactive proteins were detected with the enhanced chemiluminescent antibody 
detection system (Amersham PB, UK). Blots were developed on high performance, double-
coated, autoradiography film (Amersham PB, UK). 
As a semi-quantitative control of protein load we used antisera against α-tubulin to confirm 
and normalise the presence of membrane proteins in the samples analysed. All samples 
included in the study had a high abundance of α-tubuline. 
Densitometric analysis of western blot data was performed using software package Image J, 
available at the website of National Institutes of Health, USA (http://rsb.info.nih.gov/ij/). 
 
In vivo study:  patients and gamma camera imaging 
This study was approved by the Medical Ethics Committee of the Ghent University Hospital 
and performed according to Good Clinical Practice. All subjects gave their written informed 
consent prior to participation in the study. Three patients with a diagnosis of advanced breast 
cancer in whom first- or second-line hormonal therapy was going to be initiated were 
included. All patients had histologically proven ER+ tumours. All patients were female and 
had a mean age of 70 years (range 63-71 years). All patients had metastatic disease detected 
by various diagnostic procedures (e.g. bone scan, X-rays, CT, MRI). Patients underwent 
sequential 99mTc-depreotide scintigraphy, before and 3 weeks after initiating hormonal 
treatment. Follow-up data were retrieved from routine clinical evaluation by means of 
physical examination, imaging and blood analysis. Progressive disease was defined as an 
increase in the number of bone lesions and/or an increase in the number and/or size (>20%) of 
liver lesions. Disease status was considered stable in the absence of both progressive disease 
and a serum rise in tumour marker.  
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Planar whole-body imaging was performed 4 h after intravenous injection of 555-740 MBq 
(15-20 mCi) 99m
For quantification of radioactivity uptake after injection of 
Tc-depreotide with a small point source placed between the patient’s feet. The 
distance between the head and the table was kept constant for each patient over sequential 
scans. Images were acquired using a double- or a triple-headed gamma camera (respectively 
Axis and Irix, Marconi, Cleveland, Ohio, USA) equipped with low-energy high-resolution 
parallel-hole collimators. The energy peak was centred at 140 keV with a 15% window. 
Acquisition was performed simultaneously in the anterior and posterior projections with a 
scan speed of 15 cm/min. Matrix size was 128x512 pixels.  
99m
 
Tc-depreotide, regions of 
interest (ROI’s) were drawn over metastatic lesions and the point source. The shapes and sizes 
of the ROI’s, i.e. the number of pixels, were kept constant for the pre- and posttherapy scan. 
Correction for non-specific uptake and for activity in tissue in front of and behind the organ of 
interest was performed by using a region over the lower part of the upper leg. For each ROI, 
the geometric mean, corrected for physical decay, of total anterior and posterior counts was 
calculated. Total injected activity was calculated from the syringe activity pre- and post-
injection measured in an NaI-gammacounter. Uptake in tumor lesions was expressed as % of 
the injected dose. 
Statistical Analysis 
Box and whisker plots were used to define outliers. Comparison of the fits of a one-site 
binding equation with a two-site binding model was performed using an F test. Whether or 
not Bmax values derived from Scatchard-Rosenthal plots were normally distributed was 
assessed using the Kolmogorov-Smirnov test. Differences in Bmax
 
 values between non-
exposed and exposed cells were assessed using ANOVA and post hoc Bonferroni correction. 
The defined level of significance was P<0.05. 
3. Results  
Effect of E2
Results are shown in table 1. Scatchard-Rosenthal plot analysis performed using GraphPad, 
comparing the fits of a one-site binding equation with a two-site binding model using an F 
test, did not provide evidence for multiple classes of binding sites with different affinity for 
 on SSTR binding in human breast cancer cells 
99mTc-depreotide in either of the cell lines studied. Instead, a saturable number of specific 
binding sites for 99mTc-depreotide in all three human breast cancer cell lines with mean Kd 
values of 13 nM, 7 nM, 4 nM for T47D, ZR75-1 and MDA MB231 cells was found.  
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__________________________________________________________ 
           Control  E2  E2+TAM E2
T47D 
+ICI 
No. of exp.      6  6  6  6 
Mean   240  425*   243  271 
SD    29  67  37  32 
ZR75-1   
No. of exp.      8   9  8  7 
Mean   385  192  219  290 
SD   77  34  41  64 
___________________________________________________________ 
Bmax values of control cells and hormonal stimulated cells in fmol/106
*= P<0.05 as defined by ANOVA with post hoc Bonferroni correction  
 cells. 
Table 1. Effect of E2
 
 on SSTR binding in the absence and presence of TAM and ICI 182 780. 
After stimulating cells grown in oestrogen-depleted medium with 1nM E2 for 48 h, the ER+ 
cell line T47D demonstrated a mean increase of 81 % (P< 0.05) in 99mTc-depreotide binding 
(Fig 1.A-C). Adding the partial agonist tamoxifen and full antagonist ICI 182 780 to E2 
blocked the induced increase in T47D cells, either reducing SSTR expression or restoring it to 
control levels. Although ZR75-1 cells stimulated with E2 showed a mean decrease in 99mTc-
depreotide binding of 36% as compared to control cells, this difference proved not to be 
statistically significant, likely owing to the fairly high standard deviations of the data sets (Fig 
1.D-F). Similarly, Bmax values did not change in ZR75-1 cells exposed to E2 in combination 
with an ER antagonist as compared to control cells. Finally, no influence of E2 on 99mTc-
depreotide binding was observed in the ER– cell line MDA MB231 (data not shown).  
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Figure 1. Specific binding of 99mTc-depreotide to oestrogen receptor-positive (ER+) human breast 
cancer cell line T47D (A-C) and ZR75-1 (D-F). Before exposure experiments, cells grown in 
complete serum were transferred to phenol red-free media plus CS-FBS for 48 h to remove 
endogenous oestrogen and then treated (1 nM oestradiol) or not (control) with 1 nM E2 for 48 h. 
Saturation studies were performed in triplicate under steady-state conditions at 4°C. Intact cells were 
incubated with increasing concentrations of 99mTc-depreotide (0.5 nM-15 nM) in the absence (total 
binding) and the presence (20 µM, non-specific binding) of unlabeled octreotide.  The specific binding 
was calculated by subtracting total binding from non-specific binding. Saturation and nonlinear 
regression analyses indicated an increase in specific binding sites for 99mTc-depreotide after oestradiol 
exposure, displaying a Bmax of 240 fmol/106 cells for control cells and a Bmax of 425 fmol/106 cells for 
E2-stimulated cells in T47D cells (A). Adding the antioestrogen tamoxifen (TAM) restored the Bmax to 
243  fmol/106 cells (B). Likewise, adding the full antagonist ICI 182 780 (Faslodex) restored the Bmax 
to 271  fmol/106 cells (C). For ZR75-1 cells, Bmax of 385 fmol/106 cells for control cells decreased to 
192 fmol/106 cells after E2 stimulation (D). Addition of the antioestrogens tamoxifen and ICI 182 780 
restored the Bmax to 219 and 290 fmol/106 
  
cells respectively (E-F). 
Effect of E2
Results of western blotting assays in unexposed cell lines are shown in Table 2. SSTR2 and SSTR5 were the 
predominant isoforms in all three cell lines. Both SSTR2 and SSTR5 were expressed at high levels in 
T47D cells and ZR75-1 cells. In the ZR75-1 cell line, SSTR5 expression was much more 
pronounced than SSTR2 expression, which was not the case for the T47D cell line (Fig 2). 
 on subtype-specific SSTR protein amount 
 
   SSTR1 SSTR2 SSTR3 SSTR4 SSTR5 
T47D       -     ++      +      -    +++ 
ZR75-1      -     ++     (+)      -      (+) 
MDA MB231    -     ++      -      -      - 
Table 2. Pattern of SSTR subtype expression in human breast cancer cell lines.  
 
In both cell lines, SSTR2 protein expression was only moderately influenced by E2 
administration, i.e. a modest increase after E2 treatment and a modest decrease after E2 
removal. In contrast, SSTR5 increased in the absence of E2 and was restored to the original 
detection level after E2 
Culturing ER– MDA MB231 cells in phenol red-free medium plus CS-FBS or E
treatment. Observed changes in protein amount were consistently 
greater in ZR75-1 cells than in T47D cells.  
2 did not 
influence SSTR expression.  
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Figure 2. Western blot analysis for evaluation of SSTR receptor subtype-specific expression in ER+ 
human breast cancer cell lines ZR75-1 and T47D grown in phenol red-free media plus CS-FBS (C) 
and in phenol red-free media plus CS-FBS treated with 1 nM oestradiol for 48 h (E2).  
A Autoradiogram. Molecular weights are comparable to those found by Helboe et al, i.e. SSTR2 
ranging from 71 to 95 kDa, SSTR3 ranging from 65 to 85 kDa, SSTR5 ranging from 52 to 66 kDa 
(31). B Densitometric quantification. 
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Tc-depreotide scintigraphy visualised metastatic lesions in two of the three breast 
cancer patients. The results of radioactivity uptake upon quantification are expressed as % 
injected activity (% IA) and listed in Table 3. Mean clinical follow-up was 20 months (range 
18-22 months). In the first patient, bone metastasis was diagnosed 16 years after treatment of 
the primary tumour. Bone scan revealed extensive lesions in the lumbar and pelvic region, 
A B 
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which were confirmed by conventional imaging (CT and/or MRI). 99mTc-depreotide 
scintigraphy both before and 3 weeks after initiation of treatment with tamoxifen (Nolvadex) 
showed uptake in the known lesions. Uptake in all lesions decreased with a mean value of 
56% (range 31-86%) (Fig 3). To date, this patient has had stable disease for more than 22 
months.  
 
Figure 3. Sequential 99m
 
Tc-depreotide scintigraphy of a breast cancer patient (no. 1) with extensive 
bone metastasis in lumbar and pelvic region.  A Pretherapy scan, with visualisation of lumbar lesions 
(L2-5, full arrowhead) and sacro-iliac region on the left (arrow) and right. B Posttherapy scan 3 weeks 
after initiation of hormonal treatment with tamoxifen. There is slightly less intense uptake in  lumbar 
lesions (L2-5, full arrowhead) and sacro-iliac region on the left (arrow) and right as compared with 
the pretherapy scan. 
The second patient had bilateral malignant pleuritis and 99m
anterior 
Tc-depreotide scintigraphy showed 
high activity in both lungs. Tracer uptake in the lungs slightly increased from the pre- to the 
posttherapy scan, by 8% and 1% respectively in the left and right lung. This patient presented 
with progressive disease under hormonal treatment and eventually died. 
posterior posterior anterior 3A 3B 
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Patient 
no. 
Age 
(years) 
Lesions Pretherapy 
scan (%IA) 
Posttherapy 
scan (%IA) 
Change 
in uptake 
(%) 
Length of 
follow-up 
(months) 
Clinical status 
1 
 
 
 
 
 
2 
 
 
3 
63 
 
 
 
 
 
76 
 
 
71 
L2-L5 
SIR left 
SIR right 
Sacrum 
Coxo-femoral 
 
Malignant pleuritis right 
Malignant pleuritis left 
 
Bone lesions 
Malignant pleuritis 
 
0.00037 
0.03141 
0.01342 
0.01927 
0.00217 
 
2.15509 
1.97029 
 
- 
- 
0.00005 
0.01222 
0.00855 
0.00636 
0.00151 
 
2.17826 
2.15063 
 
- 
- 
- 86 
- 61 
- 36 
- 67 
- 31 
 
+ 1 
+ 8 
 
- 
- 
22 
 
 
 
 
 
21 
 
 
18 
Stable disease 
 
 
 
 
 
Progressive disease, 
deceased 
 
Progressive disease 
%IA, % injected activity; SIR, sacro-iliac region 
 
Table 3. Clinical data and radioactivity uptake (expressed as % injected activity) during sequential in vivo 99mTc-depreotide scintigraphy in three breast cancer 
patients.
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Finally, in the third patient, bone lesions were not visualised on 99m
 
Tc-depreotide scintigraphy 
and hence no quantification was possible. This patient had progressive disease during 
hormonal treatment, developed liver metastasis and therefore received chemotherapy. 
4. Discussion 
99mTc-depreotide is a peptide that contains a bioamino-acid active sequence mimetic of native 
somatostatin. It has the molecular formula C65H95N16O12S2 and the structure cyclo-(N-
Me)Phe-Tyr-(D-Trp)-Lys-Val-Hcy(CH2CO-(β-Dap)-Lys-Cys-Lys-NH2), where Hcy is 
homocysteine and Dap is diaminopropionic acid, the bioactive portion being Tyr-D-Tryp-
Lys334-Val (22,23). The in vitro binding properties of 99mTc-depreotide were previously 
characterized by Virgolini et al. (21). Aside from binding with high affinity to many different 
types of primary tumours, including breast carcinoma , 99mTc-depreotide was shown to bind to 
COS7 cells with transfected SSTR subtypes 2, 3 and 5 with median dissociation constant (Kd) 
of 2.5 nM, 1.5 nM and 2nM respectively (ranging from 0.1 to 10 nM). These Kd
In the series presented, physiological concentrations of E
 values are 
comparable to those found in the three breast cancer cell lines under study (range 4-13 nM).  
2 resulted in a statistically significant 
increase in the number of SSTRs at the level of the cell membrane in T47D cells but not in 
ZR75-1 and MDA MB231 cells as evidenced by binding assays. Given the minor increase in 
SSTR2 protein levels as evidenced by western blotting for the T47D cell line, this 
phenomenon is likely attributable to a predominant recycling of receptors from the inner 
towards the outer cell membrane. In the ZR75-1 cells, a mean decrease of the number of cell 
membrane SSTRs after E2 stimulation was observed, which, however, was not statistically 
significant. As shown by western blot analysis, this mean decrease may be explained by a 
drop in the number of SSTR5 receptors. T47D cells also showed a drop in SSTR5 protein 
content, but it was much less pronounced. In T47D cells, the E2 effect was reduced or 
inhibited by the antioestrogens tamoxifen and ICI 182 780; this indicates a requirement for E2 
binding and stimulation of the ER, suggestive of an exclusively E2
Oestrogen-dependent regulation of SSTR expression has been reported previously in pituitary 
cells, prolactinoma cells and MCF-7 human breast cancer cells. Kimura et al. found an 
increase in SSTR2 mRNA and a strong decrease in SSTR5 mRNA after E
-dependent regulation of 
SSTR2 expression. The reduction seen with tamoxifen as compared to the inhibition seen 
with ICI 182 780 may be explained by the partial and full antagonist character of the 
respective molecules.  
2 treatment in 
pituitary cells of ovariectomised rats. Examination of the competition curves of 125I-SRIF 
  68 
 
binding showed that pituitary membrane receptors from ovariectomised rats and E2-treated 
rats displayed similar binding properties characteristic for SSTR2 and SSTR5 (26). 
Djordejevic et al. treated rat pituitary cells with E2 for 4 days in culture and found a selective 
overexpression of SSTR2 and 3 and a decrease in SSTR1 and 5 (27). In the rat pituitary 
CH4C1 cell line, 24-h E2 treatment resulted in an increase in SSTR2 and SSTR3 mRNA but 
also in SSTR1 mRNA (28). Furthermore, Visser-Wisselaar et al. added E2 for 7-14 days to 
7315b rat prolactinoma cells in vitro and found induction of the expression of SSTR2 and 
SSTR3. In their series, administration of the antioestrogen tamoxifen (0.5 µM) decreased 125I-
Tyr3-octreotide binding by 50.5%. Of interest, subcutaneous administration of oestradiol in 
vivo to 7315b tumour-bearing rats produced SSTR2 mRNA expression only (29). So far, an 
oestrogen-responsive element within a SSTR2 promoter region has not been characterised. On 
the human SSTR2 gene, an E2-responsive region has been roughly localised to sequences 
spanning from kilobase pairs (kb) –5.3 to –3.8 with respect to the transcriptional site in front 
of the coding region (30). Finally, E2
The results obtained in T47D cells are concordant with results obtained previously by Xu et 
al. After stimulation of oestrogen-depleted cells with 1 nM E
 was shown to down-regulate SSTR5 in the human 
breast cancer cells MCF-7. In this cell line, the growth-inhibiting effect of Sandostatin 
(octreotide) was observed to be less pronounced in the presence of oestradiol (5).   
2, these authors found a 12-fold 
increase in SSTR2 mRNA in T47D cells that was blocked by addition of the antioestrogens 
tamoxifen or ICI 182 870 (20). Although the difference in the magnitude of the mRNA 
increase as compared with the increase in receptor number on T47D cells might relate to the 
much higher sensitivity of PCR detection, it should be noted that the authors did not perform 
quantitative PCR. On the other hand, in ZR75-1 cells the 48-fold increase in SSTR2 mRNA 
reported by Xu et al. did not coincide with the modest, insignificant increase in SSTR2 
protein content found in the series presented. This dissociation between receptor gene 
transcription and receptor protein translation may be due to an increase in mRNA stability or 
a decrease in the rate of global protein synthesis. Glucocorticoids are known to modulate gene 
expression via an intracellular receptor similar to the oestrogen receptor. Experiments in 
which the half-life of SSTR2 mRNA was measured and nuclear run-on assays suggested that 
the effects of dexamethasone are mainly due to changes in the transcription rate of the gene 
and not to changes in mRNA stability (28). Of interest, Xu et al. did not detect SSTR5 mRNA 
in any of the three breast cancer cell lines grown in complete medium and therefore did not 
further study SSTR5 mRNA regulation by E2. Possibly, the weak oestrogenic activity of 
phenol red, a pH indicator present in complete media, suppresses SSTR5 mRNA to very low, 
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hardly detectable levels (24). Nevertheless, inconsistent expression of somatostatin receptors 
varying with the intensity of growth during different cell cycle phase or in the course of 
consecutive passages of a cell line can not be excluded,  nor can the authenticity of  the cell 
lines used be guaranteed (31). 
As shown by Schaer et al., most human breast carcinomas with octreotide binding sites 
exhibit SSTR2 mRNA whereas in all cases of octreotide-negative tumours, SSTR2 mRNA is 
absent (32). The receptors encoded by the SSTR2 mRNA were proven to be those mainly 
responsible for high 111
Hypothetically, in analogy with the findings in T47D cells, efficient antioestrogen treatment 
of metastasised breast cancer patients may result in down-regulation of SSTR at the cell 
surface level. In an attempt to document this phenomenon, three patients with ER+ breast 
tumours in whom hormonal therapy was going to be initiated underwent sequential 
somatostatin receptor scintigraphy. Pretherapy 
In-DTPA-octreotide uptake in primary breast cancer (18).  
99mTc-depreotide scintigraphy depicted SSTR 
expression of metastatic breast cancer lesions in two of the three patients. SSTR scintigraphy 
performed 3 weeks later, at a time when intra-tumour steady state levels of tamoxifen are 
obtained, revealed substantially lower uptake in the lesions of the patient showing a 
favourable response to hormonal treatment, potentially indicating a down-regulation of SSTR 
expression and hence an efficient blockade of ER function. The non-responding patient 
showing uptake of 99mTc-depreotide in known lesions on the baseline scan exhibited no 
change in tracer uptake on the post-therapeutic scan. Finally, in the patient not showing 99m
In conclusion, the findings presented support an oestrogen-dependent regulation of SSTR 
expression in some breast cancer cell lines. In vivo imaging of this molecular event by means 
of sequential 
Tc-
depreotide uptake prior to treatment and not responding to treatment, it may be hypothesised 
that ER was already non-functional ab initio, as no SSTRs were present. 
99mTc-depreotide or 111
 
In-DTPA-octreotide scintigraphy appears feasible.  
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1. Abstract 
This paper reports on the biodistribution and dosimetry of 99mTc-depreotide in patients. Whole 
body planar images were acquired 30 minutes, 1, 2, 4, 9 and 24 hours after intravenous 
injection of 555-740 MBq 99mTc-depreotide in 5 breast cancer patients. Urine was collected 
up to 24 hours after injection, allowing for a calculation of renal clearance and interpretation 
of whole body clearance. Time activity curves were generated for the thyroid, lungs, liver, 
spleen, kidneys, colon, thoracic vertebrae/sternum, and whole body by fitting the organ-
specific geometric mean counts, obtained from regions of interest (ROIs). The Medical 
Internal Radiation Dose (MIRD) formulation was applied to calculate the absorbed radiation 
dose for various organs. The whole body images show most of the activity distributed in the 
liver, spleen and kidneys. Nearly all excretion of activity occurred by the renal system, and 
hepatobiliary excretion was negligible. Elimination of administered activity occurred 
predominantly through physical decay. The mean cumulative measured urinary excretion at 
24 hours postinjection was 14.0% (standard deviation; 11.8%) of the administered activity. 
The highest absorbed dose was received by the kidneys, thyroid, and spleen. The average 
effective dose was estimated to be 1.15E-02 mSv/MBq (standard deviation; 1.41E-03 
mSv/MBq). The biodistribution of 99m
 
Tc-depreotide demonstrated low lung and myocardial 
uptake allowing early imaging of the supradiaphragmatic region and this with a dosimetry 
favorable for clinical whole body and single photon emission computed tomography (SPECT) 
imaging. 
2. Introduction 
In vivo imaging of somatostatin receptor (SSTR) positive tumors is routinely performed using 
[111In-DTPA-D-Phe1]-octreotide scintigraphy (Octreoscan®) and uptake correlates with 
  75 
expression of SSTR2A and SSTR5 (1;2). However, technetium labeling offers clinical 
advantages when compared to indium labeling, including lower cost, better availability and 
faster tumoral visualization, enabling a 1-day-protocol. The decay characteristics of 
technetium, more adapted to the photon energy detection ability of gamma cameras, together 
with the shorter physical half-life permitting a higher dose administration, result in better 
image quality combined with lower radiation dose. Therefore the technetium-labeled 
somatostatin analog depreotide (P829) was developed (3). Depreotide is a peptide that 
contains a bioamino-acid active sequence mimetic of native somatostatin. Its structure is 
cyclo-(N-Me)Phe-Tyr-(D-Trp)-Lys-Val-Hcy(CH2CO-(β-Dap)-Lys-Cys-Lys-NH2), where 
Hcy is homocysteine and Dap is diaminopropionic acid, the bioactive portion being Tyr-D-
Tryp-Lys334-Val (4;5). The in vitro binding properties of 99mTc-depreotide were previously 
characterized by Virgolini et al (6). Aside from binding with high affinity to many different 
types of primary tumors, including breast carcinoma, 99m
Depreotide (NeoTect®, NeoSpect®) received U.S. Food and Drug Administration (FDA) 
approval for use in the imaging of suspected malignant tumors in the lung. Blum et al. 
conducted the first study in patients with suspicious solitary pulmonary nodules (7). The 
sensitivity and specificity of 
Tc-depreotide was shown to bind to 
COS7 cells with transfected SSTR subtypes 2, 3 and 5 with median dissociation constant (Kd) 
of, respectively, 2.5 nM, 1.5 nM and 2 nM (ranging from 0.1-10 nM). 
99mTc-depreotide single photon emission computed tomography 
(SPECT) were, respectively, 93% and 88% with positive and negative predictive values of, 
respectively, 87% and 93%. A multicenter trial conducted in 19 participating medical centers 
in the United States and Europe, using the same patient population, found a sensitivity and 
specificity of respectively 96.6% and 73.1% (8). These values compare favorably with results 
(e.g., 96% and 74%) obtained by fluorodeoxyglucose-positron emission tomography (FDG-
PET) for solitary pulmonary nodule characterization, as reported by Gould et al. in a recent 
meta-analysis (9). Aside from uptake by solitary pulmonary nodules, 99mTc-depreotide is also 
taken up by breast carcinoma, lymphoma and meningeoma (10-12). Available data on cell 
lines and, to a lesser extent, in patients, suggest a potential role for 99mTc-depreotide as a 
marker of response to hormonal therapy in patients suffering from breast carcinoma. As the 
biodistribution and dosimetry of  99m
 
Tc-depreotide have not been published before, we studied 
both in patients suffering from breast carcinoma (13).   
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3. Patients and Methods 
Radiopharmaceutical synthesis 
NeoSpect was kindly provided by Amersham Health (Little Chalfont, Buckinghamsire, UK). 
NeoSpect vials were reconstituted with 1480-1850 MBq (40-50 mCi) 99mTc-pertechnetate 
diluted with sodium chloride 0.9% w/v solution in a total of 1 mL. Each vial contained 50 µg 
depreotide, 5 mg sodium glucoheptonate dihydrate, 50 µg stannous chloride dihydrate, pH 
7.4. After incubation for 10 minutes in a boiling water bath, the vial was allowed to cool 
down to body temperature (about 15 minutes) at room temperature. Radiochemical purity of 
99m
 
Tc-depreotide, defined by ITLC, was greater than 97%. 
Subjects 
This study was approved by the Medical Ethics Committee of Ghent University Hospital and 
performed according to good clinical practice. All subjects gave their written informed 
consent prior to participation in the study. Five female patients, with a mean age of 58 years 
(range, 52-62 years), were included in the study. All patients had a history of breast cancer. 
All had normal kidney and liver functions based upon physical examination, serum chemical 
analysis and urine analysis. In all of these patients, the injected dose of 99m
 
Tc-depreotide was 
555-740 MBq. Total injected activity was calculated based on the syringe activity pre- and 
postinjection measured in a NaI-gammacounter.  
Imaging 
Subjects were positioned supine with their arms alongside their body and a point source of 3.7 
MBq in a syringe of 5cc placed in a phantom between their feet. Whole body images were 
performed using a double-headed or a triple-headed gamma camera (respectively, Axis and 
Irix, Marconi/Picker, Cleveland, OH), equipped with low-energy high-resolution parallel–
hole collimators. The energy peak was centered at 140 keV with a 15% window. Whole body 
planar images were acquired 30 minutes, 1, 2, 4, 9 and 24 hours postinjection. Acquisition 
was performed simultaneously in anterior and posterior position with a scan speed of 15 
cm/min. Matrix size was 256x1024 pixels. 
 
Urine sampling 
For all subjects, all voided urine from time of injection until 24 hours following injection was 
collected. The subjects were requested to collect urine prior to each emission scan and at 
home ad libitum. For each voidance, the urine was collected in a separate container and the 
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volume and time of voidance recorded. For each voidance time, two 1-mL urine aliquots were 
sampled and radioactivity was counted in a calibrated NaI (Tl) counter (Cobra III, Packards 
Instruments Co., Meriden, CT). The amount of radioactivity in the urine at each voidance 
time was expressed as the  percentage of the injected activity (% IA) of 99m
 
Tc-depreotide. 
Dosimetry 
Image analysis 
For quantification of radioactivity uptake after injection of 99m
 
Tc-depreotide, regions of 
interest (ROIs) over the total body and organs of interest were drawn on the images taken 
after 4 hours and the shapes and sizes (i.e., number of pixels) were kept constant over all 
previous and subsequent images. Correction for nonspecific uptake and for activity in tissue 
in front of and behind the organ of interest was performed by using a region over the lower 
part of the upper leg. For each ROI (i.e., each organ), the geometric mean, corrected for 
physical decay, of total anterior and posterior counts was calculated. Quantification of 
measured activity (from counts to MBq) was performed by means of a point source placed 
between patients’ feet. The total body geometric mean activity (in counts), calculated on the 
first image (30 min p.i.) was considered the total injected activity (in MBq), as no urine was 
excreted prior to the first whole body scan. As such, attenuation correction was taken into 
account when calculating %IA. 
Dosimetric calculations 
For each individual, time activity curves were generated for the thyroid, lungs, liver, spleen, 
kidneys, colon, thoracic vertebrae/sternum and whole body. Using SPSS 10.0 (SPSS Inc., 
Chicago) software, time activity curves were generated for these organs by biexponential and 
monoexponential fits. Urinary bladder residence times were estimated using the dynamic 
bladder model of Cloutier et al. and assuming a voiding interval of 4.8 hours (14). Source 
organ residence times were determined from integration of the time activity curves. Upper 
large intestine (ULI) and lower large intestine (LLI) residence times were calculated from 
colon residence times by multiplication with their respective weight factors (0.57 for ULI and 
0.43 for LLI). Red marrow residence time was calculated from thoracic vertebrae/sternum 
residence time taken into account the distribution of red bone marrow in adults (2.3% for 
sternum and 14.1% for thoracic vertebrae) (15). Residence times were then used to determine 
target organ radiation doses using the Medical Internal Radiation Dose (MIRD) methodology 
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for the nonpregnant adult woman applying the MIRDOSE 3.0 (Michael G. Stabin, Vanderbilt 
University, Nashville) software package (16-18). 
 
4. Results 
After injection of 555-740 MBq 99mTc-depreotide, no adverse or subjective side-effects were 
noticed in any of the subjects. Anterior whole body images of a female subject showing the 
biodistribution of radioactivity upon injection of 99m
Averaged ROI data over all subjects, expressed as % IA, of 
Tc-depreotide at different time points 
postinjection are presented in Figure 1. The whole body images obtained between 30 min and 
24 hours p.i. show most of the activity distributed in the liver, spleen, and kidneys. In 
addition, uptake in lungs, colon, bone marrow and bucco-pharyringeal mucosa was noticed. 
Uptake in brain and myocardium was low. Of interest, only in 1 patient was gallbladder 
activity visualized on the first images acquired. Although of low quality because of low 
counting statistics, images at 24 hours p.i. showed most of the remaining activity distributed 
in the kidneys and liver. 
99m
Averaged residence times calculated from individual time activity curves are listed in Table 1. 
For subject number 2, residence times for the lungs and sternum/thoracic vertebrae were not 
measured, as she suffered, respectively, from pleural effusion and bone metastasis in that 
particular region.  
Tc-depreotide in the total body 
and in various organs at the different points in time, are presented in Figure 2. At the moment 
of scintigraphy, 3 patients suffered from bone metastasis, whereas active disease was absent 
in the other 2 patients. The clearance curves from whole body and individual organs of 
patients presenting with active disease or of patients in whom active disease could not be 
substantiated, however, proved similar . 
Clearance from radioactivity from whole body and individual organs, except for the kidneys 
and colon, fitted a biexponential curve. The mean calculated effective whole body half-life 
was 2.3 hours (first exponent) for 14.3% IA and 6.1 hours (second exponent) for 93.6% IA, 
indicating a predominant elimination of administered activity through physical decay. Of 
interest, tracer uptake in metastatic bone lesions augmented up to 2-4 hours and remained 
stable without biological clearance. Nearly all excretion of activity occurred by the renal 
system; hepatobiliary excretion was negligible. The mean cumulative measured urinary 
excretion at 24 hours postinjection was 14.0% (standard deviation, 11.8%) of the 
administered activity (Fig. 3). The residence time was highest for the remainder of the body in 
all subjects, followed by the kidneys and the liver (Table 1).  
  
 
 
 
Figure 1. The anterior whole body images obtained at (from left to right) 30 minutes, 1, 2, 4, 9 and 24 hours postinjection. 
  
Organ Subject 
 1 2 3 4 5 Mean SD 
Thyroid 
Lungs 
Liver 
Red marrow 
Spleen 
ULI 
LLI 
Kidneys 
Urinary bladder contents 
Remainder 
0.0487 
0.5109 
0.7687 
0.6190 
0.2247 
0.2527 
0.1907 
1.1378 
0.0140 
4.5413 
0.0251 
ND* 
0.9529 
ND* 
0.2965 
0.1710 
0.1290 
0.6478 
0.1740 
5.9079 
0.0540 
0.3747 
0.5387 
0.9774 
0.1483 
0.2975 
0.2244 
0.8735 
0.0281 
4.7242 
0.0507 
0.3908 
0.4863 
0.6382 
0.1285 
0.1952 
0.1472 
0.8203 
0.0042 
5.2076 
0.0495 
0.5519 
0.7335 
0.9446 
0.1404 
0.2607 
0.1967 
0.6588 
0.0224 
4.3466 
0.0456 
0.4571 
0.6960 
0.7827 
0.1877 
0.2354 
0.1776 
0.8276 
0.0485 
5.0466 
0.0117 
0.0877 
0.1880 
0.1689 
0.0716 
0.0514 
0.0388 
0.1995 
0.0707 
0.6737 
* For subject number 2, residence time for the lungs and sternum/thoracic vertebrae was not measured, as she suffered from pleural effusion and bone metastasis in the 
respective region. 
ND, not done; SD, standard deviation; ULI, upper large intestine; LLI, lower large intestine. 
Table 1. The residence times (in hours) for 99m
 
Tc-depreotide for each source organ.  
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 Figure 2. Time-activity curves for the total body (wb) and various organs, calculated from direct 
measurements of counts in organ-specific regions of interest (ROIs). The data, expressed as % injected 
activity (IA), are averaged over 5 subjects. The error bars represent 1 standard deviation. 
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Figure 3. Mean cumulative urinary excretion measured during the first 24 hours postinjection. 
Physical decay-corrected data are averaged over 5 subjects and expressed in % injected activity (IA). 
Error bars represent 1 standard deviation. 
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The mean radiation dose estimates ( + standard deviation) were calculated for each subject 
independently, and then averaged (Table 2). The dose to the thyroid was fairly high, 
predominantly due to specific tracer uptake. Finally, high uptake resulted in a rather high dose 
to the lungs.  
Target organ Mean SD 
Adrenals 
Brain 
Breasts  
Gallbladder wall 
Lower large intestine wall 
Small intestine 
Stomach 
Upper large intestine wall  
Heart wall 
Kidneys 
Liver 
Lungs  
Muscle 
Ovaries  
Pancreas 
Red marrow 
Bone surfaces 
Skin 
Spleen 
Thymus 
Thyroid 
Urinary bladder wall 
Uterus  
Total body 
Effective dose
9.65E-03 
* 
3.12E-03 
3.20E-03 
9.25E-03 
1.43E-02 
7.67E-03 
6.62E-03 
1.53E-02 
5.89E-03 
5.39E-02 
1.42E-02 
1.01E-02 
4.39E-03 
7.75E-03 
9.08E-03 
8.04E-03 
9.52E-03 
2.66E-03 
2.62E-02 
4.39E-03 
3.34E-02 
7.07E-03 
6.04E-03 
5.39E-03 
1.15E-02 
7.91E-04 
2.20E-04 
6.19E-05 
8.16E-04 
3.04E-03 
5.88E-04 
3.52E-04 
3.03E-03 
1.81E-04 
1.14E-02 
2.77E-03 
2.84E-03 
7.56E-05 
1.03E-03 
6.81E-04 
2.14E-03 
9.27E-04 
1.11E-04 
6.68E-03 
8.68E-05 
7.94E-03 
4.30E-03 
3.29E-04 
1.47E-04 
1.41E-03 
* 
Table 2. Absorbed dose estimates (mGy/MBq) for 
Units of the effective dose are mSv/MBq. SD, standard deviation. 
99m
 
Tc-depreotide. 
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On average, the highest dose was received by the kidneys (mean, 5.39E-02 mGy/MBq; 
standard deviation, 1.14E-02 mGy/MBq) followed by the thyroid (mean, 3.34E-02 
mGy/MBq; standard deviation, 7.94E-03 mGy/MBq) and the spleen (mean, 2.62E-02 
mGy/MBq; standard deviation, 6.68E-03 mGy/MBq). The estimated mean effective dose for 
an adult, calculated using the weighting factors of ICRP publication 60, was 1.15E-02 
mSv/MBq (standard deviation, 1.41E-03 mSv/MBq) (19). 
 
5. Discussion 
Consistent with its safety profile, no adverse or subjective effects were noticed in any of the 
subjects. In phase I-III clinical trials including 909 patients, no serious adverse events were 
reported (20). In 5.4% of all enrolled patients, at least one adverse event occurred
In our study, most of the activity was observed in the liver, spleen, and kidneys. More 
specifically, 1 hour following the administration of 
. The most 
commonly reported adverse events were headache (0.9%), diarrhea (0.7%), nausea (0.7%), 
back pain (0.6%) and dizziness (0.4%). Observed changes in laboratory parameters, e.g., 
alanine aminotransferase (ALT), white blood cell (WBC) count and eosinophil count, 
following administration were transient and clinically insignificant.  
99m
Mild uptake was noted in ribs, sternum, vertebrae, pelvis and proximal femur. This 
phenomenon may be explained by specific binding of 
Tc-depreotide 8.2% of the activity was 
present in the kidneys and 7.6% in the liver. In contrast, in an animal study using tumor-
bearing rats, 30% of the activity was present in the kidneys and less than 5% in the gastro-
intestinal tract on the images at 1 hour (4). These data illustrate the species-specific clearance 
pattern. Although hepatobiliary excretion was negligible, the average activity in the large 
intestine was 4.0% IA 1 hour postinjection. This uptake is likely due to specific binding to 
SSTR2 in intestinal mucosa and lymphoid tissue (21). We found low uptake in the lungs 
representing 6.5% of the total body activity at 1 hour p.i. This is concordant with previous 
publications describing faint uptake in normal lungs (22).  
99m
Finally, absence of penetration through the blood-brain barrier and, hence, lack of tracer 
uptake in the normal brain makes it potentially useful for detection of cerebral metastasis. 
Tc-depreotide to SSTR2-expressing 
cells of the human immune system, such as monocytes, T- and B-lymphocytes, present in red 
bone marrow (21;23;24). Likewise, high uptake in the spleen likely depicts presence of 
SSTR2 on immune cells, as well as on spleen cells. 
As opposed to 99mTc-depreotide, [111In-DTPA-D-Phe]-octreotide exhibits different 
biodistribution and excretion patterns, resulting in absence of uptake in bone marrow, much 
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lower uptake in liver and mainly excretion via kidneys with minor hepatic accumulation and 
minute hepatobiliary excretion (25). Part of these differences may be attributed to the 
different affinity profiles of both tracers, respectively, a high affinity for SSTR2 and SSTR5 
(SSTR2 Kd = 1.5 nM, SSTR3 Kd = 15 nM and SSTR5 Kd = 0.5 nM) of [111In-DTPA-D-Phe]-
octreotide, whereas 99mTc-depreotide exhibits additional high affinity for SSTR3 (SSTR2 Kd 
= 2.5 nM, SSTR3 Kd = 1.5 nM and SSTR5 Kd = 2 nM) (6). The MIRDOSE 3.0 software 
provides a calculation of the effective dose as defined in the ICRP 60 (19). Based on the mean 
effective dose of 1.15E-02 mSv/MBq obtained in this study, patients could easily be 
investigated with 555-740 MBq 99m
The aforementioned mean effective dose for 
Tc-depreotide, allowing both planar and SPECT imaging 
(data not shown). The corresponding effective dose of 6.4-8.5 mSv is somewhat higher than 
the reported average effective dose per patient of 4.6 mSv for nuclear medicine procedures 
worldwide (26). On the other hand, the mean effective dose of 1.15E-02 mSv/MBq is lower 
than the estimated effective dose of 1.60E-02 mSv/MBq reported on the package leaflet (20). 
It is unclear how the latter dose (mean dose ?) was derived. More specifically, the number-, 
gender- of and presence or absence of disease in subjects included is missing on the package 
leaflet. On the other hand, the doses received by the intestines is higher in our study than the 
estimated absorbed radiation dose of 0.5E-02 mSv/MBq for both the small and upper large 
intestine reported on the package leaflet. Theoretically, the higher doses for small and large 
intestines, as found in our series, might relate to the fact that residence times were effectively 
derived from ROI analysis over these organs in our series, which may not have been the case 
in the package leaflet analysis. Lack of data, however, hampers verification of these 
assumptions.   
99mTc-depreotide (6.4-8.5 mSv/555-740 MBq) is 
substantially lower than that of [111In-DTPA-D-Phe]-octreotide (8-16 mSv/111-222 MBq). 
Given the 1% probability for severe hereditary disorders in the offspring per Gy received by 
the ovaries, the associated risk related to injection of 555-740 MBq 99mTc-depreotide is less 
than 1/10,000. This is low when compared to the 1.6% prevalence of naturally occurring 
genetic disorders (ICRP 60). After administration of 555-740 MBq 99m
 
Tc-depreotide, the dose 
to the uterus amounts to 3-4 mGy. In the event of accidental administration to a pregnant 
woman, the risk for teratogenic effects (40%/Sv) in the sensitive period (3-15 weeks 
postconception) is approximately 1/800 - 1/600. 
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6. Conclusion 
In conclusion, the biodistribution of 99m
 
Tc-depreotide demonstrated low lung and myocardial 
uptake, allowing for early imaging of the supradiaphragmatic region and this with a dosimetry 
favorable for clinical whole body and SPECT imaging. 
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1. Abstract 
The purpose of this study was to determine the potential role of 99mTc-depreotide scintigraphy 
for the evaluation of bone metastases compared with 99mTc-methylendiphosphonate (MDP) 
bone scintigraphy and for prediction of treatment response in breast cancer patients in whom 
first- or second-line hormonal therapy was to be initiated. Twelve patients with a diagnosis of 
advanced breast cancer were included. All patients underwent both a bone scan and a 
depreotide scan and at least one other conventional imaging procedure, including plain film 
radiography (n=11), CT (n=6) or MRI (n=5), for confirmation of metastatic disease.  The 
mean time interval between the bone scan and the depreotide scan was 30.6 days. Follow-up 
data were retrieved from routine clinical evaluation by means of physical examination, 
imaging and blood analysis. On patient basis we found a sensitivity, specificity and accuracy 
of, respectively 100%, 50% and 83.3% for bone scan and 62.5%, 100% and 75% for 
depreotide scan in the diagnosis of bone metastasis. In eight patients with available follow-up 
data two patients with a positive depreotide scan remained stable and five of six patients with 
a negative depreotide scan had progressive disease. In this small series of breast cancer 
patients 99mTc-depreotide scintigraphy proves less sensitive but more specific as compared to 
99mTc-MDP bone scintigraphy in measuring the extent of bone metastasis. On the other hand 
99m
 
Tc-depreotide scintigraphy elucidates, noninvasively, tumour characteristics and may be 
indicative for prognosis and response to hormonal treatment 
2. Introduction 
Bone is the most common site of metastatic breast cancer and bone metastases are detected at 
autopsy in as many as 70% of patients with advanced disease [1]. Since its introduction in 
  90 
1971, bone scintigraphy has become the most frequently used nuclear medicine procedure 
worldwide, owing to its high sensitivity for bone pathologies of various origins [2;3]. 
However, the bone scan suffers from lack of specificity. After injection of 99m
Somatostatin receptor (SSTR) expression of 50-80% in primary breast carcinoma has been 
reported, as assessed by autoradiography  [5-7].  The majority of primary breast carcinomas 
express SSTR2A and to a lesser extent SSTR1, 3 and SSTR5 [7-9]. Clinical data assign low 
differentiation grade, slow tumour growth and hence favourable prognosis to patients with 
SSTR-positive breast tumours [6;10]. In vivo visualization of primary and metastatic lesions 
in patients with breast cancer by means of SSTR scintigraphy has been previously described 
[11-13]. Depreotide, a somatostatin (SS) analogue, is a cyclic decapeptide with high affinity 
for SSTR subtypes 2, 3 and 5 [14]. 
Tc-
methylendiphosphonate (MDP), this tracer accumulates at hyperaemic sections and free 
reduced technetium competes with calcium for the binding sites at inorganic bone surfaces, 
preferably at sites of mineralization where small nuclei of calcium phosphate are being 
formed. Subsequently it visualizes osteoblastic bone reaction, in this case, to cancer cells. 
However, tracer accumulation may occur in any skeletal location with an elevated rate of 
bone turnover and thus may also accompany trauma, infection or arthropathy. Moreover, 
many breast cancer patients are likely to be simultaneously affected by degenerative or 
inflammatory bone diseases because of their higher age. The probability that an abnormal 
bone scan represents metastatic disease is directly related to the location and the number of 
abnormal foci. As such, the thoracic spine is a highly probable site and the non-axial skeleton 
is rather infrequently affected, and, for example, a situation showing a few abnormalities in 
the thoracic and lumbar spine carries a 56% positive incidence of metastases, while a solitary 
rib lesion only carries a 6% chance of being a bone metastasis [4].  
The purpose of this study was to determine the potential role of 99mTc-depreotide scintigraphy 
for evaluating bone metastases compared with 99m
 
Tc-MDP bone scintigraphy and for 
predicting treatment response in breast cancer patients in whom first- or second-line hormonal 
therapy was to be initiated. 
3. Patients, Materials and Methods 
Patients 
Between January 2002 and October 2003 12 patients with a diagnosis of advanced breast 
cancer in whom first- or second-line hormonal therapy was to be initiated, were included 
(Table 1). All patients had histologically proven oestrogen receptor-positive (ER+) tumours. 
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All patients were female and had a mean age of 63 years (range, 35-77 years). In all patients 
the diagnosis of advanced breast cancer was based on clinic and divers diagnostic procedures 
(bone scan, X-ray, computed tomography (CT), magnetic resonance imaging (MRI)). All 
patients underwent both bone scan and depreotide scan and at least one other conventional 
imaging procedure, including plain film radiography (n=11), CT (n=6) or MRI (n=5), for 
confirmation of metastatic disease. Median and mean time interval between bone scan and 
depreotide scan were, respectively, 17.5 days and 30.6 days (range, 2-189 days). The patient 
with the interval of 189 days had a negative bone scan 6 months before and 9 months after the 
depreotide scan and was as such considered eligible for inclusion.  
Follow-up data were retrieved from routine clinical evaluation by means of physical 
examination, imaging and blood analysis. Progressive disease was defined as an increase in 
number of bone lesions and/or an increase in number and/or size (>20%) of liver lesions. 
Disease state was considered stable in the absence of both progressive disease and rise of 
tumour marker. Approval for the study was obtained from the local ethics committee and all 
patients give written informed consent before scintigraphy. 
patient age  
(years) 
metastatic site bone 
scan 
depreotide scan 
  bone lesions   other    
follow-up 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
60 
57 
35 
59 
63 
55 
75 
76 
75 
71 
54 
77 
 
bone, liver, pleura 
bone, liver 
bone 
bone 
bone 
bone, liver 
bone 
bone, pleura 
liver 
bone, liver, pleura 
liver  
T4 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
- 
- 
+ 
+ 
+ 
+ 
+ 
- 
- 
- 
- 
- 
- 
- 
pleura 
- 
- 
- 
- 
- 
- 
- 
- 
- 
-  
primary lesion 
- 
- 
- 
- 
stable 
stable 
progressive 
progressive 
progressive after 6m 
progressive 
progressive after 1y 
stable 
 
Table 1. Patient information. 
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Material 
Amerscan (medronate) was purchased from Amersham Health (Little Chalfont, 
Buckinghamsire, UK). Amerscan vials were reconstituted with 11,100 MBq (300mCi) 99m
NeoSpect was kindly provided by Amersham Health (Little Chalfont, Buckinghamsire, UK). 
NeoSpect vials were reconstituted with 1480-1850 MBq (40-50 mCi) 
Tc-
pertechnetate in 8 mL. Each vial contained 6.25 mg sodium medronate, 0.34 mg stannous 
fluoride and 2 mg sodium p-aminobenzoate.    
99mTc-pertechnetate. 
Each vial contained 50 µg depreotide, 5 mg sodium glucoheptonate dihydrate, 50 µg stannous 
chloride dihydrate, pH 7.4. Radiochemical purity of 99m
 
Tc-depreotide was > 90%.  
Imaging 
Planar whole body imaging was performed 3-6h after intravenous injection of 925 MBq (25 
mCi) 99mTc-medronate and 4h after intravenous injection of 555-740 MBq (15-20 mCi) 
99mTc-depreotide. Images were acquired using a double-headed or a triple-headed gamma 
camera (respectively, Axis and Irix, Marconi, Cleveland, Ohio, USA) equipped with low-
energy high-resolution parallel-hole collimators. The energy peak was centred at 140 keV 
with a 15% window. Acquisition was performed simultaneously in the anterior and posterior 
projections with a scan speed of 15 cm·min-1
 
. Matrix size was 128 x 512 pixels.  
4. Results 
The results of the potential of the two modalities in diagnosing bone metastasis are shown in 
Table 2. Most of the patients (10/12) had positive bone scans and hence bone metastasis was 
suspected. The bone scan was true-positive in eight cases and false-positive in two cases. In  
the latter, both patients were classified as having degenerative lesions based on conventional 
imaging and clinical follow-up of more than 1 year.  
 Bone scan Depreotide scan 
Positive scans 8TP/2FP 5TP/0FP 
Pegative scans 2TN/0FN 4TN/3FN 
Sensitivity 100% (8/8) 62.5% (5/8) 
Specificity 50% (2/4) 100% (4/4) 
Accuracy 83.3% (10/12) 75% (9/12) 
TP, true-positive; FP, false-positive; TN, true-negative; FN, false-negative. 
Table 2. Bone scan and depreotide scan results in the diagnosis of bone metastasis. 
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Five patients had a true-positive depreotide scan, whereas in three patients with proved 
metastasis no uptake of depreotide in bony lesions was present. One of these patients had a 
single lesion on bone scan at the lower thoracic spine that was classified as degenerative by 
plain film radiography, but proved to be of metastatic origin during follow-up. Possibly, this 
lesion was masked by liver activity (see below) and was therefore missed on the depreotide 
scan. 
In two patients both the bone scan and depreotide scan were true-negative and bone 
metastasis was excluded by radiography and follow-up.  
Overall in this small series, on patient basis we found a sensitivity, specificity and accuracy of 
respectively 100%, 50% and 83.3% for bone scan and 62.5%, 100% and 75% for depreotide 
scan in the diagnosis of bone metastasis. 
Lesion Bone scan NeoSpect scan 
 TP/FP TP/FP TN/FN 
Vertebrae 
Rib 
Pelvic 
Skull 
Glenohumeral 
Femur 
Acromioclav. 
15 /3 
11/0 
14/1 
2/0 
1/0 
2/0 
0/1 
7/0 
4/0 
12/0 
1/0 
1/0 
1/0 
- 
3/8 
0/7 
1/2 
0/1 
- 
0/1 
1/0 
Total 45/5 26/0 5/19 
TP, true-positive; FP, false-positive; TN, true-negative; FN, false-negative. 
Table 3. Bone scan positive metastatic lesions in patients (5/12) having a positive depreotide scan and 
their respective appearance. 
 
Table 3 summarizes in detail all individual bone scan-positive metastatic lesions in patients 
(5/12) having a positive depreotide scan and compares their respective appearance. Five of 50 
lesions judged positive for metastasis on bone scan were defined as degenerative according to 
CT and/or MRI and were situated in cervical vertebra (n=3), near the coxo-femoral (n=1) or 
acromio-clavicular (n=1) junction. Only 26 of 45 (57.8%) bone scan true-positive lesions 
were concordantly detected on depreotide scan. Overall, lesions were consistently less 
pronounced in the latter due to lower tracer uptake in the lesions and higher background 
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activity in bone marrow (Fig 1). Physiological uptake of depreotide in liver, spleen, intestines, 
kidneys and thyroid hampered visualization of lesions in the respective areas on planar images 
(Fig 2). As such high liver activity masked 11 of the 19 missed lesions, these were situated in 
the lower thoracic vertebra (5/11) or lower ribs (6/11). Likewise detection of three cervical 
spine lesions was hampered by thyroid uptake. Other 5/19 were situated in the upper ribs, 
skull and coxo-femoral region. In addition, increased tracer uptake is noted in the inflamed 
right knee, possibly due to specific binding to activated T-lymphocytes and aspecific 
accumulation in synovial fluid [15]. 
  
Figure 1. A 57-year-old female with both positive bone and depreotide scans. A. Respectively, anterior 
and posterior views of 99mTc-MDP bone scan, showing multiple lesions, amongst others of skull 
(arrow head), shoulder (thin arrow) and pelvic (thick arrow) region. B. Respectively, anterior and 
posterior views of 99m
A 
Tc-depreotide (NeoSpect) scan,  showing lower uptake in the respective 
pathological lesions, amongst others in skull (arrow head), shoulder (thin arrow) and pelvic (thick 
arrow) region. 
B 
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Figure 2. Planar whole body image, respectively anterior (A) and posterior (B) projections, of normal 
biodistribution of 99m
 
Tc-depreotide (NeoSpect), with physiological uptake in thyroid, liver, spleen, 
kidneys, bone marrow. The subject is a 62-year-old healthy female with pain in the right knee. 
Increased tracer uptake is noted in the inflammated right knee due to specific binding to activated T-
lymphocytes and aspecific accumulation in synovial fluid. 
Clinical follow-up of more than 1 year (range, 14-22 months) was obtained in eight patients 
who were progressive and therefore started first- or second-line hormonal treatment at the 
time of depreotide scanning, and in one patient who started with primary palliative hormonal 
treatment. Three patients responded to hormonal treatment and remained stable for, 
respectively, 22, 20 and 15 months up to today whereas five had progressive disease: three 
immediately, one after 6 months and one after 1 year. Of the three responders two had 
positive depreotide scans while no uptake was noted in the five nonresponders. However two 
A B 
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of the latter had only liver metastasis and hence could not be evaluated on depreotide scan due 
to high physiological liver uptake. 
 
5. Discussion 
In the present study we compared the diagnostic accuracy of 99mTc-depreotide scintigraphy 
with 99mTc-MDP bone scintigraphy for evaluating bone metastasis in a small series of breast 
cancer patients. Regarding diagnostic accuracy on a patient basis, bone scan proved superior 
(75% vs 83.3%) due to its higher sensitivity (100% vs 62.5%), whereas specificity was 
significantly higher on NeoSpect scan (100% vs 50%). In fact depreotide is a SS analogue 
that binds specifically to SSTR2, 3 and 5 which are overexpressed in 50-80% of breast 
tumours. In contrast, 99m
In previous studies SSTR scintigraphy using 
Tc-MDP accumulates aspecifically in any skeletal location with an 
elevated rate of bone turnover such as arthropathy, leading in our study to two false-positive 
diagnoses of bony metastasis.  
111In-DTPA-octreotide visualized 61-75% of 
primary breast tumours [11;12]. The sensitivity (62.5%) of 99m
Fourteen of 19 (73.7%) missed individual lesions in patients with positive depreotide scan 
were probably due to masking by organs with high physiological tracer uptake (thyroid, liver, 
spleen, intestines). SPECT imaging, a tomographical technique that provides cross-sectional 
images of tracer distribution and thus has the ability to remove overlying structures which 
may obscure abnormal tracer uptake, can overcome similar problems. An additional 
explanation for the lack of sensitivity of 
Tc-depreotide scintigraphy was 
in accord with the latter findings and in line with expectations based on SSTR expression 
patterns assessed by autoradiography.   
99m
In our series, follow-up data are available in eight patients who had progressive disease and 
therefore started first- or second-line hormonal treatment at the time of depreotide scanning 
and in one patient who started with primary palliative hormonal treatment. Three patients 
responded to hormonal treatment and remained stable whereas five had progressive disease: 
three immediately, one after 6 months and one after 1 year. Both patients with uptake of 
Tc-depreotide in detecting individual lesions lies 
in the heterogenous distribution of SSTR expression in breast tumours. The latter often 
display SSTR only in certain tumour regions, although the whole tumour appears to be 
histopathologically homogenous [16]. This observation supports the idea that some breast 
tumours are composed of numerous different clones with different biological properties. As a 
consequence metastatic lesions originating from an SSTR-negative clone may be SSTR-
negative even though the primary tumour is SSTR-positive.  
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depreotide in, respectively, bony lesions and primary tumour had continuously stable disease 
for, respectively, 20 and 15 months up to today. In six patients without uptake of depreotide 
five eventually had progressive disease. However, two of the latter had only liver metastasis 
and hence could not be evaluated on depreotide scan due to high physiological liver uptake. 
Experimental data suggest that in breast carcinoma the SSTR is an oestrogen response 
element that is upregulated in the presence of oestradiol [17]. As such, SSTR expression or 
inversely depreotide positivity may indicate functionality of the oestradiol receptor, a 
prerequisite for response to hormonal treatment. Accordingly, depreotide scintigraphy may 
have the potential to select patients that are likely to benefit from hormonal treatment. 
In conclusion, in this small series of breast cancer patients 99mTc-depreotide scintigraphy 
proves less sensitive but more specific when compared to 99mTc-MDP bone scintigraphy in 
measuring extent of bone metastasis. On the other hand 99m
 
Tc-depreotide scintigraphy 
elucidates, noninvasively, tumour characteristics and may be indicative for response to 
hormonal treatment. 
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1. Abstract 
In analogy with the oestrogen-dependent regulation of somatostatin receptor (SSTR) 
expression in endocrine-responsive human breast cancer cell lines, efficient antioestrogen 
treatment may result in a downregulation of SSTR at the cell surface in breast tumours. In 
vivo imaging of this molecular event by means of sequential 99mTc-depreotide scintigraphy 
could enable selection of breast cancer patients susceptible for endocrine therapy. Twenty 
patients with a diagnosis of advanced breast cancer in whom first- or second-line hormonal 
therapy was to be initiated, were included. Patients underwent sequential 99mTc-depreotide 
scintigraphy, respectively before and 3 weeks after initiating hormonal treatment. Lesion-to-
background ratio’s (L/BGs)  were calculated on planar and single photon emission computed 
tomography (SPECT) images and a change of > 25% between pre- and posttherapy scan was 
considered significant. At 6 months after initiation of treatment eight patients had stable 
disease and were considered as responding to hormonal treatment, whereas 10 patients had 
progressive disease and were considered nonresponders. All responders had positive scans 
and seven of 10 nonresponders had negative scans. Thus all patients with a negative scan did 
not respond to therapy. Sequential scans were always both positive or both negative. The 
relative change in 99mTc-depreotide uptake between sequential scans significantly differed in 
responders compared to nonresponders (P=.017), uptake decreased in the first group and 
increased in the latter. Sequential 99m
 
Tc-depreotide scintigraphy could allow for separation of 
responders and nonresponders immediately or as early as 3 weeks after treatment initiation.  
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2. Introduction 
Hormone-dependent breast tumours are characterized primarily by a functional and intact 
oestrogen receptor (ER) system. Antioestrogen agents selectively target the ER pathway to 
abolish its effect on cell growth. Since only about one third of breast cancer patients initially 
respond to endocrine therapy, there is a need for patient selection. So far, the only predictive 
factor approved for clinical routine use is the in vitro assessment of hormone receptor status 
on tissue samples by ligand binding assay (LBA) or immunohistochemistry (IHC). Still, only 
50%-60% of patients with ER-positive tumours show response to hormonal therapy, whereas 
lack of detectable ERs is usually associated with 5%-10% response (1,2,3)
Possible causes of discordance between hormone receptor status and endocrine 
responsiveness include limits inherent to the available techniques (IHC, LBA) for hormone 
receptor assessment, such as sampling error and variations in specificity (animal dependent) 
seen with the preparation of antibodies. Scintigraphy could circumvent these inaccuracies and 
moreover offers the advantage of noninvasive and repetitive whole body evaluation.  
.   
Assessment of hormone receptor status is usually based on tissue samples from the primary 
tumour, whilst this information is being utilized years or decades later in the metastatic 
situation, when the biology of the tumour might have changed (4,5,6). Since breast cancer DNA 
is reported to undergo structural modification with progression, the predictive value of the 
hormone receptor status might be limited by its time dependency and decreases about 20% 
per year, losing significance after approximately 8 years (7,8). In addition, breast tumours 
contain multiple cell populations exhibiting a wide range of genetic, biochemical, 
immunological and biological characteristics (9,10). Although the whole tumour appears to be 
histopathologically homogenous, ERs are often displayed only in certain tumour regions 
(11,12). Metastatic lesions originating from an ER-negative clone may be ER-negative 
nevertheless the primary tumour is ER-positive. Scintigraphy has the ability to address the 
intrinsic heterogeneity of tumoural receptor expression without tissue manipulation and 
provides an in vivo image of all disease sites at the moment of treatment need. A lot of efforts 
have been put into synthesis and evaluation of radiopharmaceuticals of which tumoural 
uptake is believed to relate to ER expression and hence endocrine responsiveness, 
nevertheless, no clinically useful tracers are available (13,14)
Another explanation for lack of response to endocrine treatment in ER-positive disease is 
nonfunctioning of the ER. These receptors are recognized and measured by IHC, but in such 
tumours steroid hormone occupancy of the receptor is not the drive for cellular proliferation 
and hence antioestrogen therapy is inefficient. Assessment of an end-product of ER 
. 
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stimulation, such as the progesteron receptor (PgR), could by-pass this problem and has 
proven to increase predictive accuracy (15,16,17). Likewise, experimental data suggest that the 
expression of the somatostatin receptor (SSTR) is mediated by oestrogens (18,19). In human 
endocrine-responsive breast cancer cells oestradiol (E2) stimulation of functional ER results 
in upregulation of SSTR subtype 2 (SSTR2) at the cell surface (Fig 1). Vice versa, blocking 
the ER by means of an antioestrogen leads to a decrease of SSTR expression. About 50%-
75% of breast tumours are SSTR-positive and express predominantly SSTR2 (20,21,22,23). SSTR 
expression is associated with ER-positivity and hormone responsiveness and hence with a 
better clinical prognosis (24,12). Hypothetically, in analogy with the in vitro findings, efficient 
antioestrogen treatment of metastasised breast cancer patients may result in downregulation of 
SSTR at the cell surface level, which could be visualised in vivo using sequential SSTR 
scintigraphy (Fig. 1).  
ER: oestrogen receptor, E2
Figure 1. Mechanism of oestradiol-mediated regulation of somatostatin receptor subtype 2 (SSTR2) 
expression and its in vivo imaging by means of a radiolabelled somatostatin analogue. 
: oestradiol, SSTR2: somatostatin receptor subtype 2 
 
Depreotide (P829 - NeoSpect/NeoTect) is a 99mTc-labelled somatostatin analogue. It is a 
cyclic decapeptide with high affinity for SSTR2, 3 and 5 (25,26,27)
This study was undertaken to evaluate the potential of sequential 
. 
99mTc-depreotide 
scintigraphy to select patients likely to respond to endocrine therapy. 
  103 
3. Patients and Methods 
Patients 
This study was approved by the Medical Ethics Committee of the Ghent University Hospital 
and performed according to Good Clinical Practice. All subjects gave their written informed 
consent prior to participation in the study. Twenty patients suffering from advanced breast 
cancer in whom first- or second-line hormonal therapy was to be initiated, were included. One 
patient received chemotherapy immediately after starting hormonal treatment and in one 
patient endocrine therapy was eventually not initiated, both were excluded. As such 18 
patients were eligible for the study and patient characteristics are summarized in table 1. All 
patients were female and had a mean age of 63 years (range 46-76 years). One patient had a 
first diagnosis of advanced breast cancer and 17 patients suffered progression of previously 
treated breast cancer, all detected by plural diagnostic procedures (e.g., bone scan, CT, MRI, 
ultrasound, X-ray). Time to initial diagnosis in the latter patients was 72 ± 68 months. Patients 
underwent sequential 99mTc-depreotide scintigraphy, respectively before (pretherapy) and 3 
weeks after (posttherapy) initiating hormonal treatment. This timing was chosen since steady-
state intratumoural concentrations of tamoxifen are usually achieved following 2 to 3 weeks 
of daily tamoxifen administration (28). Plasma concentrations of the aromatase inhibitors 
anastrozole and letrozole approach steady-state levels at about 7 days respectively 2 to 6 
weeks of once daily dosing (29,30). Two patients had only a pretherapy scan. Follow-up data 
were retrieved from routine clinical evaluation by means of physical examination, imaging 
(e.g., bone scan, CT, MRI, ultrasound, X-ray) and blood analysis. Response evaluation was 
assessed according to RECIST guidelines (31). Progressive disease was defined as an increase 
in number of nonmeasurable lesions (e.g., bone lesions) and/or an increase in number and/or 
size (>20%) of measurable lesions (e.g., liver lesions). Disease status was considered stable in 
the absence of both progressive disease and a serum rise in tumour marker (32). Since durable 
stable disease appears to be a clinically useful criterium of therapeutic remission, patients 
with stable disease for 6 months or more were considered as responding to hormonal 
treatment (33,34)
 
. Patients suffering disease progression within 6 months were considered 
nonresponders. 
Radiopharmaceutical Synthesis 
NeoSpect kits were kindly provided by Amersham Health (now part of GE Healthcare, 
Little Chalfont, Buckinghamsire, UK) and prepared according to the manufacturers’ 
guidelines. 
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Imaging Studies 
Planar whole body and single photon emission computed tomography (SPECT) imaging was 
performed 4 hours after intravenous injection of 555-740 MBq (15-20 mCi) 99m
For whole body imaging, subjects were positioned supine with their arms alongside their body 
and a point source of 3.7 MBq in a syringe of 5 cc placed in a phantom between their feet. 
Acquisition was performed simultaneously in anterior and posterior position with a scan 
speed of 15 cm/min. Matrix size was 256x1024 pixels.  
Tc-depreotide. 
Total injected activity was calculated based on the syringe activity pre- and postinjection 
measured in a NaI-gamma counter. Images were acquired using a double-headed or a triple-
headed gamma camera (respectively Axis and Irix, Marconi/Picker, Cleveland, Ohio, USA), 
equipped with low-energy high-resolution parallel–hole collimators. The energy peak was 
centered at 140keV with a 15% window.  
For SPECT imaging, patients were positioned supine and at times of imaging of the thoracic 
region, with the arms raised alongside the head. Images were acquired over 15 minutes by 40 
views of 20 seconds per detector with the triple-headed gamma camera and over 23 minutes 
by 60 views of 20 seconds per detector with the dual-headed gamma camera (120 steps; 3° 
per step; matrix size: 128x128). Transversal, coronal and sagittal slices were reconstructed 
iteratively using OSEM (Ordered Subset Expectation Maximization) algorithm with 2 
iterations and 6 subsets and postfiltered using a Butterworth filter (cut-off frequency: 1.2 
cycles/cm, order 5). 
 
Data analysis 
For semiquantification of radioactivity uptake after injection of 99mTc-depreotide, regions of 
interest (ROIs) were drawn over lesions and background on planar scans and SPECT images 
if available. As background, a region over the lower part of the upper leg was chosen on 
planar scans and a region adjacent to the lesion on SPECT images. The shapes and sizes (i.e. 
number of pixels) were kept constant for the pre- and posttherapy scan. For each ROI the 
geometric mean, corrected for physical decay, of total anterior and posterior counts was 
calculated. Lesion-to-background ratio (L/BG) was calculated for each lesion on planar 
images and, for SPECT images, activity ratio was calculated in several consecutive slices for 
each lesion and averaged. In addition, uptake in tumour lesions was expressed as percentage 
of the injected dose (% ID), calculated on planar images. Since changes in % ID and L/BG 
were equivalent in the same lesion on sequential scans and assessment of L/BG is simpler and 
less subject to errors compared to % ID, we further expressed tracer uptake solely as L/BG.  
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  ‡ Endocrine Treatment Receptor Expression  99m  Tc-depreotide uptake  
 
No 
Age 
(y) 
 
†
 
 date ER 
 
PgR 
 
Type 
 
Indication 
 
Disease Site(s) 
Pretherapy *Change pre-                                                                      
post 
PFI 
 (mo) 
Follow-
up 
1 
2 
3 
4 
5 
 
6 
 
7 
8 
9 
 
10 
 
111
2 
13 
 
14 
15 
16 
 
17 
 
18 
 
74 
74 
74 
72 
59 
 
54 
 
69 
52 
60 
 
46 
 
61 
75 
53 
 
76 
57 
56 
 
59 
 
59 
2000 
1997 
2002 
2001 
2000 
 
1999 
 
1999 
2002 
1997 
 
2002 
 
1985 
2002 
2001 
 
2000 
1996 
1997 
 
2002 
 
1996 
90% 
0% 
100% 
++ 
30% 
 
90% 
 
98% 
0% 
95% 
 
70% 
 
(+) 
95% 
80% 
 
90% 
100% 
100% 
 
100% 
 
80% 
30% 
0% 
100% 
+ 
50% 
 
90% 
 
99% 
<5% 
68% 
 
50% 
 
(+) 
5% 
0% 
 
40% 
20% 
10% 
 
100% 
 
10% 
tam → AI 
tam → AI 
tam 
AI 
AI 
 
AI → FA 
 
tam → AI 
tam → AI 
tam → AI 
 
AI 
 
tam 
AI  
tam 
 
tam → AI 
tam 
AI 
 
tam → AI 
 
tam → AI 
diagnosis M+ 
progression 
diagnosis M+ 
diagnosis M+ 
stabilisation after 
CT 
progression 
 
progression 
progression 
progression 
 
diagnosis M+ 
 
diagnosis M+ 
first diagnosis 
stabilisation after 
CT  
progression 
diagnosis M+ 
progression 
 
progression  
 
diagnosis M+ 
bone  
bone,  pleura  
liver, bone  
bone  
bone, liver  
 
bone, liver, soft 
tissue 
bone, pleura 
soft tissue 
bone, liver, pleura,  
lung 
bone, liver 
 
bone 
breast, skin  
liver 
 
bone 
bone 
bone, pleura 
 
bone, breast  
 
bone  
 
negative 
negative 
negative 
negative 
negative 
 
negative 
 
negative 
positive 
positive 
 
positive 
 
positive 
positive 
positive 
 
positive 
positive 
positive 
 
positive 
 
positive  
NA 
NA 
NA 
NA 
NA 
 
NA 
 
NA 
↑ (+116%) 
↑ (+29%) 
 
 ↑ (+63%)/ 
= (5%) 
↓ (- 42%) 
↓ (- 33%) 
= (+1%) 
 
= (- 4%) 
= (+ 5%) 
↓ (- 50% )/ 
= (+ 4%) 
↓ (-29%)/ 
= (- 15%)  
only preR scan 
0 
0 
3 
0 
0 
 
0 
 
0 
3 
0 
 
0 
 
31 
°16 
12 
 
°22 
14 
°11 
 
°11 
 
12 
 
NR 
NR 
NR 
NR 
NR 
 
NR 
 
NR 
NR 
NR 
 
NR 
 
R 
R 
R 
 
R 
R 
R 
 
R 
 
R 
‡ Evaluation of hormone receptor status was performed using IHC, except for patient no.11 LBA was applied. Scores immunostaining: percentage of positively stained cells or  
-: negative; (+): weakly positive; +: intermediately positive; ++: strongly positive. †
Table 1 Summary of patient characteristics, imaging data and follow-up. 
 most recent biopsy. * mean percentage change in all lesions per group. Groups: ↑ (increase 
in uptake of > 25%), = (increase or decrease in uptake of  ≤25%), ↓ (decrease in uptake of  >25%).° still responding at concl usion of study. ER, oestrogen receptor; PgR, 
progesterone receptor; tam, tamoxifen; AI, aromatase inhibitor; FA, full antagonist of ER (fulvestrant); M+, metastasis; CT, chemotherapy; NA, not applicable; PFI, 
progression-free interval; NR, nonresponder; R, responder.  
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Change in uptake between pre- and posttherapy scan as percentage of initial uptake on 
pretherapy scan was recorded. A change of > 25% between pre- and posttherapy scan was 
considered significant. This cut-off of 25% was chosen based on the uptake measured in a 
series of organs and soft tissue over sequential scans that never varied more than 25% within 
the same patient. This is in agreement with biological variations observed in tracer kinetics 
and the reported reproducibility of nuclear imaging techniques in general (35,36)
 
.  
Statistical Analysis 
Absolute 99m
 
Tc-depreotide uptake on pretherapy scan and relative changes in tracer uptake 
between pre- and posttherapy scan were compared in responders and nonresponders with use 
of the Mann-Whitney U test. 
4. Results 
Table 1 and 2 summarize the results of the study. The mean follow-up interval was 20 months 
(range 8-35 months). Four patients died during this follow-up period. At 6 months after 
initiation of treatment eight patients had stable disease and were considered as responding to 
hormonal treatment, whereas 10 patients had progressive disease and were considered 
nonresponders. Of nine patients receiving first-line hormonal treatment five (56%) responded, 
of eight patients with acquired endocrine resistance three (38%) responded to second-line 
antioestrogen therapy. The one patient that initiated third-line endocrine treatment did not 
respond.  
99m Responder Tc-depreotide 
scintigraphy 
Nonresponder Total 
Negative - 7 7 
Positive 
 
∆Uptake 
(preR versus postR) 
8* 
 
↓ (2) 
= and ↓ (2) 
= (3) 
3 
 
↑ (1) 
= and ↑ (2) 
 
10 
Total 8 10 18 
* one patient had only a pretherapy scan; ∆Uptake, change in uptake of 99m
Table 2. Data on tracer uptake and change in tracer uptake on sequential 
Tc-depreotide; ( ), number of patients; 
preR, pretherapy scan; postR, posttherapy scan.  
99mTc-depreotide scintigraphy 
in responders and nonresponders. 
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Figure 2. A 57-year-old female (no.15) presented with bone metastasis and achieved sustained disease 
stabilization upon endocrine treatment. 99mTc-methylendiphosphonate (MDP) bone scan shows 
multiple metastatic lesions, amongst others of the skull (arrow head), shoulder (thin arrow) and pelvic 
(thick arrow) region (A). 99m
 
Tc-depreotide scintigraphy, assessed before initiation of tamoxifen, shows 
uptake in the respective pathological lesions (B).  
99mTc-depreotide scintigraphy assessed before initiation of antioestrogen treatment was 
positive in all (or major part of) lesions in 11 (61%) patients (Fig. 2). Contrast of lesions is 
less compared with 99mTc- methylendiphosphonate (MDP) bone scan because of relatively 
high background activity in the bone marrow (37). Visualization of lesions situated in the low 
thoracic and high lumbar spine is hampered on planar images because of high physiologic 
uptake in liver, spleen and kidneys (38).  In some patients, not all lesions could be evaluated 
since cross-sectional SPECT images were not available for all lesions. In one of the latter 
patients (no.17), on planar images, tracer uptake was initially only noted in the primary 
tumour since relatively uniform tracer uptake in the fully invaded spine mimicked the high 
physiological uptake of 99mTc-depreotide in normal bone marrow. Upon fusion of MRI with 
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sagittal SPECT images, bulky lesions coincided with regions of enhanced tracer uptake on 
SPECT (Fig. 3). All responders had positive pretherapy scans and seven of 10 nonresponders 
had negative pretherapy scans. Thus all patients with a negative scan did not respond to 
therapy (Fig. 4). Tracer uptake (expressed as L/BG) on the pretherapy scan was higher for 
responders compared to nonresponders, with a median [25 – 75 percentile] of 4.43 [3.74 – 
5.16] respectively 2.54 [2.37 – 4.36], however this difference was not significant (P=.102) 
(Fig. 5A). 
 
Fig. 3 A 59-year-old patient (no.17) with progression of bone metastasis on tamoxifen switched to 
second-line endocrine treatment. Posterior view of planar 99mTc-depreotide scintigraphy shows 
relatively uniform tracer uptake in the fully invaded spine, mimicking the high physiological uptake of 
99m
 
Tc-depreotide in normal bone marrow (A). Sagittal MRI image depicting extensive tumoural 
invasion of the full spine with total destruction of corpus of thoracic vertebra (T) 11 (arrow head) and 
bulky lesion and T5-6 (arrow) (B). Upon fusion with sagittal SPECT images, these lesions coincide 
with regions of enhanced tracer uptake (C-D).  
Sequential scans, acquired before and 3 weeks after initiation of antioestrogen treatment, were 
always both positive or both negative. The relative change in 99m
A cut-off of 25% was considered to define a significant increase or decrease in tracer uptake 
(Fig. 5C). Uptake that changed with less than 25% compared to the uptake on the pretherapy 
scan was considered as stable. In the group of responders, lesion uptake was stable in three 
patients, L/BG decreased in two patients and in two patients uptake decreased in some lesions 
and was stable in others (Fig. 6). In one responding patient only the pretherapy scan was 
acquired and as such change in uptake could not be assessed. In contrast, of the nonresponders 
with a positive scan, L/BG increased in one patient and in two patients uptake increased in 
some lesions and was stable in others. 
Tc-depreotide uptake 
between sequential scans significantly differed in responders compared to nonresponders 
(P=.017), uptake decreased in the first group and increased in the latter. The median [25 – 75 
percentile] change in L/BG on the posttherapy scan compared to the pretherapy scan was 
─19.3% [─33% – 1%] for responders and 34% [29% – 116%] for nonresponders (Fig. 5B). 
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Figure 4. A 74-year-old patient (no.1), under tamoxifen treatment, presented with positive bone scan 
showing multiple lesions in vertebral spine T3 and ribs, T9 (small arrows), right sacro-iliacal region 
(thick arrow) and left femur (circle)(A). 99mTc-depreotide scintigraphy, assessed before switch to 
second-line hormonal therapy, was negative (B). She was a nonresponder and the number of bone 
lesions increased. 
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Figure 5. A. Scatter plot of 99m
 
Tc-depreotide uptake (expressed as L/BG) on pretherapy scan, averaged 
over all lesions, in nonresponders and responders. B. Scatter plot of relative change in tracer uptake 
(expressed as percentage of uptake on pretherapy scan) on sequential scans, averaged over all lesions, 
in nonresponders and responders. C. Scatter plot of relative change in tracer uptake (expressed as 
percentage of tracer uptake on pretherapy scan) on sequential scans, split into 3 groups (increase, 
stable, decrease) using a cut-off of 25% and averaged, in nonresponders and responders.  
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Figure 6. A 61-year-old patient (no.11)  presented with multiple lesions on bone scan and had stable 
disease for 31 months upon tamoxifen treatment (A). Sequential 99mTc-depreotide scintigraphy 
visualizes similar extensive bone metastasis as on bone scan, amongst others in lumbar (L2-5) and 
sacro-iliacal region (B1: pretherapy scan – B2: posttherapy scan). Regions-of-interest (ROIs) were 
drawn over lesions (ROI 1-3) and background (ROI 4) on transversal SPECT images and measured 
counts were averaged over several slices of total tumour volume (C1: pretherapy scan – C2: 
posttherapy scan). Lesion-to-background ratio’s and change in uptake (Δ uptake – expressed as 
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percentage of uptake first scan) were calculated (D). 99m
 
Tc-depreotide uptake significantly decreased 
with values of –42% to –55%. 
5. Discussion 
Endocrine therapy is one of primary treatment options for the majority of patients with 
metastatic breast cancer. Upon patient selection based on hormone receptor status 50%-75% 
of patients with ER and/or PgR expressing tumours initially respond. Nearly all responding 
patients eventually suffer disease progression, but approximately half of patients with 
acquired resistance obtain clinical benefit from other endocrine therapies. Although response 
rates progressively decline, they remain in the 20% to 40% range (39)
In our study, all patients with hormone-sensitive tumours had positive scans. This could be 
expected since E
. Our limited patient data 
are concordant with these reported figures for sequential endocrine responsiveness.  
2 stimulation of functional ER enhances SSTR2 gene transcription and hence 
SSTR2 expression at the cell surface, which is visualized by 99mTc-depreotide scintigraphy. In 
this group of responders, tracer uptake on the posttherapy scan tended to be lower compared 
to the pretherapy scan and, considering a cut-off of 25%, uptake significantly decreased or 
remained stable. According to our hypothesis, this decrease could be interpreted as a 
downregulation of SSTR2 at the cell surface level caused by an efficient block of the 
functional ER that inhibits further transcription of the SSTR2. Unfortunately, for availability 
reasons, binding of radioligand to breast tumour cells per se could not be confirmed using 
autoradiography. Therefore, binding of 99mTc-depreotide to other kinds of cells expressing 
SSTR2, 3 or 5, such as activated lymphocytes (SSTR2), cannot be excluded (40). The presence 
of tumour infiltrating lymphocytes (TILs) has been associated with therapy response and good 
prognosis, however controversy exists (41,42). Equivalent uptake on both sequential scans could 
be interpreted as absence of active stimulation of ER and subsequently absence of SSTR2 
transcription. Possibly, intratumoural levels of antioestrogen could have only just or not yet 
achieved steady state and balance between receptor synthesis and endocytosis/degradation has 
not yet turned in favour of degradation. However, one patient initiated anastrozole (no.13) 
which achieves steady state within 7 days (29)
Three patients of the group of responders had acquired resistance to tamoxifen and had 
positive 
. Though this concerns serum levels and not 
concentrations in the respective tissues of action. 
99mTc-depreotide scans before they switched to a second-line aromatase inhibitor. 
This is in agreement with considerable amount of data indicating that ER in acquired resistant 
breast cancer commonly remains functional and moreover pivotal to the growth regulation 
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and gene expression profile of breast tumours on their relapse, despite the presence of 
tamoxifen (43). Following their inhibition by tamoxifen during initial responsive phase of the 
disease, oestrogen-regulated genes can be reexpressed on disease relapse. Clinical experience 
has shown that hormonal resistance is often reversible, suggesting a cellular adaptation, rather 
than genetic alterations in many breast cancer patients (44). Changes in local metabolism and 
more in particular reduced concentrations of tamoxifen and its metabolites are reported in 
tamoxifen-resistant tumours (45)
All negative 
. Accordingly, efflux of tamoxifen out of the tumour cell in the 
presence of a functional ER results in a tamoxifen resistant tumour, expressing oestrogen-
regulated genes (e.g., SSTR2), sensitive to aromatase inhibitors. Besides prediction of the 
likelihood of response to second-line hormonal treatment such as aromatase inhibitors 
requiring a functional ER, this could allow for prediction of early resistance to tamoxifen 
treatment. 
99mTc-depreotide scans belonged to patients with tumours resistant to hormonal 
therapy. This was in line with expectations since we anticipated a nonfunctional ER, not 
capable of stimulating transcription and expression of SSTR2. Loss of ER is generally not a 
feature of acquired endocrine resistance either in vitro or in vivo, hence repeated hormone 
receptor assessment using routine techniques (LBA, IHC) for determination of endocrine-
responsiveness would be inadequate (46)
Three patients (30%) of the group of nonresponders had positive 
.  
99mTc-depreotide 
scintigraphies. This suggests a ligand-independent stimulation of ER and oestrogen-
independent regulation of SSTR2 expression. Constitutively active ER variants might 
contribute to a tamoxifen resistance breast tumour with similar characteristics, however 
mutations are extremely rare in vivo and thus refer only to a minority of cases (47). Even in 
tumours that are oestrogen-dependent, it is likely that an appropriate growth factor 
environment is necessary for efficient mitogenesis, with steroid hormone and growth factor 
signalling pathways "cross talking" to reinforce each others' signalling (48,49,50). 
Overexpression of a growth factor (EGF, epidermal growth factor; TGFα, transforming 
growth factor α; IGF-1, insulin-like growth factor 1) or its receptor (EGFR, HER2/Neu, IGF-
1R) may perturb this balance of steroid hormone and growth factor interaction, providing a 
selective advantage for tumour cell proliferation despite hormone therapy. As such, several 
kinases, which are themselves activated by membrane growth factor receptors, phosphorylate 
ER at sites that influence its biological activity. On the posttherapy scan tracer uptake was 
increased in these patients, suggesting an upregulation of SSTR2 expression as a result of 
continuous or enhanced stimulation of SSTR2 transcription. However in vitro data in human 
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breast cancer cells attribute this increase predominantly to an enhanced recycling of the 
receptor rather than an increased synthesis (19). Several postreceptor alterations, including 
changes in coregulators or cAMP and phosphorylation pathways, known to affect 
transcriptional activity of ER and to enhance the agonistic activity of tamoxifen-like 
antioestrogens could explain an increase in SSTR2 expression (51)
Presumably regulation of SSTR expression in breast tumour cells is not exclusively 
oestrogen-dependent and is influenced by a series of other mediators, as is the case in normal 
tissue (e.g., pancreas, hypothalamus) 
. However, in these three 
patients endocrine treatment with an aromatase inhibitor was initiated.  
(52). Growth factors and cytokines secreted by tumour 
cells or adjacent host cells may modify SSTR expression in an autocrine or paracrine manner. 
A series of radiopharmaceuticals have been developed to specifically investigate this feature 
(53,54). Interestingly, the cytokines IL-6 (interleukin 6) and TNF-α (tumor necrosis factor α) 
that stimulate activity of aromatase, the enzyme that catalyses conversion from androgen to 
oestrogen in tumour cells, also enhance SSTR expression (55,56). These cytokines are secreted 
by tumour associated lymphocytes and other adjacent host cells (e.g., adipocytes) in response 
to the tumour cells themselves. Upon administration of an aromatase inhibitor, absence of 
positive feedback could supposedly result in an abundance of the cytokines and augmentation 
of SSTR at the cell surface. However, regulation of SSTR by IL-6 or TNF-α has not yet been 
described in human breast cancer cells. Furthermore, SSTR expression is inhibited by growth-
inhibitory factor TGF-β (transforming growth factor β) present in breast tumour cells (57). 
Several studies have demonstrated increases in plasma and tumour levels of TGF-β in patients 
following initial exposure to tamoxifen therapy mirroring effective tamoxifen response 
(58,59,60,61). In addition, IGF signalling by growth factors IGF-1 and more importantly IGF-2 is 
likely to play a crucial role in pathogenesis of steroid-hormone-dependent disease and many 
ER-positive breast carcinomas express high levels of the respective receptor IGF-1R (62,63). 
Tamoxifen treatment substantially reduces IGF signalling partly through a decrease in levels 
of IGF-1 and IGF-2, both also known to stimulate SSTR expression (64,52,65,66). These 
mechanisms could play a complementary or alternative role in the decrease in SSTR2 
expression and 99mTc-depreotide binding in the responders in our study. Moreover, a high 
expression of IGF signalling elements and paradoxically high TGF-β production have been 
reported in tamoxifen-resistant tumours, which could potentially contribute to the SSTR-
positive respectively SSTR-negative phenotype of nonresponders (67,63)
In our series we found a consistent relationship between 
. 
99mTc-depreotide uptake and 
response to endocrine treatment in metastasized breast cancer patients. Underlying 
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mechanism is suggested to be an ER-mediated regulation of SSTR2 expression but additional 
influence by a series of cytokines and/or growth factors present in the tumoural environment 
is to be expected. Nevertheless, if a larger scale study confirms these findings, this could 
entail a powerful tool to accurately evaluate endocrine-responsiveness. A protocol with 
somatostatin receptor scintigraphy before initiation of endocrine treatment and repetition of 
the scan if positive could be proposed (Fig. 7). 
 
Figure 7. Proposed protocol for selection of advanced breast cancer patients for endocrine treatment 
using  sequential 99m
 
Tc-depreotide scintigraphy. 
Realistic goals for treatment of metastatic breast cancer are palliation of symptoms and 
prolongation of survival with maximizing the quality of life. In general, significant palliation 
is more likely for a patient who experiences a response to endocrine therapy compared to a 
similar response induced by chemotherapy, due to a lower toxicity profile. A delay in 
effective therapy may lead to a decline in performance status and organ function, and as such 
reduce the likelihood of a subsequent response. Using clinical follow-up and conventional 
morphological imaging modalities using volumetric changes easily 3 to 6 months are needed 
for response evaluation. The proposed protocol would allow for separation of responders and 
nonresponders immediately (negative pretherapy scan) or as early as 3 weeks after treatment 
initiation (positive pretherapy scan).  
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GENERAL DISCUSSION 
Hormone-dependent breast tumours are characterized primarily by a functional and intact 
oestrogen receptor (ER) system. Antioestrogen agents selectively target the ER pathway to 
abolish its effect on cell growth. Since only about one third of breast cancer patients initially 
respond to endocrine therapy, there is a need for patient selection. So far, the only predictive 
factor approved for clinical routine use is the in vitro assessment of hormone receptor status 
on tissue samples by ligand binding assay (LBA) or immunohistochemistry (IHC). Still, only 
50%-60% of patients with ER-positive tumours exhibit response to hormonal therapy, 
whereas lack of detectable ERs is usually associated with 5%-10% response (1,2,3). Possible 
causes of discordance between hormone receptor status and endocrine responsiveness include 
limits inherent to the available techniques (IHC, LBA) for hormone receptor assessment, such 
as sampling error and variations in specificity (animal dependent) seen with the preparation of 
antibodies. Assessment of hormone receptor status is usually based on tissue samples from the 
primary tumour, whilst this information is being utilized years or decades later in the 
metastatic situation, when the biology of the tumour might have changed (4,5,6). In addition, 
breast tumours contain multiple cell populations exhibiting a wide range of genetic, 
biochemical, immunological and biological characteristics (7,8). Metastatic lesions originating 
from an ER-negative clone may be ER-negative nevertheless the primary tumour is ER-
positive. Another explanation for lack of response to endocrine treatment in ER-positive 
disease is nonfunctioning of the ER. These receptors are recognized and measured by IHC, 
but in such tumours steroid hormone occupancy of the receptor is not the drive for cellular 
proliferation and hence antioestrogen therapy is inefficient. Assessment of end-product of ER 
stimulation, such as PgR receptor, could by-pass this problem and has proven to increase 
predictive accuracy (9,10,11)
Scintigraphy is the imaging technique of choice since it is noninvasive and offers the 
advantage of repetitive whole body evaluation. Furthermore, it has the ability to address the 
intrinsic heterogeneity of tumoural receptor expression without tissue manipulation and 
provides an in vivo image of all disease sites at the moment of treatment need. In chapter 2 we 
amplify on receptor imaging by means of nuclear medicine in oncology. In breast cancer in 
particular, many efforts have been put into synthesis and evaluation of radiopharmaceuticals 
of which tumoural uptake is believed to relate to ER expression and hence endocrine 
responsiveness 
.  
(20,21). Available data demonstrate a lack of concordance between uptake of 
radiolabelled oestradiol derivates and ER status (22,23). This can be explained by the fact that 
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oestradiol needs are provided by both uptake and local biosynthesis and are highly variable 
inter- as well as intratumourally (24,25). Sequential 123I-labelled cis-11β-methoxy-17α-
iodovinyl-estradiol (123I-z-MIVE) imaging visualised ER-blockage in patients with longer 
progression-free interval upon antioestrogen treatment (26). However, this effect was related to 
a selected patient population, screened for 123I-z-MIVE uptake prior to inclusion. Similarly, 
imaging of ER-blockade or metabolic flare reaction by means of sequential 16α-18F-
fluoroestradiol-17β (18F-FES) positron emission tomography (PET) respectively 18F-
fluorodeoxyglucose (18F-FDG) PET was related to response to tamoxifen treatment (27). Both 
studies included only patients who received tamoxifen and the latter represent just part of the 
actual group of breast cancer patients with metastatic disease eligible for endocrine treatment. 
Tamoxifen derived single photon emission computed tomography (SPECT) tracer suffered 
from high background activity due to extensive tissue binding related to its lipophilic 
characteristics and the respective PET tracer showed no correlation with hormone receptor 
status nor treatment response (28,29). Several PgR-specific radioligands have been synthesized 
and validated in animal models, but their potential in patients have yet to be assessed (30,31,32)
Experimental data in human breast cancer cell lines suggest that the somatostatin 
receptor (SSTR) is another oestrogen-regulated gene 
. 
(12). The SSTR is a membrane bound G-
protein-coupled receptor that undergoes rapid internalisation upon agonist binding (13). To 
date, five distinct subtypes (SSTR1-5, with SSTR2 having two splice variant isoforms, 
respectively SSTR2A-SSTR2B), encoded by separate genes, have been identified (14,15). The 
former data, however, are based on mRNA expression, which may not necessarily reflect 
functional receptor levels. In fact, recent reports have suggested a lack of parallelism between 
SSTR mRNA and receptor protein in some human tumours (16,17,18). In chapter 3 we 
demonstrated oestrogen-mediated SSTR expression in 2 endocrine responsive ER-positive 
human breast cancer cell lines (T47D and ZR75-1) but not in endocrine unresponsive ER-
negative MDA MB231 cells. Physiological concentrations of E2 resulted in a statistically 
significant increase of the number of SSTRs at the level of the cell membrane of T47D cells 
but not in ZR75-1 and MDA MB231 cells as evidenced by binding assays. Given the minor 
increase in SSTR2 protein levels as evidenced by western blotting for the T47D cell line, this 
phenomenon is likely attributable to a predominant recycling of receptors from inner towards 
the outer cell membrane. In the ZR75-1 cells a mean decrease of the number of cell 
membrane SSTRs after E2 stimulation was noticed, which however was not statistically 
significantly different. As shown by western blot analysis, this mean decrease may be 
explained by a drop in the number of SSTR5 receptors. T47D cells also evidenced a drop in 
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SSTR5 protein content but much less pronounced. In T47D cells, the E2-effect was reduced or 
inhibited by the antioestrogens tamoxifen and ICI 182 780 (fulvestrant), indicating a 
requirement for E2 binding and stimulation of the ER suggestive of an exclusively E2-
dependent regulation of SSTR2 expression. The reduction seen with tamoxifen as compared 
to the inhibition seen with ICI 182 780 may be explained by the partial- and full antagonist 
character of the respective molecules. On the human SSTR2 gene, an E2-responsive region 
has been roughly localized to sequences spanning from kilobase pairs (kb) –5.3 to –3.8 with 
respect to the transcriptional site in front of the coding region (19)
For SSTR imaging, we chose to work with depreotide (P829 - NeoSpect/NeoTect), 
a 
. 
99mTc-labelled somatostatin analogue with high affinity for SSTR2, 3 and 5 (33,34,35). 
Depreotide received US Food and Drug Administration approval for use in the imaging of 
suspected malignant tumors in the lung. In vivo imaging of SSTR-positive tumours is 
routinely performed using [111In-DTPA-D-Phe1]-octreotide scintigraphy (SMS 201-995 – 
Octreoscan®) and uptake correlates with expression of SSTR2A and SSTR5. However, 
technetium labelling offers clinical advantages when compared to indium labelling including 
lower cost, better availability and faster tumoural visualization enabling a 1-day-protocol. The 
decay characteristics of technetium, more adapted to the photon energy detection ability of 
gamma cameras, together with the shorter physical half life permitting a higher dose 
administration, result in better image quality combined with lower radiation dose. In the 
biodistribution and dosimetry study of 99mTc-depreotide in chapter 4, most of the activity was 
observed in the liver, spleen and kidneys and administered activity was predominantly 
eliminated through physical decay. In addition, uptake in lungs, colon, bone marrow and 
bucco-pharyringeal mucosa was noticed. Uptake pattern may be explained by the renal 
excretion of the tracer and the specific binding of 99mTc-depreotide to SSTR2-expressing cells 
of the human immune system, such as monocytes, T- and B-lymphocytes, and to SSTR3-
expressing cells of spleen, liver and intestinal mucosa (36,14). Of interest, tracer uptake in 
metastatic bone lesions augmented up to 2-4 hours and remained stable without biological 
clearance. As opposed to 99mTc-depreotide, [111In-DTPA-D-Phe]-octreotide exhibits different 
biodistribution and excretion patterns, resulting in absence of uptake in bone marrow, much 
lower uptake in liver and mainly excretion via kidneys with minor hepatic accumulation and 
minute hepatobiliary excretion (37). Part of these differences may be attributed to the different 
affinity profiles of both tracers, respective a high affinity for SSTR2 and SSTR5 (SSTR2 Kd 
= 1.5 nM, SSTR3 Kd = 15 nM and SSTR5 Kd =0.5 nM) of [111In-DTPA-D-Phe]-octreotide, 
whereas 99mTc-depreotide exhibits additional high affinity for SSTR3 (SSTR2 Kd = 2.5 nM, 
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SSTR3 Kd = 1.5 nM and SSTR5 Kd = 2nM) (33). The latter feature may entail an additional 
benefit since breast tumours express SSTR3 besides SSTR2, albeit to a lesser extent, and 
SSTR3 expression is also positively regulated by E2 (38). The mean effective dose for 99mTc-
depreotide was 6.4-8.5 mSv, which is substantially lower than that for [111
Bone is the most common site of metastatic breast cancer and bone scintigraphy is a 
sensitive but aspecific technique for evaluation of various bone pathologies. In chapter 5 we 
compared the diagnostic accuracy of planar 
In-DTPA-D-Phe]-
octreotide (8-16 mSv). 
99mTc-depreotide scintigraphy with planar 99mTc- 
methylendiphosphonate (MDP) bone scintigraphy for evaluating bone metastasis in a small 
series of breast cancer patients. Regarding diagnostic accuracy on a patient basis, bone scan 
proved superior (75% versus 83.3%) due to its higher sensitivity (100% versus 62.5%), 
whereas specificity was significantly higher on NeoSpect scan (100% versus 50%). In fact 
depreotide binds specifically to SSTR2, 3 and 5 that are over expressed in 50-80% of breast 
tumours. In contrast, 99mTc-MDP accumulates aspecifically in any skeletal location with an 
elevated rate of bone turnover such as arthropathy, leading to false-positive diagnoses of bony 
metastasis. Seventy-four percent of missed individual lesions in patients with positive 
depreotide scan were probably due to masking by organs with high physiological tracer 
uptake (thyroid, liver, spleen, intestines). SPECT imaging, a tomographical technique that 
provides cross-sectional images of tracer distribution and thus has the ability to remove 
overlying structures which may obscure abnormal tracer uptake, can overcome similar 
problems. An additional explanation for the lack of sensitivity of 99mTc-depreotide in 
detecting individual lesions lies in the heterogeneous distribution of SSTR expression in 
breast tumours. The latter often display SSTR only in certain tumour regions, although the 
whole tumour appears to be histopathologically homogenous (39)
Since SSTR2 is the dominant SSTR subtype in breast cancer, we hypothesized, in 
analogy with the in vitro findings, that efficient treatment of metastasized breast cancer 
patients by means of antioestrogens or aromatase inhibitors may result in downregulation of 
SSTR at the cell surface level, which could be visualized in vivo using sequential 
somatostatin receptor scintigraphy. In chapter 6 we evaluated the potential of sequential 
. This observation supports 
the idea that some breast tumours are composed of numerous different clones with different 
biological properties. As a consequence metastatic lesions originating from a SSTR-negative 
clone may be SSTR-negative nevertheless the primary tumour is SSTR-positive.  
99mTc-depreotide scintigraphy to select patients likely to respond to endocrine therapy. In our 
study, all patients with hormone-sensitive tumours had positive scans. This could be expected 
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since E2 stimulation of functional ER enhances SSTR2 gene transcription and hence SSTR2 
expression at the cell surface, which is visualized by 99mTc-depreotide scintigraphy. In this 
group of responders, tracer uptake on the posttherapy scan tended to be lower compared to the 
pretherapy scan and, considering a cut-off of 25%, uptake significantly decreased or remained 
stable. According to our hypothesis, this decrease could be interpreted as a downregulation of 
SSTR2 at the cell surface level caused by an efficient block of the functional ER that inhibits 
further transcription of the SSTR2. Unfortunately, for availability reasons, binding of 
radioligand to breast tumour cells per se could not be confirmed using autoradiography. 
Therefore, binding of 99mTc-depreotide to other kinds of cells expressing SSTR2, 3 or 5, such 
as activated lymphocytes (SSTR2), cannot be excluded (40). The presence of tumour 
infiltrating lymphocytes (TILs) has been associated with therapy response and good 
prognosis, however controversy exists (41,42). Equivalent uptake on both sequential scans could 
be interpreted as absence of active stimulation of ER and subsequently absence of SSTR2 
transcription. Possibly, intratumoural levels of antioestrogen could have only just or not yet 
achieved steady state and balance between receptor synthesis and endocytosis/degradation has 
not yet turned in favour of degradation. Three patients of the group of responders had 
acquired resistance to tamoxifen and had positive 99mTc-depreotide scans before they 
switched to a second-line aromatase inhibitor. This is in agreement with considerable amount 
of data indicating that ER in acquired resistant breast cancer commonly remains functional 
and moreover pivotal to the growth regulation and gene expression profile of breast tumours 
on their relapse, despite the presence of tamoxifen (43). Following their inhibition by 
tamoxifen during initial responsive phase of the disease, oestrogen-regulated genes can be re-
expressed on disease relapse. Clinical experience has shown that hormonal resistance is often 
reversible, suggesting a cellular adaptation, rather than genetic alterations in many breast 
cancer patients (44). Changes in local metabolism and more in particular reduced 
concentrations of tamoxifen and its metabolites are reported in tamoxifen-resistant tumours 
(45). Accordingly, efflux of tamoxifen out of the tumour cell in the presence of a functional ER 
results in a tamoxifen resistant tumour, expressing oestrogen-regulated genes (eg, SSTR2), 
sensitive to aromatase inhibitors. Besides prediction of the likelihood of response to second-
line hormonal treatment such as aromatase inhibitors requiring a functional ER, this could 
allow for prediction of early resistance to tamoxifen treatment. All negative 99mTc-depreotide 
scans belonged to patients with tumours resistant to hormonal therapy. This was in line with 
expectations since we anticipated a nonfunctional ER, not capable of stimulating transcription 
and expression of SSTR2. Loss of ER is generally not a feature of acquired endocrine 
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resistance either in vitro or in vivo, hence repeated hormone receptor assessment using routine 
techniques (LBA, IHC) for determination of endocrine-responsiveness would be inadequate 
(46). Three patients (30%) of the group of nonresponders had positive 99mTc-depreotide 
scintigraphies. This suggests a ligand-independent stimulation of ER and oestrogen-
independent regulation of SSTR2 expression. Constitutively active ER variants might 
contribute to a tamoxifen resistance breast tumour with similar characteristics, however 
mutations are extremely rare in vivo and thus refer only to a minority of cases (47). Even in 
tumours that are oestrogen-dependent, it is likely that an appropriate growth factor 
environment is necessary for efficient mitogenesis, with steroid hormone and growth factor 
signalling pathways "cross talking" to reinforce each others' signalling (48,49,50). 
Overexpression of a growth factor (EGF, epidermal growth factor; TGFα, transforming 
growth factor α; IGF-1, insulin-like growth factor 1) or its receptor (EGFR, HER2/Neu, IGF-
1R) may perturb this balance of steroid hormone and growth factor interaction, providing a 
selective advantage for tumour cell proliferation despite hormone therapy. As such, several 
kinases, which are themselves activated by membrane growth factor receptors, phosphorylate 
ER at sites that influence its biological activity. On the posttherapy scan tracer uptake was 
increased in these patients, suggesting an upregulation of SSTR2 expression as a result of 
continuous or enhanced stimulation of SSTR2 transcription. However in vitro data in human 
breast cancer cells attribute this increase predominantly to an enhanced recycling of the 
receptor rather than an increased synthesis (51). Several postreceptor alterations, including 
changes in coregulators or cAMP and phosphorylation pathways, known to affect 
transcriptional activity of ER and to enhance the agonistic activity of tamoxifen-like 
antioestrogens could explain an increase in SSTR2 expression (52). However, in these 3 
patients endocrine treatment with an aromatase inhibitor was initiated. Presumably regulation 
of SSTR expression in breast tumour cells is not exclusively oestrogen-dependent and is 
influenced by a series of other mediators, as is the case in normal tissue (e.g., pancreas, 
hypothalamus) (14). Growth factors and cytokines secreted by tumour cells or adjacent host 
cells may modify SSTR expression in an autocrine or paracrine manner. A series of 
radiopharmaceuticals have been developed to specifically investigate these agents (53,54). 
Interestingly, the cytokines IL-6 (interleukin 6) and TNF-α (tumor necrosis factor α) that 
stimulate activity of aromatase, the enzyme that catalyses conversion from androgen to 
oestrogen in tumour cells, also enhance SSTR expression (55,56). These cytokines are secreted 
by tumour associated lymphocytes and other adjacent host cells (e.g., adipocytes) in response 
to the tumour cells themselves. Upon administration of an aromatase inhibitor, absence of 
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positive feedback could supposedly result in an abundance of the cytokines and augmentation 
of SSTR at the cell surface. However, regulation of SSTR by IL-6 or TNF-α has not yet been 
described in human breast cancer cells. Furthermore, SSTR expression is inhibited by growth-
inhibitory factor TGF-β (transforming growth factor β) present in breast tumour cells (57). 
Several studies have demonstrated increases in plasma and tumour levels of TGF-β in patients 
following initial exposure to tamoxifen therapy mirroring effective tamoxifen response 
(58,59,60,61). In addition, IGF signalling by growth factors IGF-1 and more importantly IGF-2 is 
likely to play a crucial role in pathogenesis of steroid hormone-dependent disease and many 
ER-positive breast carcinomas express high levels of the respective receptor IGF-1R (62,63). 
Tamoxifen treatment substantially reduces IGF signalling partly through a decrease in levels 
of IGF-1 and IGF-2, both also known to stimulate SSTR expression (64,14,65,66). These 
mechanisms could play a complementary or alternative role in the decrease in SSTR2 
expression and 99mTc-depreotide binding in the responders in our study. Moreover, a high 
expression of IGF signalling elements and paradoxically high TGF-β production have been 
reported in tamoxifen-resistant tumours, which could potentially contribute to the SSTR-
positive respectively SSTR-negative phenotype of nonresponders (67,63)
 
.  
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FUTURE PROSPECTS 
We found a consistent relationship between 99m
Realistic goals for treatment of metastatic breast cancer are palliation of symptoms and 
prolongation of survival with maximizing the quality of life. In general, significant palliation 
is more likely for a patient who experiences a response to endocrine therapy compared to a 
similar response induced by chemotherapy, due to a lower toxicity profile. A delay in 
effective therapy may lead to a decline in performance status and organ function, and as such 
reduce the likelihood of a subsequent response. Using clinical follow-up and conventional 
morphological imaging modalities using volumetric changes easily 3 to 6 months are needed 
for response evaluation. The proposed protocol would allow for separation of responders and 
nonresponders immediately (negative pretherapy scan) or as early as 3 weeks after treatment 
initiation (positive pretherapy scan).  
Tc-depreotide uptake and response to 
endocrine treatment in metastasized breast cancer patients. Underlying mechanism is 
suggested to be an ER-mediated regulation of SSTR2 expression but additional influence by a 
series of cytokines and/or growth factors present in the tumoural environment is to be 
expected. Nevertheless, if a larger scale study confirms these findings, this could entail a 
powerful tool to accurately evaluate endocrine-responsiveness. A protocol with somatostatin 
receptor scintigraphy before initiation of endocrine treatment and repetition of the scan if 
positive could be proposed.  
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SUMMARY 
Endocrine therapy achieves good results with minimal toxicity and therefore remains 
one of primary treatment options for the majority of patients with metastatic breast cancer. 
Since only about one third of patients initially respond, there is a need for patient selection. So 
far, the only predictive factor approved for clinical routine use is the in vitro assessment of 
hormone receptor status on tissue samples by ligand binding assay (LBA) or 
immunohistochemistry (IHC). Still only 50%-60% of patients with oestrogen receptor (ER)-
positive tumours exhibit response to hormonal therapy. A possible explanation for lack of 
response to endocrine treatment in ER-positive disease is nonfunctioning of the ER. 
Assessment of an endproduct of ER stimulation, such as progesteron receptor, could by-pass 
this problem and has proven to increase predictive accuracy. Experimental data in human 
breast cancer cell lines, based on mRNA expression, suggest that the somatostatin receptor 
(SSTR) is another oestrogen-regulated gene. This thesis elucidates the role of oestrogen in 
SSTR expression and explores the potential of the visualization of this molecular event by 
means of nuclear medicine techniques for selection of breast cancer patients likely to respond 
to endocrine treatment.  
Scintigraphy is the imaging technique of choice since it is noninvasive and offers the 
advantage of repetitive whole body evaluation. Furthermore, it has the ability to address the 
intrinsic heterogeneity of tumoural receptor expression without tissue manipulation and 
provides an in vivo image of all disease sites at the moment of treatment need. In chapter 2 we 
amplify on receptor imaging by means of nuclear medicine in oncology. In breast cancer in 
particular, many efforts have been put into synthesis and evaluation of radiopharmaceuticals 
of which tumoural uptake is believed to relate to ER expression and hence endocrine 
responsiveness. 
In chapter 3 we demonstrated oestrogen-mediated SSTR expression in 2 endocrine-
responsive ER-positive human breast cancer cell lines (T47D and ZR75-1) but not in 
endocrine-unresponsive ER-negative MDA MB231 cells. Physiological concentrations of 
oestradiol (E2) resulted in a statistically significant increase of the number of SSTRs at the 
level of the cell membrane of T47D cells but not in ZR75-1 and MDA MB231 cells as 
evidenced by binding assays. Given the minor increase in SSTR2 protein levels as evidenced 
by western blotting for the T47D cell line, this phenomenon is likely attributable to a 
predominant recycling of receptors from inner towards the outer cell membrane. The E2-effect 
was reduced or inhibited by the antioestrogens tamoxifen and ICI 182 780 (fulvestrant), 
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indicating a requirement for E2 binding and stimulation of the ER suggestive of an exclusively 
E2
For SSTR imaging, we chose to work with depreotide (P829 - NeoSpect/NeoTect), 
a 
-dependent regulation of SSTR2 expression. In analogy with the in vitro findings, we 
hypothesized that efficient antioestrogen treatment of metastasized breast cancer patients may 
result in downregulation of SSTR at the cell surface level, which could be visualized in vivo 
using sequential somatostatin receptor scintigraphy. 
99mTc-labelled somatostatin analogue with high affinity for SSTR2, 3 and 5. In chapter 4 we 
studied the biodistribution and dosimetry study of 99mTc-depreotide in breast cancer patients. 
Most of the activity was observed in the liver, spleen and kidneys and administered activity 
was predominantly eliminated through physical decay. In addition, uptake in lungs, colon, 
bone marrow and bucco-pharingeal mucosa was noticed. The mean effective dose for 99mTc-
depreotide was 6.4-8.5 mSv, which is substantially lower than that for [111
In chapter 5 we compared the diagnostic accuracy of planar 
In-DTPA-D-Phe]-
octreotide (8-16 mSv), the tracer routinely used for imaging of SSTR-positive tumours. 
99mTc-depreotide 
scintigraphy with planar 99mTc-methylendiphosphonate (MDP) bone scintigraphy for 
evaluating bone metastasis in a small series of breast cancer patients. Bone scan proved 
superior (75% versus 83.3%) due to its higher sensitivity (100% versus 62.5%), whereas 
specificity was significantly higher on NeoSpect scan (100% versus 50%). In fact, depreotide 
binds specifically to SSTR2, 3 and 5 that are over expressed in 50-80% of breast tumours. In 
contrast, 99m
We evaluated the potential of sequential 
Tc-MDP accumulates aspecifically in any skeletal location with an elevated rate 
of bone turnover such as arthropathy, leading to false-positive diagnoses of bony metastasis. 
99mTc-depreotide scintigraphy to select 
patients likely to respond to endocrine therapy in chapter 6. In our study, all patients with 
hormone-sensitive tumours had positive scans. Tracer uptake on the posttherapy scan, 
acquired 3 weeks after treatment initiation, tended to be lower compared to the pretherapy 
scan and, considering a cut-off of 25%, uptake significantly decreased or remained stable. All 
negative 99mTc-depreotide scans belonged to patients with tumours resistant to hormonal 
therapy. Three patients (30%) of the group of nonresponders had positive 99m
We found a consistent relationship between 
Tc-depreotide 
scintigraphies and increase of tracer uptake on the posttherapy scan.  
99mTc-depreotide uptake and response to 
endocrine treatment in metastasized breast cancer patients. Underlying mechanism is 
suggested to be an ER-mediated regulation of SSTR2 expression but additional influence by a 
series of cytokines and/or growth factors present in the tumoural environment is to be 
expected. Nevertheless, if a larger scale study confirms these findings, this could entail a 
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powerful tool to accurately evaluate endocrine responsiveness. A protocol with somatostatin 
receptor scintigraphy before initiation of endocrine treatment and repetition of the scan if 
positive could be proposed. The latter would allow for separation of responders and 
nonresponders immediately (negative pretherapy scan) or as early as 3 weeks after treatment 
initiation (positive pretherapy scan).  
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SAMENVATTING 
Hormonale therapie levert goede resultaten met een minimum aan toxiciteit en blijft 
daarom een van de belangrijkste behandelingsopties voor het merendeel van de patiënten met  
gemetastaseerd borstkanker. Maar aangezien enkel een derde van hen initieel reageert op deze 
therapie, moeten patiënten zorgvuldig gescreend worden. Tot op heden is de enige 
‘voorspellende’ factor die goedgekeurd is voor klinisch routineus gebruik de bepaling van de 
hormoon-receptor status in vitro op stukjes weefsel door middel van bindingsproef of 
immunohistochemie. Maar ook van de patiënten met oestrogeenreceptor (ER)-positieve 
tumoren reageert slechts 50% - 60% positief op hormonale therapie. Een mogelijke verklaring 
voor dit uitblijven van effect is een niet-functionerende ER. De bepaling van een eindproduct 
van ER-stimulatie, zoals de progesteron receptor, zou dit probleem kunnen omzeilen en heeft 
reeds bewezen de predicatieve accuraatheid te verhogen. Data bekomen uit experimenten met 
humane borstkanker cellijnen gebaseerd op mRNA expressie doen vermoeden dat de 
somatostatine receptor (SSTR) eveneens een gen is waarvan de expressie door oestrogenen 
geregeld wordt.  
In deze thesis wordt de rol van oestrogenen in de expressie van SSTR verder 
opgehelderd en wordt het vermogen onderzocht dit moleculair gebeuren in beeld te brengen 
door middel van technieken uit de nucleaire geneeskunde, met de bedoeling borstkanker 
patiënten te selecteren die hoogstwaarschijnlijk zullen beantwoorden aan endocriene therapie. 
We kozen voor scintigrafie als beeldvormende techniek omdat deze niet invasief is en 
het voordeel biedt het hele lichaam repetitief te kunnen evalueren. Bovendien brengt het de 
intrinsieke heterogeniteit van de tumorale receptor-expressie in kaart zonder weefsel- 
manipulatie en verschaft het in vivo beelden van alle ziektehaarden op het ogenblik dat er 
nood is aan behandeling. In hoofdstuk 2 weidden we uit over receptor beeldvorming in de 
oncologie door middel van technieken uit de nucleaire geneeskunde. Wat betreft borstkanker 
in het bijzonder, werden veel inspanningen geleverd voor de synthese en evaluatie van 
radiopharmaca waarvan men vermoedt dat de opname in de tumor gerelateerd is aan de ER 
expressie en dus aan hormoongevoeligheid.  
In hoofdstuk 3 toonden we aan dat expressie van SSTR door oestrogenen bemiddeld 
wordt in 2 hormoongevoelige, ER-positieve, humane borstkankercellijnen (T47D en ZR75-1) 
maar niet in hormoonongevoelige, ER-negatieve, MDA MB231 cellen. Uit bindingsproeven 
bleek dat fysiologische concentraties van oestradiol (E2) resulteerden in een statistisch 
significante stijging van het aantal SSTRs ter hoogte van het celmembraan van T47D cellen 
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maar niet in ZR75-1 en MDA MB231 cellen. Aangezien Western blot slechts een minimale 
stijging aantoonde van SSTR2 proteïne in T47D cellen, is dit fenomeen waarschijnlijk 
voornamelijk te wijten aan het recycleren van receptoren van in de cel naar buiten op het 
celmembraan. Het E2-effect werd gereduceerd of verhinderd door de antioestrogenen 
tamoxifen of ICI 182 780 (fulvestrant), wat erop wijst dat binding van E2 en stimulatie van 
ER vereist zijn, en dit doet een exclusieve E2
Voor de beeldvorming van SSTR verkozen we te werken met depreotide (P829 - 
NeoSpect/NeoTect), een technetium (
-afhankelijke regulatie van SSTR expressie 
vermoeden. Naar analogie met de in vitro bevindingen, hebben we als hypothese gesteld dat 
een efficiënte hormonale behandeling van patiënten met gemetastaseerd borstkanker 
aanleiding kan geven tot een daling van SSTRs ter hoogte van het celmembraan. Dit zou dan 
in vivo in beeld kunnen gebracht worden  door  sequentiële somatostatine receptor 
scintigrafie. 
99mTc)-gemerkt somatostatine analoog met hoge 
affiniteit voor SSTR2, 3 en 5. In hoofdstuk 4 bestudeerden we de biodistributie en dosimetrie 
van 99mTc-depreotide in borstkanker patiënten. We troffen de meeste radioactiviteit aan in de 
lever, milt en nieren, en de toegediende radioactiviteit werd hoofdzakelijk geëlimineerd via 
fysisch verval. Bijkomend werd opname opgemerkt in longen, colon, beenmerg en mucosa 
van bucco-farynx. De gemiddelde effectieve dosis voor 99mTc-depreotide was 6.4-8.5mSv, 
wat substantieel lager is dan voor [111
In hoofdstuk 5 vergeleken we de diagnostische accuraatheid van planaire 
In-DTPA-D-Phe]-octreotide (8-16mSv), de radioligand 
die routineus gebruikt wordt voor beeldvorming van SSTR-positieve tumoren. 
99mTc-
depreotide scintigrafie met planaire 99mTc-methyleendifosfonaat (MDP) bot scintigrafie voor 
de evaluatie van botmetastasen in een kleine reeks van borstkanker patiënten. Botscan bewees 
beter te zijn (75% versus 83.3%) wegens zijn hogere sensitiviteit (100% versus 62.5%). 
Daarentegen was  de specificiteit van de NeoSpect® scan significant hoger (100% versus 
50%). Depreotide bindt namelijk specifiek op SSTR2, 3 en 5 die tot overexpressie komen in 
50-80% van de borst tumoren. In tegenstelling daarmee accumuleert 99m
We evalueerden het potentieel van sequentiële 
Tc-MDP aspecifiek in 
elke plaats van het skelet met een verhoogde bot-turnover, zoals bij arthropatie, wat 
aanleiding geeft tot een vals-positieve diagnose van botmetastasen.  
99mTc-depreotide scintigrafie voor de 
selectie van patiënten die waarschijnlijk zouden beantwoorden aan hormonale therapie in 
hoofdstuk 6. In onze studie hadden alle patiënten met hormoongevoelige tumoren een 
positieve scan. Opname van de radioligand op posttherapie scan, opgenomen 3 weken na start 
van de behandeling, was over het algemeen lager dan op de pretherapie scan en, een cut-off 
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van 25% in acht nemend, daalde de opname of bleef ze stabiel. Alle negatieve 99mTc-
depreotide scans behoorden bij patiënten met tumoren die resistent waren tegen hormonale 
therapie. Drie patiënten (30%) van de groep die niet reageerde op de behandeling hadden een 
positieve 99m
We vonden een consistent verband tussen opname van 
Tc-depreotide scintigrafie en stijging van opname van de radioligand op de 
posttherapie scan. 
99mTc-depreotide en het 
beantwoorden aan hormonale behandeling bij patiënten met gemetastaseerd borstkanker. Het 
onderliggend mechanisme wordt verondersteld de regulatie van de SSTR expressie via ER te 
zijn, maar een reeks cytokines en/of groeifactoren aanwezig in de omgeving van de tumor 
kunnen een bijkomende invloed uitoefenen. Hoe dan ook, indien een studie op grotere schaal 
deze bevindingen bevestigt, zou deze methode een krachtig middel kunnen bieden om de 
hormoongevoeligheid van borsttumoren meer accuraat te evalueren. Een protocol bestaand uit 
het maken van een somatostine receptor scintigrafie vóór de start van een hormonale 
behandeling en een herhaling van de scan, indien positief, zou kunnen voorgesteld worden. 
Dit zou toelaten een onderscheid te maken tussen patiënten waarvoor al dan niet een effect 
van hormonale behandeling kan verwacht worden, en dit zou ofwel onmiddellijk kunnen 
gebeuren (in geval van negatieve pretherapie scan) ofwel 3 weken na start van de behandeling 
(in geval van positieve pretherapie scan). 
  147 
RESUME 
La thérapie hormonale assure de bons résultats avec un minimum de toxicité et reste 
un traitement de choix privilégié pour la plupart des patientes atteintes d’un cancer du sein 
metastasé. Mais du fait que un tiers seulement des patientes réagit dès l’abord à cette thérapie, 
il est nécessaire d’effectuer une sélection des patientes avec grand soin. Présentement, le seul 
indice à valeur prédictive homologué en utilisation clinique de routine est le degré d’affinité 
hormone-récepteur mesuré in vitro dans un  tissu prélevé au moyen d’étude des liaison ligand 
ou d’immunohistochimie. Mais du nombre de patientes ayant une tumeur exprimant le 
récepteur d’oestrogènes (RO), 50% à 60 % seulement réagissent positivement à la thérapie 
hormonale. Une explication possible à l’absence de résultat semble être le non-
fonctionnement du RO. La quantification de la substance produite lors de la stimulation RO, 
comme le récepteur de progesterone, pourrait contourner cette difficulté et a déjà prouvé 
augmenter la précision prédicative. Des résultats déjà obtenus sur base de l’expression de 
ARNm dans des lignées cancéreuses humaines (cancer du sein) laissent supposer que le 
récepteur de somatostatine (SSTR) soit également un gène dont l’expression est régulée par 
des oestrogènes.  
Dans cette thèse le rôle des oestrogènes dans l’expression de SSTR continue à 
s’éclaircir et on étudie la possibilité de l’illustrer au moyen de techniques appartenant à la 
médecine nucléaire, avec l’espoir de repérer parmi les patientes atteintes d’un cancer du sein, 
celles qui réagiront plus que probablement de façon positive à la thérapie endocrine. 
Nous avons choisi la scintigraphie comme technique d’imagerie pour la raison suivante: celle-
ci n’est pas invasive et a l’avantage de permettre l’évaluation du corps de façon répétitive. Il 
est de surcroît possible de détecter l’hétérogénéité intrinsèque de l’expression des récepteurs 
tumoraux sans manipulation d’organes et fournit des images in vivo de tous les foyers de 
contagion lorsqu’un traitement s’avère nécessaire. Le chapitre 2 est consacré à l’imagerie des 
récepteurs en oncologie au moyen des techniques provenant de la médecine nucléaire. Pour ce 
qui en est du cancer du sein en particulier, beaucoup d’efforts ont été fournis en ce qui 
concerne l’expression de la synthèse et l’évaluation de radiopharmaca dont on suppose que 
l’absorption dans la tumeur est relatée à l’expression  RO et donc à  la sensibilité hormonale. 
Au chapitre 3 nous avons démontré que l’expression de SSTR au moyen d’oestrogènes 
se retrouve dans deux lignées cellulaires humaines de cancer du sein (T47D et ZR75-1) 
hormonalement sensibles, RO-positives, et non pas dans les cellules MDA MB231, 
hormonalement non-sensibles et RO-négatives. Les expériences de combinaisons ont 
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démontré que les concentrations physiologiques d’oestradiol résultaient en une augmentation 
statistiquement significative du nombre de SSTR situé sur les membranes cellulaires des 
cellules T47D, mais non pas sur celles des cellules ZR75-1 et MDA MB231. Etant donné que 
western blot n’a démontré qu’une très faible augmentation de protéine SSTR2 dans les 
cellules T47D, ce phénomène sera probablement dû au recyclage de récepteurs de l’intérieur 
vers l’extérieur de la membrane cellulaire. L’effet E2 est soit réduit, soit empêché par les 
antioestrogènes tamoxifen ou ICI 182 780 (fulvestrant), ce qui indique la nécessité d’une 
liaison  E2 et d’une stimulation RO, ce qui à son tour laisse supposer une expression SSTR 
entièrement régulée par E2
Nous avons choisi de travailler avec dépréotide (P829-NeoSpect
. Par analogie avec les données in vitro nous émettons l’hypothèse 
qu’un traitement hormonal efficace de patientes atteintes de cancer du sein métastasé peut 
induire une diminution de SSTR au niveau de la membrane cellulaire. Ceci pourrait être rendu 
visible in vivo par scintigraphie séquentielle du récepteur de somatostatine. 
®/NeoTect®), un 
analogue de somatostatine marqué au technétium (99mTc) à haute affinité au SSTR2, 3 et 5. 
Au chapitre 4 nous avons étudié la biodistribution et la dosimétrie du 99mTc-dépréotide auprès 
de malades atteintes du cancer du sein. Nous avons détecté la plus intense radioactivité dans 
le foie, dans la rate et dans les reins; la radioactivité est principalement éliminée 
physiquement. Nous avons de plus remarqué une absorption par les poumons, le colon, la 
moelle osseuse et la muqueuse du bucco-pharynx. La dose moyenne effective pour le 99mTc-
dépréotide  est de 6.4-8.5 mSv, ce qui est substantiellement inférieur à celle de [111
Au chapitre 5 nous avons comparé la précision diagnostique de la scintigraphie 
In-DTPA-
D-Phe]-octréotide (8-16 mSv), un radioligand de routine dans la détection des tumeurs SSTR-
positives. 
99mTc-
dépréotide planaire et la scintigraphie osseuse 99mTc-diphosfate de méthylène (MDP) dans 
l’évaluation des métastases osseuses chez une série de patientes atteintes du cancer du sein. 
La scintigraphie osseuse a prouvé être meilleur (75% contre 83.3%), grâce à sa plus grande 
sensibilité (100% contre 62.5%). La spécificité de NeoSpect® scan était toutefois plus élevée 
(100% contre 50%). Le dépréotide se lie notamment spécifiquement sur SSTR2, 3 et 5 qui 
sont sur-exprimés sur 50%-80% des cellules cancéreuses. Tout au contraire de 99m
Nous avons évalué le potentiel de scintigraphie séquentielle 
Tc-MDP 
qui est accumulé à tout endroit où le squelette montre un turnover important, comme pour 
l’artropathie, ce qui donne un diagnostic faussement positif des métastases osseuses. 
99mTc-dépréotide pour une 
sélection de patientes qui répondraient  favorablement à la thérapie hormonale au chapitre 6. 
Tous les scans des patientes reprises dans notre étude et ayant des tumeurs sensibles aux 
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hormones sont positifs. L’absorption du radioligand en scan postthérapeutique –pris 3 
semaines après le début du traitement – fut en ligne générale plus bas que celui pris en pré-
thérapie, et, en tenant compte d’un cut-off de 25% resta égale ou inférieure. Tous les scans 
99mTc-dépréotide négatifs appartenaient à des patientes ayant des tumeurs résistant à la 
thérapie hormonale. Trois patientes (30%) du groupe qui ne réagit pas au traitement 
montraient une scintigraphie 99m
Nous avons trouvé un rapport consistant entre l’absorption du 
Tc-dépréotide positive et une augmentation de l’absorption du 
radioligand. 
99mTc-dépréotide et la 
réponse au traitement chez des patientes attentes de cancer du sein métastasé. Le mécanisme 
sous-jacent est sensé être la régulation de l’expression SSTR par RO, mais un nombre de 
cytokine et/ou facteurs de croissance présents aux alentours de la tumeur peuvent avoir un 
surcroît d’ impact. De toute façon, si une étude à une échelle plus importante entérinait les 
données,  cette méthode représenterait un formidable outil d’évaluation fine de la sensibilité 
aux hormones des tumeurs du sein. Un protocole consistant en une scintigraphie des 
récepteurs de somatostine avant traitement (en cas de scan préthérapeutique positif) et une  
reprise du scan en cas positif pourrait être préconisée. Ceci permettrait de faire la distinction 
entre les patientes pouvant ou non répondre à la thérapie hormonale, et cela pourrait se faire 
immédiatement en cas de scan préthérapeutique négatif), soit 3 semaines après début du 
traitement (en cas de scan préthérapeutique positif). 
